WO2024038282A1 - 2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors - Google Patents
2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors Download PDFInfo
- Publication number
- WO2024038282A1 WO2024038282A1 PCT/GB2023/052166 GB2023052166W WO2024038282A1 WO 2024038282 A1 WO2024038282 A1 WO 2024038282A1 GB 2023052166 W GB2023052166 W GB 2023052166W WO 2024038282 A1 WO2024038282 A1 WO 2024038282A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heterocycloalkyl
- substituted
- ring
- alkyl
- compound
- Prior art date
Links
- 239000002532 enzyme inhibitor Substances 0.000 title description 3
- BVXWHRDWRQPPSI-UHFFFAOYSA-N 3-oxabicyclo[2.1.1]hexane Chemical class C1C2CC1CO2 BVXWHRDWRQPPSI-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 566
- 239000000203 mixture Substances 0.000 claims abstract description 201
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000003814 drug Substances 0.000 claims abstract description 17
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 371
- 125000003118 aryl group Chemical group 0.000 claims description 345
- 125000000217 alkyl group Chemical group 0.000 claims description 301
- 125000001072 heteroaryl group Chemical group 0.000 claims description 282
- 125000001424 substituent group Chemical group 0.000 claims description 278
- 229910052799 carbon Inorganic materials 0.000 claims description 223
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 210
- 150000003839 salts Chemical class 0.000 claims description 209
- 239000012453 solvate Substances 0.000 claims description 192
- 125000003545 alkoxy group Chemical group 0.000 claims description 178
- 125000005843 halogen group Chemical group 0.000 claims description 166
- 125000004122 cyclic group Chemical group 0.000 claims description 150
- -1 methylenedioxy Chemical group 0.000 claims description 133
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 113
- 125000004043 oxo group Chemical group O=* 0.000 claims description 113
- 229910052757 nitrogen Inorganic materials 0.000 claims description 107
- 101100240523 Caenorhabditis elegans nhr-19 gene Proteins 0.000 claims description 100
- 125000005592 polycycloalkyl group Polymers 0.000 claims description 93
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 76
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 56
- 125000004432 carbon atom Chemical group C* 0.000 claims description 54
- 206010019860 Hereditary angioedema Diseases 0.000 claims description 51
- 208000028185 Angioedema Diseases 0.000 claims description 48
- 229910052760 oxygen Inorganic materials 0.000 claims description 40
- 229910052717 sulfur Inorganic materials 0.000 claims description 38
- 102100035792 Kininogen-1 Human genes 0.000 claims description 35
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 35
- 230000001404 mediated effect Effects 0.000 claims description 34
- 101800004538 Bradykinin Proteins 0.000 claims description 32
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 32
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 32
- 125000002619 bicyclic group Chemical group 0.000 claims description 31
- 125000003003 spiro group Chemical group 0.000 claims description 30
- 208000007536 Thrombosis Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 29
- 125000002950 monocyclic group Chemical group 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 230000000694 effects Effects 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 25
- 150000002430 hydrocarbons Chemical class 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 19
- 229920006395 saturated elastomer Polymers 0.000 claims description 18
- 150000001721 carbon Chemical group 0.000 claims description 17
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004215 Carbon black (E152) Substances 0.000 claims description 13
- 229930195733 hydrocarbon Natural products 0.000 claims description 13
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 11
- 101100495912 Arabidopsis thaliana CHR12 gene Proteins 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- 108010074864 Factor XI Proteins 0.000 claims description 9
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 239000004305 biphenyl Chemical group 0.000 claims description 7
- 235000010290 biphenyl Nutrition 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 abstract description 2
- 229910052721 tungsten Inorganic materials 0.000 abstract description 2
- 229910052720 vanadium Inorganic materials 0.000 abstract description 2
- 229910052727 yttrium Inorganic materials 0.000 abstract description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- 239000003112 inhibitor Substances 0.000 description 55
- 238000007429 general method Methods 0.000 description 49
- 238000003818 flash chromatography Methods 0.000 description 47
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 44
- 239000000047 product Substances 0.000 description 43
- 206010012812 Diffuse cutaneous mastocytosis Diseases 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- 238000006243 chemical reaction Methods 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 238000002953 preparative HPLC Methods 0.000 description 25
- 108010080865 Factor XII Proteins 0.000 description 23
- 102000000429 Factor XII Human genes 0.000 description 23
- 239000011541 reaction mixture Substances 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 22
- 239000012043 crude product Substances 0.000 description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000012071 phase Substances 0.000 description 21
- 108090000113 Plasma Kallikrein Proteins 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- 150000001412 amines Chemical class 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 18
- 238000000746 purification Methods 0.000 description 18
- 230000004913 activation Effects 0.000 description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- 239000007832 Na2SO4 Substances 0.000 description 14
- 102000003827 Plasma Kallikrein Human genes 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 239000012267 brine Substances 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- 235000011152 sodium sulphate Nutrition 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 201000011190 diabetic macular edema Diseases 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 230000004064 dysfunction Effects 0.000 description 10
- 239000012074 organic phase Substances 0.000 description 10
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 9
- 208000006011 Stroke Diseases 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 210000003486 adipose tissue brown Anatomy 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 206010014522 Embolism venous Diseases 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 208000004043 venous thromboembolism Diseases 0.000 description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 description 7
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000003455 anaphylaxis Diseases 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 7
- 150000002825 nitriles Chemical class 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 238000006722 reduction reaction Methods 0.000 description 7
- 125000006413 ring segment Chemical group 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- 206010002198 Anaphylactic reaction Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 208000008589 Obesity Diseases 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 6
- 230000036783 anaphylactic response Effects 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 208000022715 Autoinflammatory syndrome Diseases 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 201000010183 Papilledema Diseases 0.000 description 5
- 206010038886 Retinal oedema Diseases 0.000 description 5
- 206010040047 Sepsis Diseases 0.000 description 5
- 208000024780 Urticaria Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 206010064930 age-related macular degeneration Diseases 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 238000005804 alkylation reaction Methods 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 201000005008 bacterial sepsis Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000003709 heart valve Anatomy 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 230000001771 impaired effect Effects 0.000 description 5
- 208000017169 kidney disease Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000002780 macular degeneration Diseases 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 230000003959 neuroinflammation Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 201000002793 renal fibrosis Diseases 0.000 description 5
- 201000011195 retinal edema Diseases 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000002568 urticarial effect Effects 0.000 description 5
- 208000009304 Acute Kidney Injury Diseases 0.000 description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 208000005189 Embolism Diseases 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000032382 Ischaemic stroke Diseases 0.000 description 4
- 206010023421 Kidney fibrosis Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010050216 Paget-Schroetter syndrome Diseases 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 208000033626 Renal failure acute Diseases 0.000 description 4
- 206010063837 Reperfusion injury Diseases 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 208000001435 Thromboembolism Diseases 0.000 description 4
- 208000004519 Upper Extremity Deep Vein Thrombosis Diseases 0.000 description 4
- 201000011040 acute kidney failure Diseases 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000011882 arthroplasty Methods 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000013877 carbamide Nutrition 0.000 description 4
- 238000005660 chlorination reaction Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000002618 extracorporeal membrane oxygenation Methods 0.000 description 4
- 206010061989 glomerulosclerosis Diseases 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002008 hemorrhagic effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 208000028867 ischemia Diseases 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 230000003331 prothrombotic effect Effects 0.000 description 4
- 208000004644 retinal vein occlusion Diseases 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 208000007056 sickle cell anemia Diseases 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 235000019345 sodium thiosulphate Nutrition 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N Di-tert-butyl dicarbonate Substances CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 description 3
- 108010093008 Kinins Proteins 0.000 description 3
- 102000002397 Kinins Human genes 0.000 description 3
- 101710151321 Melanostatin Proteins 0.000 description 3
- 102400000064 Neuropeptide Y Human genes 0.000 description 3
- 238000010934 O-alkylation reaction Methods 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 102100034869 Plasma kallikrein Human genes 0.000 description 3
- 102000013566 Plasminogen Human genes 0.000 description 3
- 108010051456 Plasminogen Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000005707 acquired angioedema Diseases 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 150000001502 aryl halides Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000004154 complement system Effects 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 229910052805 deuterium Inorganic materials 0.000 description 3
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000002314 neuroinflammatory effect Effects 0.000 description 3
- 230000009437 off-target effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 229940012957 plasmin Drugs 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000012041 precatalyst Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 2
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000016918 Complement C3 Human genes 0.000 description 2
- 108010028780 Complement C3 Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101150072419 F12 gene Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 101000603877 Homo sapiens Nuclear receptor subfamily 1 group I member 2 Proteins 0.000 description 2
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 description 2
- 101000713170 Homo sapiens Solute carrier family 52, riboflavin transporter, member 1 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000002020 Protease-activated receptors Human genes 0.000 description 2
- 108050009310 Protease-activated receptors Proteins 0.000 description 2
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 101150097162 SERPING1 gene Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical group C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 108010011867 ecallantide Proteins 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- QURWXBZNHXJZBE-SKXRKSCCSA-N icatibant Chemical compound NC(N)=NCCC[C@@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2SC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@H](CC3=CC=CC=C3C2)C(=O)N2[C@@H](C[C@@H]3CCCC[C@@H]32)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C[C@@H](O)C1 QURWXBZNHXJZBE-SKXRKSCCSA-N 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- VBGWSQKGUZHFPS-VGMMZINCSA-N kalbitor Chemical compound C([C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]2C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=3C=CC=CC=3)C(=O)N[C@H](C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)NCC(=O)NCC(=O)N[C@H]3CSSC[C@H](NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CO)NC(=O)[C@H](CC=4NC=NC=4)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O)CSSC[C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC3=O)CSSC2)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1)[C@@H](C)CC)[C@H](C)O)=O)[C@@H](C)CC)C1=CC=CC=C1 VBGWSQKGUZHFPS-VGMMZINCSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000003328 mesylation reaction Methods 0.000 description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000009038 pharmacological inhibition Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000000476 thermogenic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical class CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- GLDQAMYCGOIJDV-UHFFFAOYSA-N 2,3-dihydroxybenzoic acid Chemical class OC(=O)C1=CC=CC(O)=C1O GLDQAMYCGOIJDV-UHFFFAOYSA-N 0.000 description 1
- QPEJAHMNOVMSOZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane Chemical compound C1CCC21CNC2 QPEJAHMNOVMSOZ-UHFFFAOYSA-N 0.000 description 1
- NINJAJLCZUYDGV-UHFFFAOYSA-N 2-azaspiro[4.4]nonane Chemical compound C1CCCC21CNCC2 NINJAJLCZUYDGV-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical class CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 239000012388 BrettPhos 3rd generation precatalyst Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100030556 Coagulation factor XII Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
- 108700036031 EC 3.4.21.38 Proteins 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229940123849 Factor IXa inhibitor Drugs 0.000 description 1
- 230000026769 Factor XII activation Effects 0.000 description 1
- 108010080805 Factor XIa Proteins 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000295146 Gallionellaceae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 1
- 101001081555 Homo sapiens Plasma protease C1 inhibitor Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 229940127379 Kallikrein Inhibitors Drugs 0.000 description 1
- 102100038297 Kallikrein-1 Human genes 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 229910010199 LiAl Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910020284 Na2SO4.10H2O Inorganic materials 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102100032341 PCNA-interacting partner Human genes 0.000 description 1
- 101710196737 PCNA-interacting partner Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010042682 Swelling face Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- HYLXOQURIOCKIH-VQVTYTSYSA-N Thr-Arg Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N HYLXOQURIOCKIH-VQVTYTSYSA-N 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 108010059382 Zea mays trypsin inhibitor Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940075791 berinert Drugs 0.000 description 1
- UXNXMBYCBRBRFD-NDEPHWFRSA-N berotralstat Chemical compound NCC1=CC=CC(=C1)N1N=C(C=C1C(=O)NC1=C(F)C=CC(=C1)[C@@H](NCC1CC1)C1=CC(=CC=C1)C#N)C(F)(F)F UXNXMBYCBRBRFD-NDEPHWFRSA-N 0.000 description 1
- 229940121533 berotralstat Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 229940088949 cinryze Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 108700005721 conestat alfa Proteins 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960001174 ecallantide Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940050762 firazyr Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940121565 garadacimab Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000005748 halopyridines Chemical class 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 102000044507 human SERPING1 Human genes 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 108700023918 icatibant Proteins 0.000 description 1
- 229960001062 icatibant Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940018902 kalbitor Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 229950005287 lanadelumab Drugs 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 231100000623 nanotoxicology Toxicity 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 description 1
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003805 procoagulant Substances 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960003876 ranibizumab Drugs 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229940009560 ruconest Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RSIJVJUOQBWMIM-UHFFFAOYSA-L sodium sulfate decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].[O-]S([O-])(=O)=O RSIJVJUOQBWMIM-UHFFFAOYSA-L 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- LBJQKYPPYSCCBH-UHFFFAOYSA-N spiro[3.3]heptane Chemical compound C1CCC21CCC2 LBJQKYPPYSCCBH-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 239000003856 thrombin receptor antagonist Substances 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000006000 trichloroethyl group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 108020005087 unfolded proteins Proteins 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- This invention relates to enzyme inhibitors that are inhibitors of Factor XI la (FXIIa), and to pharmaceutical compositions comprising, and uses of, such inhibitors.
- the compounds of the present invention are inhibitors of factor Xlla (FXIIa) and thus have a number of possible therapeutic applications, particularly in the treatment of diseases or conditions in which factor Xlla inhibition is implicated.
- FXIIa is a serine protease (EC 3.4.21.38) derived from its zymogen precursor, factor XII (FXII), which is expressed by the F12 gene.
- Single chain FXII has a low level of amidolytic activity that is increased upon interaction with negatively charged surfaces and has been implicated in its activation (see Invanov et al., Blood. 2017 Mar 16;129(11):1527-1537. doi: 10.1182/blood-2016-10-744110).
- Proteolytic cleavage of FXII to heavy and light chains of FXIIa dramatically increases catalytic activity.
- FXIIa that retains its full heavy chain is aFXIIa.
- FXIIa that retains a small fragment of its heavy chain is PFXIIa.
- the separate catalytic activities of aFXIIa and PFXIIa contribute to the activation and biochemical functions of FXIIa.
- Mutations and polymorphisms in the F12 gene can alter the cleavage of FXII and FXIIa.
- FXIIa has a unique and specific structure that is different from many other serine proteases. For instance, the Tyr99 in FXIIa points towards the active site, partially blocking the S2 pocket and giving it a closed characteristic. Other serine proteases containing a Tyr99 residue (e.g. FXa, tPA and FIXa) have a more open S2 pocket. Moreover, in several trypsin-like serine proteases the P4 pocket is lined by an "aromatic box" which is responsible for the P4-driven activity and selectivity of the corresponding inhibitors. However, FXIIa has an incomplete "aromatic box" resulting in more open P4 pocket. See e.g.
- FXIIa converts plasma prekallikrein (PK) to plasma kallikrein (PKa), which provides positive feedback activation of FXII to FXIIa.
- PK plasma prekallikrein
- PKa plasma kallikrein
- HK high molecular weight kininogen
- FXIIa mediated conversion of plasma prekallikrein to plasma kallikrein can cause subsequent cleavage of HKto generate bradykinin, a potent inflammatory hormone that can also increase vascular permeability, which has been implicated in disorders such as hereditary angioedema (HAE).
- HAE hereditary angioedema
- the contact system is activated via a number of mechanisms, including interactions with negatively charged surfaces, negatively charged molecules, unfolded proteins, artificial surfaces, foreign tissue (e.g. biological transplants, that include bio-prosthetic heart valves, and organ/tissue transplants), bacteria, and biological surfaces (including endothelium and extracellular matrix) that mediate assembly of contact system components.
- the contact system is activated by plasmin, and cleavage of FXII by other enzymes can facilitate its activation.
- FXIIa has additional substrates both directly, and indirectly via PKa, including Proteinase-activated receptors (PARs), plasminogen, and neuropeptide Y (NPY) which can contribute to the biological activity of FXIIa. Inhibition of FXIIa could provide clinical benefits by treating diseases and conditions associated with these systems, pathways, receptors, and hormones.
- PARs Proteinase-activated receptors
- NPY neuropeptide Y
- PKa activation of PAR2 mediates neuroinflammation and may contribute to neuroinflammatory disorders including multiple sclerosis (see Gbbel et al., Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116).
- PKa activation of PARI and PAR2 on vascular smooth muscle cells has been implicated in vascular hypertrophy and atherosclerosis (see Abdallah et al., J Biol Chem. 2010 Nov 5;285(45):35206-15. doi: 10.1074/jbc.M110.171769).
- FXIIa activation of plasminogen to plasmin contributes to fibrinolysis (see Konings et al., Thromb Res. 2015 Aug;136(2):474-80. doi: 10.1016/j.thromres.2015.06.028).
- PKa proteolytically cleaves NPY and thereby alters its binding to NPY receptors (Abid et al., J Biol Chem. 2009 Sep ll;284(37):24715-24. doi: 10.1074/jbc.M109.035253).
- Inhibition of FXIIa could provide clinical benefits by treating diseases and conditions caused by PAR signaling, NPY metabolism, and plasminogen activation.
- BK bradykinin
- Garadacimab (CSL-312), a monoclonal antibody inhibitory against FXIIa, recently completed a phase 3 study where monthly prophylactic subcutaneous treatment was reported to reduce attacks in patients with type l/ll hereditary angioedema (HAE), which results in intermittent swelling of face, hands, throat, gastro-intestinal tract and genitals (see https://www.clinicaltrials.gov/ct2/show/NCT04656418 and Craig et al., The Lancet. 2023;401(10382):1079-1090. doi: 10.1016/50140-6736(23)00350-1).
- HAE hereditary angioedema
- FXIIa mediates the generation of PK to PKa
- inhibitors of FXIIa could provide protective effects of all form of BK-mediated angioedema, including HAE and non-hereditary bradykinin-mediated angioedema (BK-AEnH).
- Hereditary angioedema can be defined as any disorder characterised by recurrent episodes of bradykinin-mediated angioedema (e.g. severe swelling) caused by an inherited genetic dysfunction/fault/mutation.
- bradykinin-mediated angioedema e.g. severe swelling
- HAE normal Cl inhibitor HAE
- HAE type 1 is caused by mutations in the SERPING1 gene that lead to reduced levels of Cl inhibitor in the blood.
- HAE type 2 is caused by mutations in the SERPING1 gene that lead to dysfunction of the Cl inhibitor in the blood.
- the cause of normal Cl-lnh HAE is less well defined and the underlying genetic dysfunction/fault/mutation can sometimes remain unknown. What is known is that the cause of normal Cl-lnh HAE is not related to reduced levels or dysfunction of the Cl inhibitor (in contrast to HAE types 1 and 2).
- Normal Cl-lnh HAE can be diagnosed by reviewing the family history and noting that angioedema has been inherited from a previous generation (and thus it is hereditary angioedema). Normal Cl-lnh HAE can also be diagnosed by determining that there is a dysfunction/fault/mutation in a gene other than those related to Cl inhibitor. For example, it has been reported that dysfunction/fault/mutation with plasminogen can cause normal Cl-lnh HAE (see e.g. Veronez et al., Front Med (Lausanne). 2019 Feb 21;6:28. doi: 10.3389/fmed.2019.00028; or Recke et al., Clin Transl Allergy. 2019 Feb 14;9:9.
- BK-AEnH bradykinin mediated angioedema non-hereditary
- HAE bradykinin mediated angioedema non-hereditary
- BK-AEnH is characterised by recurrent acute attacks where fluids accumulate outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues such as in the hands, feet, limbs, face, intestinal tract, airway or genitals.
- BK-AEnH include: non hereditary angioedema with normal Cl Inhibitor (AE-nCl Inh), which can be environmental, hormonal, or drug induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE) inhibitor induced angioedema; dipeptidyl peptidase 4 inhibitor induced angioedema; and tPA induced angioedema (tissue plasminogen activator induced angioedema).
- AE-nCl Inh non hereditary angioedema with normal Cl Inhibitor
- ACE angiotensin converting enzyme
- dipeptidyl peptidase 4 inhibitor induced angioedema
- tPA induced angioedema tissue plasminogen activator induced angioedema
- Environmental factors that can induce AE-nCl Inh include air pollution (Kedarisetty et al, Otolaryngol Head Neck Surg. 2019 Apr 30:194599819846446. doi: 10.1177/0194599819846446) and silver nanoparticles such as those used as antibacterial components in healthcare, biomedical and consumer products (Long et al., Nanotoxicology. 2016;10(4):501-ll. doi: 10.3109/17435390.2015.1088589).
- BK-medicated AE can be caused by thrombolytic therapy.
- tPA induced angioedema is discussed in various publications as being a potentially life threatening complication following thrombolytic therapy in acute stroke victims (see e.g. Simao et al., Blood. 2017 Apr 20;129(16):2280-2290. doi: 10.1182/blood-2016-09-740670; Frohlich et al., Stroke. 2019 Jun 11:STROKEAHA119025260. doi: 10.1161/STROKEAHA.119.025260; Rathbun, Oxf Med Case Reports. 2019 Jan 24;2019(1):omyll2.
- Hermanrud et al. (BMJ Case Rep. 2017 Jan 10;2017. pii: bcr2016217802) reports recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV and also discusses acquired angioedema related to angiotensin-converting enzyme inhibitors (ACEI-AAE).
- Kim et al. (Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):115-122. doi: 10.1111/bcpt.l3097) reports angiotensin II receptor blocker (ARB)-related angioedema.
- Reichman et al. (Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1190- 1196.
- FXIIa has been implicated in mediating both vascular endothelial growth factor (VEGF) independent DME (see Kita et al., Diabetes. 2015 Oct;64(10):3588-99. doi: 10.2337/dbl5-0317) and VEGF mediated DME (see Clermont et al., Invest Ophthalmol Vis Sci. 2016 May l;57(6):2390-9. doi: 10.1167/iovs.15-18272). FXII deficiency is protective against VEGF induced retinal edema in mice (Clermont et al., ARVO talk 2019).
- VEGF vascular endothelial growth factor
- FXIIa inhibition will provide therapeutic effects for diabetic retinopathy and retinal edema caused by retinal vascular hyperpermeability, including DME, retinal vein occlusion, age-related macular degeneration (AMD).
- DME retinal vascular hyperpermeability
- AMD age-related macular degeneration
- FXIIa has been implicated in the treatment of sepsis and bacterial sepsis (see Morrison et al., J Exp Med. 1974 Sep l;140(3):797-811). Therefore, FXIIa inhibitors could provide therapeutic benefits in treating sepsis, bacterial sepsis and disseminated intravascular coagulation (DIC).
- FXIIa mediated activation of the KKS and production of BK have been implicated in neurodegenerative diseases including Alzheimer's disease, multiple sclerosis, epilepsy and migraine (see Zamolodchikov et al., Proc Natl Acad Sci U S A.
- FXIIa inhibitors could provide therapeutic benefits in reducing the progression and clinical symptoms of these neurodegenerative diseases.
- FXIIa has also been implicated in anaphylaxis (see Bender et al., Front Immunol. 2017 Sep 15;8:1115. doi: 10.3389/fimmu.2017.01115; and Sala-Cunill et al., J Allergy Clin Immunol. 2015 Apr;135(4):1031-43.e6. doi: 10.1016/j.jaci.2014.07.057). Therefore, FXIIa inhibitors could provide therapeutic benefits in reducing the clinical severity and incidence of anaphylactic reactions.
- FXIIa The role of FXIIa in coagulation was identified over 50 years ago, and has been extensively documented in publications using biochemical, pharmacological, genetic and molecular studies (see Davie et al., Science. 1964 Sep 18;145(3638):1310-2).
- FXIIa mediated activation of factor XI (FXI) triggers the intrinsic coagulation pathway.
- FXIIa can increase coagulation in a FXI independent manner (see Radcliffe et al., Blood. 1977 Oct;50(4):611-7; and Puy et al., J Thromb Haemost. 2013 Jul;ll(7):1341-52. doi: 10.1111/jth.12295).
- FXII deficiency prolongs activated partial prothrombin time (APTT) without adversely affecting hemostasis (see Renne et al., J Exp Med. 2005 Jul 18;202(2):271-81; and Simao et al., Front Med (Lausanne). 2017 Jul 31;4:121. doi: 10.3389/fmed.2017.00121).
- Pharmacological inhibition of FXIIa also prolongs APTT without increasing bleeding (see Worm et al., Ann Transl Med. 2015 Oct;3(17):247. doi: 10.3978/j.issn.2305-5839.2015.09.07).
- FXIIa inhibitors could be used to treat a spectrum of prothrombotic conditions including venous thromboembolism (VTE); cancer associated thrombosis; complications caused by mechanical and bioprosthetic heart valves, catheters, extracorporeal membrane oxygenation (ECMO), left ventricular assisted devices (LVAD), dialysis, cardiopulmonary bypass (CPB); sickle cell disease, joint arthroplasty, thrombosis induced by tPA, Paget-Schroetter syndrome and Budd-Chari syndrome.
- VTE venous thromboembolism
- LVAD left ventricular assisted devices
- CPB cardiopulmonary bypass
- FXIIa inhibitors may also be useful for treating or preventing thromboembolism by lowering the propensity of devices that come into contact with blood to clot blood.
- devices that come into contact with blood include vascular grafts, stents, in-dwelling catheters, external catheters, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.
- FXIIa inhibition may improve clinical neurological outcomes in the treatment of patients with stroke.
- FXII deficiency has been shown to reduce the formation of atherosclerotic lesions in Apoe _/_ mice (Didiasova et al., Cell Signal. 2018 Nov;51:257-265. doi: 10.1016/j.cellsig.2018.08.006). Therefore, FXIIa inhibitors could be used in the treatment of atherosclerosis.
- FXIIa either directly, or indirectly via PKa, has been shown to activate the complement system (Ghebrehiwet et al., Immunol Rev. 2016 Nov;274(1):281-289. doi: 10.1111/imr.l2469).
- BK increases complement C3 in the retina, and an in vitreous increase in complement C3 is associated with DME (Murugesan et al., Exp Eye Res. 2019 Jul 24;186:107744. doi: 10.1016/j.exer.2019.107744).
- Both FXIIa and PKa activate the complement system (see Irmscher et al., J Innate Immun. 2018;10(2):94-105. doi: 10.1159/000484257; and Ghebrehiwet et al., J Exp Med. 1981 Mar l;153(3):665-76).
- Pulmonary Fibrosis through direct stimulation of fibroblasts to produce pro-fibrotic cytokine IL-6.
- Gbbel et al. (The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders— A Systematic Review, Front. Immunol., 26 July 20181 https://doi.org/10.3389/fimmu.2018.01731) relates to FXII's role in the rheumatoid arthritis (RA).
- Wygrecka et al. (“Use of a FXIIa-lnhibitor in the treatment of renal fibrosis and/or kidney disease” WO2019/113642) relates to an inhibitor of Factor XII for use in treating or preventing kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury.
- FXII/FXIIa inhibitors are said to have been described by Nolte et al. ("Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces” W02012/120128).
- Compounds that are said to be modulators of FXIIa have been described by Philippou et al. (“Factor XI la Inhibitors” WO 2019/211585 and WO 2019/186164).
- Macrocylic peptides that are said to be inhibitors of FXIIa have been described by Wilbs et al. (Nat Commun 11, 3890 (2020). Doi: 10.1038/s41467-020-17648- w).
- FXIIa inhibitors have been approved for medical use, and there are no small molecule FXIIa inhibitors in clinical development.
- certain known compounds are said to be modulators or inhibitors of FXIIa, these compounds can suffer from limitations such as being non-reversible or covalent binders, being poorly selective for FXIIa over other related enzymes, or not having pharmacokinetic properties suitable for oral therapy.
- compounds with acylating reactivity e.g. acylated aminotriazoles, are typically non-reversible covalent binders, and can sometimes also be unstable in water and/or blood plasma due to their inherent reactivity.
- HAE angioedema
- HAE normal Cl inhibitor HAE
- BK-AEnH including AE-nCl Inh, ACE and tPA induced angioedema
- vascular hyperpermeability stroke including ischemic stroke and haemorrhagic accidents
- retinal edema diabetic retinopathy
- impaired visual acuity DME
- retinal vein occlusion AMD
- neuroinflammation neuroinflammatory/neurodegenerative disorders such as MS (multiple sclerosis); other neurodegenerative diseases such as Alzheimer's disease, epilepsy and migraine; sepsis; bacterial sepsis; inflammation; anaphylaxis; thrombosis; thromboembolism caused by increased propensity of medical devices
- the present invention relates to a series of inhibitors of Factor Xlla (FXIIa).
- the compounds of the invention are potentially useful in the treatment of diseases or conditions in which factor Xlla inhibition is implicated.
- the invention further relates to pharmaceutical compositions of the inhibitors, to the use of the compositions as therapeutic agents, and to methods of treatment using these compositions.
- V is selected from -O- and -N(R23)-
- Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
- R20 and R21 are independently selected from H, alkyl and CF 3 , or R20 and R21 together with the carbon atom to which they are attached form a carbon-containing 3-, 4-, 5- or 6- membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H;
- R22 is a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkyl, alkoxy, OH, CN, CF 3 , halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6bicyclic ring is not aryl substituted with ethylenedioxy;
- Y is selected from -O- and -N(R12)-;
- B is selected from:
- AW- is selected from:
- V is -O-
- R8 is independently selected from H, alkyl, cycloalkyl, and heterocycloalkyl
- R12 is independently selected from H, alkyl, and cycloalkyl
- R13 and R14 are independently selected from H, alkyl b , aryl b and heteroaryl b or R13 and R14 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkyl b , alkoxy, OH, halo and CF3;
- R15 is selected from alkyl, halo, CF 3 , CN, OH, alkoxy, NR13R14, and CONR13R14;
- R16 and R17 are independently selected from H and small alkyl; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated analogues, and pharmaceutically acceptable salts and/or solvates thereof.
- the compounds of formula (I) have been developed to be inhibitors of FXIIa, which as noted above, has a unique and specific binding site.
- the compounds of formula (I) aim to address the need for small molecule FXIIa inhibitors, particularly with pharmacokinetic properties suitable for use as oral therapies.
- the compounds of formula (I) can also avoid including groups associated with covalent binding properties e.g. groups with acylating reactivity such as acylated aminotriazoles, and thus can provide compounds that are reversible inhibitors, to further reduce the risk of off-target effects and cytotoxicity.
- the present invention also provides a prodrug of a compound as herein defined, or a pharmaceutically acceptable salt and/or solvate thereof.
- the present invention also provides an N-oxide of a compound as herein defined, or a prodrug or pharmaceutically acceptable salt and/or solvate thereof.
- methylenedioxy refers to -O-CH2-O- only, wherein “methylenedioxy” cannot be substituted.
- ethylenedioxy refers to -O-CH2-CH2-O- only, wherein “ethylenedioxy” cannot be substituted.
- aryl substituted with methylenedioxy refers to aryl as defined above, wherein aryl is substituted with -O-CH2-O-. For example, .
- aryl substituted with ethylenedioxy refers to aryl as defined above, wherein aryl is substituted with -O-CH2-CH2-O-.
- R22 is not aryl substituted with methylenedioxy, which as mentioned above excludes ; and R22 is not aryl substituted with ethylenedioxy which as mentioned above excludes R22 can include fused 6,5- or 6,6- bicyclic rings containing an aryl ring fused to a non-aromatic ring, wherein the non-aromatic ring contains two O ring members, positioned as for but wherein the non-aromatic ring is substituted as for
- R22 can be any organic radical.
- R22 can be any organic radical.
- a and A' as defined above, contain at least one N ring member.
- the remaining ring members are carbon.
- pharmaceutically acceptable salts and/or solvates thereof means “pharmaceutically acceptable salts thereof", “pharmaceutically acceptable solvates thereof”, and “pharmaceutically acceptable solvates of salts thereof”.
- the compounds of the present invention can be provided as mixtures of more than one stereoisomer.
- one stereoisomer can be present at a purity >90 % relative to the remaining stereoisomers. More specifically, when provided as a mixture of stereoisomers, one stereoisomer can be present at a purity >95 % relative to the remaining stereoisomers.
- substituents may be named as its free unbonded structure (e.g. piperidine) or by its bonded structure (e.g. piperidinyl). No difference is intended.
- B can be heteroaryl a , which more specifically can be isoquinolinyl.
- isoquinolinyl can be optionally substituted in the same manner as “heteroaryl a ".
- a fused ring system refers to a ring system where two rings in the ring system share two adjacent atoms (i.e., one common covalent bond).
- a fused ring system specifically a fused bicyclic ring system
- a fused ring system which can be considered as a benzene ring and a piperidine ring sharing a common bond.
- a bridged ring system refers to a ring system having two rings sharing three or more atoms.
- a bridged ring system (specifically a bridged bicyclic ring system) which can be considered as a cyclopentane ring and a second cyclopentane ring joined at a bridge and sharing three common atoms.
- a spiro ring system refers to a ring system where two rings in the ring system share one common atom.
- a spiro ring system (specifically a spiro bicyclic ring system) which can be considered as a cyclobutane ring and an azetidine ring sharing a common carbon atom.
- the ring system A can be fully saturated, or have any degree of unsaturation.
- the ring system can be fully saturated, partially unsaturated, aromatic, non-aromatic, or have an aromatic ring bridged, fused or spiro to a non-aromatic ring.
- ring system A can contain non-carbon ring members, and that these non-carbon ring members can, where possible, be optionally substituted themselves (as well, or as opposed to the carbon ring members), with the optional substituents included in the definition of A.
- bradykinin-mediated angioedema means hereditary angioedema, and any non- hereditary bradykinin-mediated angioedema.
- bradykinin-mediated angioedema encompasses hereditary angioedema and acute bradykinin-mediated angioedema of unknown origin.
- hereditary angioedema means any bradykinin-mediated angioedema caused by an inherited genetic dysfunction, fault, or mutation.
- HAE includes at least HAE type 1, HAE type 2, and normal Cl inhibitor HAE (normal Cl-lnh HAE).
- the invention provides compounds of formula (I) wherein the compound is a compound of formula (la), formula (lb), or formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- the invention provides compounds of formula (I) wherein the compound is a compound of formula (la), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- the invention provides compounds of formula (I) wherein the compound is a compound of formula (lb), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- the invention provides compounds of formula (I) wherein the compound is a compound of formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- B can be selected from:
- B can be aryl; or B can be a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be aryl; or B can be 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be aryl; or B can be 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryl a .
- B can be phenyl substituted as for aryl; or B can be a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be phenyl substituted as for aryl; or B can be a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be phenyl substituted as for aryl; or B can be a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryl a .
- B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be a 6- membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be a 6- membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be a 6- membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryl a .
- B can be phenyl optionally substituted as for aryl, or B can be pyridyl or isoquinolinyl, optionally substituted as for heteroaryl a .
- B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl, or B can be pyridyl or isoquinolinyl, optionally substituted as for heteroaryl a . or optionally substituted as for heteroaryl a , or B can be phenyl optionally substituted as for aryl. B can be optionally substituted as for heteroaryl a . B can be optionally substituted as for heteroaryl a . B can be phenyl optionally substituted as for aryl.
- B can be or optionally substituted as for heteroaryl a , or B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl. B can be phenyl substituted with
- B can be unsubstituted; or B can be aryl, wherein B can be substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be heteroaryl a , wherein B can be substituted with alkyl, halo, OH, or NH2, and optionally 1 or 2 further substituents as for heteroaryl a .
- B can be selected from optionally further substituted with 1 or 2 substituents as for heteroaryl a ; or each optionally further substituted with 1 or 2 substituents as for heteroaryl a ; with no substituents; or no further substituents.
- B can be , optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be
- . B can be
- B can be selected from the following groups: optionally further substituted with 1 or 2 substituents as for heteroaryl a ; or B can be with no substituents; or B can be with no further substituents.
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be , optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B can be with no substituents.
- B can be with no further substituents.
- B is heteroaryl a .
- B can be heteroaryl a and Y can be attached to B at a carbon atom on the heteroaryl a ring.
- B can be heteroaryl a and Y can be attached to B at a carbon atom on the heteroaryl a ring, and the two ring atoms adjacent to the carbon atom on the heteroaryl a ring to which Y attaches are both carbon.
- B When B is heteroaryl a , B can be a 9 or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be a 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B can be a 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryl a .
- B is heteroaryl a
- B is preferably isoquinolinyl, optionally substituted as for heteroaryl a .
- B is preferably isoquinolinyl, wherein Y is attached to B at a carbon atom on the heteroaryl a ring, and the two ring atoms adjacent to the carbon atom on the heteroaryl a ring to which Y attaches are both carbon.
- B is preferably optionally substituted as for heteroaryl a .
- B is heteroaryl a
- B is preferably substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a .
- B is preferably substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a .
- B can be substituted with NH 2 at the 1- position and optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B When B is isoquinolinyl, B can be optionally further substituted with 1 or 2 substituents as for heteroaryl a .
- B is
- Y can be as defined above.
- Y is -N(R12)-.
- Y is -NH- or -N(CH3)-.
- Y is -N(R12)-.
- Y is -NH- or -N(CH3)-.
- Y is -NH- or -N(CH3)-.
- Y is -NH-.
- B is heteroaryl a and Y is -NH-.
- B is heteroaryl a substituted with NH 2 , and optionally substituted with 1 or 2 further substituents as for heteroaryl a ; and Y is -NH-.
- B is isoquinolinyl, optionally substituted as for heteroaryl a ; and Y is -NH-.
- B is and Y is -NH-.
- AW- can be as defined above.
- AW- can be selected from
- AW- can be selected from -(CH 2 )0-3-A, and -(CH2)0-3-0-(CH2)0-3-A.
- AW- can be selected from -(CH2)0-1-A, and -(CH2)0-1-O-A.
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A.
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and Y is -NH-.
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and B is heteroaryl a .
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a .
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and B is isoquinolinyl, optionally substituted as for heteroaryl a .
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and B is
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; B is heteroaryl a ; and Y is -NH-.
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ; and
- Y is -NH-.
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ; and
- Y is -NH-.
- AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; B is and Y is -NH-.
- the invention provides compounds of formula (I), wherein
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-.
- the invention provides compounds of formula (I) wherein the compound is a compound of formula (la) or formula (lb), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- R16 can be H.
- R16 and R17 can both be H.
- R16 and R17 are both H; and B is heteroaryl a .
- R16 and R17 are both H; and B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a .
- R16 and R17 are both H; and B is isoquinolinyl, optionally substituted as for heteroaryl a .
- R16 and R17 are both H; and B is
- R16 and R17 are both H; and Y is -NH-.
- R16 and R17 are both H; B is heteroaryl a ; and Y is -NH-.
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH 2 , and optionally substituted with 1 or 2 further substituents as for heteroaryl a ; and
- Y is -NH-.
- R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryl a ; and Y is - NH-.
- R16 and R17 are both H; B is ; and Y is -NH-.
- heterocycloalkyl b a 6- membered carbon-containing aromatic ring containing one or two N ring members substituted with one cycloalkyl substituent;
- R18 can be selected from:
- R18 can be selected from:
- R18 can be selected from:
- R18 can be selected from:
- R18 is selected from:
- R18 is selected from:
- the compound of the invention can be a compound of formula (la), wherein R18 is as described above, or a compound of formula (lb) and R23 is selected from
- B is and the compound of the invention is a compound formula (la), wherein
- B is heteroaryl a ;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with
- R19 can be selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22,
- R19 can be selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, and
- Heterocycloalkyl a can be a 4-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyl a may optionally be substituted with 1 or 2 substituents independently selected from alkyl, aryl, halo, and heterocycloalkyl; wherein when heterocycloalkyl a is a bicyclic ring system, the bicyclic ring system is spiro.
- Heterocycloalkyl a can be selected from:
- Heterocycloalkyl a can be selected from:
- Heterocycloalkyl b can be selected from:
- Heterocycloalkyl b can be selected from:
- Polycycloalkyl can be selected from:
- R22 can be a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
- R22 can be a fused 6,5- or 6,6- bicyclic ring containing a 6-membered aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
- R22 can be selected from:
- R22 is selected from:
- R20 and R21 together with the carbon atom to which they are attached can form a carbon-containing 3-, 4- or 6-membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H.
- R20 or R21 can be independently selected from H, (Ci-sjalkyl and CF3, wherein R20 and R21 are not both H.
- R20 or R21 can be independently selected from H, methyl and CF3, wherein R20 and R21 are not both H.
- R16 and R17 are both H; and R19 is selected from (CH 2 h-z-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
- Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O- phenyl, and (CH2)3-O-(CH2)-phenyl.
- B is heteroaryl a ; and R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ; and R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
- B is isoquinolinyl, optionally substituted as for heteroaryl a ; and R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- (CH2)1-2-cycloalkyl selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- B is heteroaryl a ;
- Y is -NH-; and
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1- polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- Y is -NH-; and
- R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- R16 and R17 are both H; B is heteroaryl a ; and R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryl a ; and R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 ) O.2 -R22, (C(R20)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and
- R16 and R17 are both selected from (CH 2 )1-2-cycloalkyl,
- R16 and R17 are both H; Y is -NH-; and R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R20)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- R16 and R17 are both H; B is heteroaryl a ; Y is -NH-; and R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R20)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- R16 and R17 are both H; B is heteroaryl a substituted with NH 2 , and optionally substituted with 1 or 2 further substituents as for heteroaryl a ; Y is -NH-; and R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R20)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl.
- R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryl a ; Y is -NH-; and R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 ) 0.2 -R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22,
- R16 and R17 are both selected from (CH 2 )I. 2 - cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22,
- R16 and R17 are both H;
- Y is -NH-;
- B is heteroaryl a ;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- B is heteroaryl a ;
- Y is -NH-;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- Y is -NH-;
- R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22,
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with
- Y is -NH-;
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-;
- AW- can be -(CH 2 )-O-A.
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-;
- AW- can be -(CH 2 )-O-A.
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-;
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-;
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-;
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-;
- A can be substituted, where possible, with 1, 2 or 3 substituents independently selected from alkyl and oxo.
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-;
- A can be selected from:
- R16 and R17 are both H;
- Y is -NH-;
- B is heteroaryl a ;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alk
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22,
- B is heteroaryl a ;
- Y is -NH-;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- Y is -NH-;
- R16 and R17 are both H;
- B is heteroaryl a ;
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH 2 , and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- R16 and R17 are both H;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH 2 , and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- R16 and R17 are both H;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo
- Y is -NH-;
- AW- is -(CH 2 )-O-A.
- B is heteroaryl a ;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo,
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1,
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl,
- B is heteroaryl a ;
- Y is -NH-;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- Y is -NH-;
- a JL 'h f if c ; or a compound of formula (lb) and R23 is C( O)(CH2)1-2cycloalkyl;
- AW- is -(CH 2 )-O-A.
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from hal
- AW- is -(CH 2 )-O-A.
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH 2 , and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optional
- R16 and R17 are both H;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with
- Y is -NH-;
- R16 and R17 are both H;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22,
- B is heteroaryl a ;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
- B is heteroaryl a substituted with NH 2 , and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl; and
- B is R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- B is heteroaryl a ;
- Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- B is heteroaryl a substituted with NH2, optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 )3-O-(CH 2 )-phenyl; and
- B is Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl,
- R16 and R17 are both H;
- B is heteroaryl a ;
- R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl;
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alk
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22,
- R16 and R17 are both H;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )O-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and
- R16 and R17 are both H; B is R19 is selected from (CH2)1-2-cycloalkyl,
- R16 and R17 are both H;
- Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1- polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH 2
- R16 and R17 are both H;
- B is heteroaryl a ;
- Y is -NH-;
- R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl; and
- A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, ox
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22,
- R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryl a ; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22,
- R16 and R17 are both H; B is ; Y is -NH-; R19 is selected from (CH 2 )1-2-cycloalkyl,
- R16 and R17 are both H;
- Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alk
- B is heteroaryl a ;
- (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 )3-O-(CH 2 )-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH 2 )0-2-heteroaryl, heterocycloalkyl, C( O)R12, C(
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 )3-O-(CH 2 )-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH 2 )0-2-heteroaryl, heterocycloalkyl, C( O)R12, C(
- B is heteroaryl a ;
- Y is -NH-;
- R19 is selected from
- (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 ) 3 -O-(CH 2 )-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH 2 )0-2-heteroaryl, heterocycloalkyl, C( O)
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- Y is -NH-;
- R19 is selected from (CH 2 )1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)
- B is Y is -NH-;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocyclo
- (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 )3-O-(CH 2 )-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH 2 )0-2-heteroaryl, heterocycloalkyl, C( O)R12, C(
- R16 and R17 are both H;
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with
- R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryl a ; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH2)1-2-heterocycloalkyl b , (CH2)0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 )3-
- the invention also provides compounds wherein A is A'; wherein
- V is -O-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -O-.
- the invention also provides compounds wherein A is A', wherein the compound is a compound of formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- A is A'
- the compound is a compound of formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- V is -O-
- Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or, V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -O-; wherein A is A'; R16 can be H.
- R16 and R17 can both be H.
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl. More preferably, A' is selected from:
- A' is selected from:
- A'W- can be -(CH 2 )0-3-A'.
- A'W- can be -(CH2)0-1-A'.
- A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- Y is -NH-;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is heteroaryl a ;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- A'W- can be -(CH 2 )0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is heteroaryl a ;
- Y is -NH-;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is isoquinolinyl, optionally substituted as for heteroaryl a ;
- Y is -NH-;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- B is Y is -NH-;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H; B is heteroaryl a ; A'W- can be -(CH 2 )0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryl a ; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H;
- B is A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H; B is heteroaryl a ; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5- membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H;
- B is heteroaryl a substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryl a ;
- Y is -NH-;
- A'W- can be -(CH2)0-1-A'; and
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryl a ; Y is -NH-; and A'W- can be -(CH 2 )0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- R16 and R17 are both H; B is Y is -NH-; A'W- can be -(CH 2 )0-1-A'; and A' is a 5- membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- the invention provides compounds of formula (I), selected from Table 1, Table 2, Table 3, Table 4, and Table 5, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
- the invention provides compounds of formula (I), selected from Table 1; Table 2; compounds 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92 of Table 3; compounds 93, 94, 95, 96, 97, 98, 99, and 101 of Table 4; and Table 5, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
- the present invention therefore provides the compounds below in Table 1, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore also provides stereoisomers of the compounds below in Table 1, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore provides the compounds below in Table 2, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore also provides stereoisomers of the compounds below in Table 2, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore provides the compounds below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore also provides stereoisomers of the compounds below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore provides compounds 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92 below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore also provides stereoisomers of compounds 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92 below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore provides the compounds below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore also provides stereoisomers of the compounds below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore provides compounds 93, 94, 95, 96, 97, 98, 99, and 101 below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore also provides stereoisomers of compounds 93, 94, 95, 96, 97, 98, 99, and 101 below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore provides the compounds below in Table 5, and pharmaceutically acceptable salts and/or solvates thereof.
- the present invention therefore also provides stereoisomers of the compounds below in Table 5, and pharmaceutically acceptable salts and/or solvates thereof.
- example compound 93 in Table 4 has a Q1 group: and a Q.2 group "OCH2". Therefore, the Qi group is attached to the
- the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 , 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 102, 103, 104, or 105, and pharmaceutically acceptable salts and/or solvates thereof.
- the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 , 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 102, or 103, and pharmaceutically acceptable salts and/or solvates thereof. More preferably, the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
- the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6,
- the compound of formula (I) is a compound selected from example numbers: 3, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 104, or 105, and pharmaceutically acceptable salts and/or solvates thereof.
- the compound of formula (I) is a compound selected from example numbers: 3, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 97, and pharmaceutically acceptable salts and/or solvates thereof.
- the compound of formula (I) is a compound selected from example numbers: 3, 15, 17, 30, 38, 43, 44, 45, 52, 57, 59, 60, 62, 65, 66, 69, 90, or 105, and pharmaceutically acceptable salts and/or solvates thereof.
- the compound of formula (I) is a compound selected from example numbers: 3, 15, 17, 30, 38, 43, 44, 45, 52, 57, 59, 60, 62, 65, 66, 69, or 90, and pharmaceutically acceptable salts and/or solvates thereof.
- the compound of formula (I) is a compound selected from example numbers 104 or 105, and pharmaceutically acceptable salts and/or solvates thereof.
- the compounds (or pharmaceutically acceptable salts and/or solvates thereof), and pharmaceutical compositions comprising the compounds (or pharmaceutically acceptable salts and/or solvates thereof) of the present invention are inhibitors of FXIIa. They are therefore useful in the treatment of disease conditions for which FXIIa is a causative factor. Accordingly, the present invention provides a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), or a pharmaceutical composition comprising a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), for use in medicine.
- the present invention also provides for the use of a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), or a pharmaceutical composition comprising the compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), in the manufacture of a medicament for the treatment or prevention of a disease or condition in which FXIIa activity is implicated.
- the present invention also provides a method of treatment of a disease or condition in which FXIIa activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), or a pharmaceutical composition comprising the compound of the invention (ora pharmaceutically acceptable salt and/or solvate thereof).
- FXIIa can mediate the conversion of plasma kallikrein from plasma prekallikrein. Plasma kallikrein can then cause the cleavage of high molecular weight kininogen to generate bradykinin, which is a potent inflammatory hormone. Inhibiting FXIIa has the potential to inhibit (or even prevent) plasma kallikrein production. Thus, the disease or condition in which FXIIa activity is implicated can be a bradykinin-mediated angioedema.
- the bradykinin-mediated angioedema can be non-hereditary.
- the non-hereditary bradykinin-mediated angioedema can be selected from non-hereditary angioedema with normal Cl Inhibitor (AE-nCl Inh), which can be environmental, hormonal, or drug-induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE or ace) inhibitor-induced angioedema; dipeptidyl peptidase-4 inhibitor-induced angioedema; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema).
- AE-nCl Inh normal Cl Inhibitor
- the bradykinin-mediated angioedema can be hereditary angioedema (HAE), which is angioedema caused by an inherited dysfunction/fault/mutation.
- HAE hereditary angioedema
- Types of HAE that can be treated with compounds according to the invention include HAE type 1, HAE type 2, and normal Cl inhibitor HAE (normal Cl Inh HAE).
- the disease or condition in which FXIIa activity is implicated can be selected from vascular hyperpermeability, stroke including ischemic stroke and haemorrhagic accidents; retinal edema; diabetic retinopathy; impaired visual acuity; DME; retinal vein occlusion; and AMD. These conditions can also be bradykinin-mediated.
- FXIIa can activate FXIa to cause a coagulation cascade. Thrombotic disorders are linked to this cascade. Thus, the disease or condition in which FXIIa activity is implicated can be a thrombotic disorder.
- the thrombotic disorder can be thrombosis; thromboembolism caused by increased propensity of medical devices that come into contact with blood to clot blood; prothrombotic conditions such as disseminated intravascular coagulation (DIC), Venous thromboembolism (VTE), cancer associated thrombosis, complications caused by mechanical and bioprosthetic heart valves, complications caused by catheters, complications caused by ECMO, complications caused by LVAD, complications caused by dialysis, complications caused by CPB, sickle cell disease, joint arthroplasty, thrombosis induced to tPA, Paget-Schroetter syndrome and Budd-Chari syndrome; atherosclerosis; COVID-19; acute respiratory distress syndrome (ARDS); idiopathic pulmonary fibrosis (IPF); rheumatoid arthritis (RA); and cold-induced urticarial autoinflammatory syndrome.
- DIC disseminated intravascular coagulation
- VTE Venous thromboembolism
- the compounds (or pharmaceutically acceptable salts and/or solvates thereof) and pharmaceutical compositions of the present invention can be coated on the surfaces of devices that come into contact with blood to mitigate the risk of the device causing thrombosis. For instance, they can lower the propensity these devices to clot blood and therefore cause thrombosis.
- devices that come into contact with blood include vascular grafts, stents, in dwelling catheters, external catheters, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.
- FXIIa is a causative factor
- neuroinflammation neuroinflammatory/neurodegenerative disorders such as MS (multiple sclerosis); other neurodegenerative diseases such as Alzheimer's disease, epilepsy and migraine; sepsis; bacterial sepsis; inflammation; vascular hyperpermeability; and anaphylaxis.
- Brown adipose tissue (BAT) thermogenic activity can be mediated by the kallikrein-kinin system, and impaired BAT activity is associated with obesity and insulin resistance.
- Inhibiting FXIIa has the potential to inhibit (or even prevent) BAT activity mediated by the kallikrein-kinin system.
- the compounds or pharmaceutically acceptable salts and/or solvates thereof) and pharmaceutical compositions of the invention can therefore treat disease conditions such as obesity and diabetes.
- Factor XII inhibition is further implicated in the treatment of disease conditions such as kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, and acute kidney injury.
- the compounds of the present invention may be administered in combination with other therapeutic agents.
- suitable combination therapies include any compound of the present invention (or a pharmaceutically acceptable salt and/or solvate thereof) combined with one or more agents selected from agents that inhibit platelet-derived growth factor (PDGF), endothelial growth factor (VEGF), integrin alpha5betal, steroids, other agents that inhibit FXIIa and other inhibitors of inflammation.
- therapeutic agents that may be combined with the compounds of the present invention include those disclosed in EP2281885A1 and by S. Patel in Retina, 2009 Jun;29(6 Suppl):S45-8.
- Suitable combination therapies include a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof) combined with one or more agents selected from agents that treat HAE (as defined generally herein), for example bradykinin B2 antagonists such icatibant (Firazyr®); plasma kallikrein inhibitors such as ecallantide (Kalbitor®), lanadelumab (Takhzyro®) and berotralstat (ORLADEYOTM); or Cl esterase inhibitor such as Cinryze® and Haegarda® and Berinert® and Ruconest®.
- agents that treat HAE as defined generally herein
- bradykinin B2 antagonists such as icatibant (Firazyr®); plasma kallikrein inhibitors such as ecallantide (Kalbitor®), lanadelumab (Takhzyro®) and berotralstat (ORLADEYOTM); or Cl esterase inhibitor such as Cinryze® and Haegarda® and Ber
- Suitable combination therapies include a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof) combined with one or more agents selected from agents that are antithrombotics (as outlined above), for example other Factor Xlla inhibitors, thrombin receptor antagonists, thrombin inhibitors, factor Vila inhibitors, factor Xa inhibitors, factor Xia inhibitors, factor IXa inhibitors, adenosine diphosphate antiplatelet agents (e.g., P2Y12 antagonists), fibrinogen receptor antagonists (e.g. to treat or prevent unstable angina or to prevent reocclusion after angioplasty and restenosis) and aspirin) and platelet aggregation inhibitors.
- agents that are antithrombotics as outlined above
- agents that are antithrombotics for example other Factor Xlla inhibitors, thrombin receptor antagonists, thrombin inhibitors, factor Vila inhibitors, factor Xa inhibitors, factor Xia inhibitors, factor IX
- the compounds of the present invention and said combination agents may exist in the same or different pharmaceutical compositions, and may be administered separately, sequentially or simultaneously.
- the compounds of the present invention can be administered in combination with laser treatment of the retina.
- the combination of laser therapy with intravitreal injection of an inhibitor of VEGF for the treatment of diabetic macular edema is known (Elman M, Aiello L, Beck R, et al. "Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema" Ophthalmology. 27 April 2010).
- alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy,
- alkyl b is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl b may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, CN, CF3, halo.
- alkyl or alkyl b groups include, but are not limited, to C1 - methyl, C2 - ethyl, C3 - propyl and C4-n-butyl, C3 - iso-propyl, C4 - sec-butyl, C4 - iso- butyl, C4 - tert-butyl and C 5 - neo-pentyl, optionally substituted as noted above.
- alkyl or “alkyl b” can be a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6), optionally substituted as noted above.
- alkyl or “alkyl b” can be a linear saturated hydrocarbon having up to 4 carbon atoms (C1-C4) or a branched saturated hydrocarbon of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above, which is herein called “small alkyl” or “small alkyl b ", respectively.
- alkyl or “alkyl b” can be defined as a “small alkyl” or “small alkyl b ".
- Aryl and "aryl b " are as defined above. Typically, “aryl” or “aryl b “ will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable aryl or aryl b groups include phenyl, biphenyl and naphthyl (each optionally substituted as stated above). Preferably “aryl” is selected from phenyl, substituted phenyl (wherein said substituents are selected from those stated above) and naphthyl. Most preferably “aryl” is selected from phenyl and substituted phenyl (wherein said substituents are selected from those stated above).
- cycloalkyl is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo.
- suitable monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, optionally substituted as noted above.
- cycloalkyl can be a monocyclic saturated hydrocarbon ring of between 3 and 5 carbon atoms, more specifically, between 3 and 4 carbon atoms, optionally substituted as noted above.
- alkoxy is -OCF3, a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted, where possible, with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro.
- alkoxy groups include, but are not limited to, C1 - methoxy, C2 - ethoxy, C3 - n-propoxy and C4 - n-butoxy for linear alkoxy, and C3 - iso-propoxy, and C4 - sec-butoxy and tert-butoxy for branched alkoxy, optionally substituted as noted above. More specifically, “alkoxy” can be linear groups of between 1 and 4 carbon atoms (C1-C4), more specifically, between 1 and 3 carbon atoms (C1- C3). More specifically, “alkoxy” can be branched groups of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above.
- alkoxy can be defined as above. Specifically, “alkoxy” is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro.
- alkoxy groups include, but are not limited to, C1 - methoxy, C2 - ethoxy, C3 - n-propoxy and C4 - n-butoxy for linear alkoxy, and C3 - iso-propoxy, and C4 - sec-butoxy and tert-butoxy for branched alkoxy, optionally substituted as noted above. More specifically, “alkoxy” can be linear groups of between 1 and 4 carbon atoms (C1-C4), more specifically, between 1 and 3 carbon atoms (C1- C3). More specifically, “alkoxy” can be branched groups of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above.
- Halo can be selected from Cl, F, Br and I. More specifically, halo can be selected from Cl and F.
- heteroaryl is a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3.
- heteroaryl can be selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine, optionally substituted as noted above.
- Heteroaryl a and “heteroaryl b” are as defined above. Typically, “heteroaryl a “ or “heteroaryl b” will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above.
- heteroaryl a or heteroaryl b groups include thienyl, furanyl, pyrrolyl, pyrazolyl, imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 5-azathianaphthenyl, indolizinyl, isoindolyl, indazolyl, benzothiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-napthyridinyl and phthalazinyl (optionally substituted as stated above).
- heteroaryl a or “heteroaryl b” can be a 9- or 10- membered bi-cyclic ring as defined, and optionally substituted as stated above.
- suitable 9- or 10- membered heteroaryl a or heteroaryl b groups include indolyl, benzimidazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 5-azathianaphthenyl, indolizinyl, isoindolyl, indazolyl, benzothiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-napthyridinyl and phthalazinyl.
- heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N, N(R12), S, and O; heterocycloalkyl may be optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo.
- heterocycloalkyl can be a non-aromatic carbon- containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N(R12), and O; heterocycloalkyl may be optionally substituted with 1 or 2 substituents independently selected from alkyl alkoxy, OH, CN, CF3, halo.
- polycycloalkyl is a bi- or tri-cyclic saturated hydrocarbon ring system of between 5 and 10 carbon atoms (C5-C10), wherein the bi- or tri-cyclic ring system is bridged or spiro.
- examples of such polycycloalkyls include, but are not limited to, adamantane, spiro[3.3]heptane, bicyclo[2.2.2]octane, bicyclo[2.2.1]heptane, and bicyclo[l.l.l]pentane.
- heterocycloalkyl a is a 3-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyl a may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, aryl, halo, OH, CN, CF3, and heterocycloalkyl; wherein when heterocycloalkyl a is a bicyclic ring system, the bicyclic ring system is spiro.
- heterocycloalkyl a can be morpholine, tetrahydrofuran, piperidine, 2-azaspiro[3.3]heptane, and 2-azaspiro[4.4]nonane optionally substituted as noted above. More specifically, “heterocycloalkyl a " can be a 4-10 membered non-aromatic carbon- containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O. More specifically, heterocycloalkyl a may optionally be substituted with 1 or 2 substituents independently selected from alkyl, aryl, halo, and heterocycloalkyl.
- heterocycloalkyl b can be tetrahydro-2H-pyran, tetrahydrofuran, or oxetane, optionally substituted as noted above.
- heterocycloalkyl b can be piperidine, wherein the point of attachment is not at the ring nitrogen.
- the attachment of Y to the rest of compound of formula (I) can be at any of the following ring atoms: refers to the point at which heterocycloalkyl b is attached to the rest of the compound of formula (I), it does not refer to the position of any optional substituents.
- Heterocycloalkyl b " can be substituted at a ring nitrogen.
- heterocycloalkyl b can be More specifically, "heterocycloalkyl b " is a
- heterocycloalkyl b may optionally be substituted with 1 or 2 substituents independently selected from alkyl, phenyl and oxo.
- O-linked such as in "O-linked hydrocarbon residue" means that the hydrocarbon residue is joined to the remainder of the molecule via an oxygen atom.
- Y is defined above, and does not encompass Yttrium.
- V is defined above, and does not encompass Vanadium.
- Salt means a physiologically or toxicologically tolerable salt and includes, when appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts.
- base addition salts including pharmaceutically acceptable base addition salts
- organic amines such as, diethylamine, A/-methyl- glucamine, diethanolamine or amino acids (e.g.
- acid addition salts include hydrochlorides, hydrobromides, sulfates, phosphates, acetates, citrates, lactates, tartrates, mesylates, succinates, oxalates, phosphates, esylates, tosylates, benzenesulfonates, naphthalenedisulphonates, maleates, adipates, fumarates, hippurates, camphorates, xinafoates, p-acetamidobenzoates, dihydroxybenzoates, hydroxynaphthoates, succinates, ascorbates, oleates, bisulfates, trifluoroacetates and the like.
- Hemisalts of acids and bases can also be formed, for example, hemisulfate and hemicalcium salts.
- Prodrug refers to a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of the invention. Suitable groups for forming prodrugs are described in 'The Practice of Medicinal Chemistry, 2 nd Ed. pp561-585 (2003) and in F. J. Leinweber, Drug Metab. Res., 1987, 18, 379.
- the compounds of the invention can exist in both unsolvated and solvated forms.
- the term 'solvate 1 is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
- the term 'hydrate' is employed when the solvent is water.
- compounds of the invention exist in one or more geometric, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and trans-forms, E- and Z-forms, R-, S- and meso- forms, keto-, and enol-forms.
- a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof.
- such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques).
- such isomers can be prepared by the application or adaptation of known methods (e.g. asymmetric synthesis).
- one stereoisomer can be present at a purity of >90% relative to the remaining stereoisomers, or more specifically at a purity of >95% relative to the remaining stereoisomers, or yet more specifically at a purity of >99% relative to the remaining stereoisomers.
- the compound can be >90% enantiomeric excess (ee), or more specifically >95% enantiomeric excess (ee), or yet more specifically, >99% ee.
- the compounds of the invention include compounds that differ only in the presence of one or more isotopically enriched atoms.
- compounds wherein hydrogen is replaced by deuterium or tritium, or wherein carbon is replaced by 13 C or 14 C are within the scope of the present invention.
- Such compounds are useful, for example, as analytical tools or probes in biological assays.
- deuterated analogues Methods for the preparation of deuterated analogues will be readily apparent to those skilled in the art. For example, methods may include the use of deuterated starting materials in the synthesis of the compounds described herein. Deuterated starting materials will be readily available to the skilled person, from standard commercial sources. Methods for making deuterated analogues and deuterated starting materials may also include deuterium exchange. For example, deuterium exchange may be achieved by mixing the compounds with D2O.
- references herein to "treatment” include references to curative, palliative and prophylactic treatment.
- treatment includes preventing the symptoms of the disease conditions for which FXIIa is a causative factor.
- the compounds of the invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
- excipient' is used herein to describe any ingredient other than the compound(s) of the invention which may impart either a functional (i.e., drug release rate controlling) and/or a non-functional (i.e., processing aid or diluent) characteristic to the formulations.
- the choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
- compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
- the compounds of the invention may be administered in a form suitable for injection into the ocular region of a patient, in particular, in a form suitable for intra-vitreal injection. It is envisaged that formulations suitable for such use will take the form of sterile solutions of a compound of the invention in a suitable aqueous vehicle. The compositions may be administered to the patient under the supervision of the attending physician.
- the compounds of the invention may also be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ.
- Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous.
- Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
- Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but not restricted to glucose, manitol, sorbitol, etc.), salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- excipients such as sugars (including but not restricted to glucose, manitol, sorbitol, etc.), salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
- Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
- degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides.
- parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
- solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
- the compounds of the invention may be administered orally.
- Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
- Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solids and liquids (including multiple phases or dispersed systems).
- Exemplary formulations suitable for oral administration include tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
- Liquid (including multiple phases and dispersed systems) formulations include emulsions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
- the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 2001, 11 (6), 981-986.
- the formulation of tablets is discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
- the total daily dose of the compounds of the invention is typically in the range 0.1 mg and 10,000 mg, or between 1 mg and 5000 mg, or between 10 mg and 1000 mg depending, of course, on the mode of administration.
- the total dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
- V is selected from -O- and -N(R23)-
- Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-;
- R19 is selected from (CH 2 )1-3-cycloalkyl, (CH 2 )0-3-polycycloalkyl, heterocycloalkyl a , (CH 2 )i- 3 -heterocycloalkyl b , (CH 2 )0-3-R22, (C(R2O)(R21))-(CH 2 ) o.3 -phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH 2 )i- 3 -O-(CH 2 )-phenyl;
- R20 and R21 are independently selected from H, alkyl and CF3, or R20 and R21 together with the carbon atom to which they are attached form a carbon-containing 3-, 4-, 5- or 6- membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H;
- R22 is a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6bicyclic ring is not aryl substituted with ethylenedioxy;
- Y is selected from -O- and -N(R12)-;
- B is selected from:
- AW- is selected from:
- V is -O-
- R8 is independently selected from H, alkyl, cycloalkyl, and heterocycloalkyl
- R12 is independently selected from H, alkyl, and cycloalkyl
- R13 and R14 are independently selected from H, alkyl b , aryl b and heteroaryl b or R13 and R14 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkyl b , alkoxy, OH, halo and CF3;
- R15 is selected from alkyl, halo, CF 3 , CN, OH, alkoxy, NR13R14, and CONR13R14;
- R16 and R17 are independently selected from H and small alkyl; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated analogues, and pharmaceutically acceptable salts and/or solvates thereof.
- V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH 2 - and -C(R16)(R17)-; or, V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-.
- a compound of formula (I) according to any of the preceding numbered embodiments, wherein the compound is a compound of formula (la) or formula (lb), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- a compound of formula (I) according to any of the preceding numbered embodiments, wherein the compound is a compound of formula (la), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
- 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one substituent selected from cycloalkyl and heterocycloalkyl b , and optionally one or two further substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF 3 ; and wherein R13 and R14 together with the nitrogen atom to which they are attached form a carbon- containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO 2 , and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkyl b , alkoxy, OH, halo and CF3.
- a compound according to any of the preceding numbered embodiments or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding numbered embodiments, or a compound of formula (lb) and R23 is C( O)R19.
- a compound according to numbered embodiment 15, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding numbered embodiments, or a compound of formula (lb) and R23 is C( O)(CH2)1-3Cycloalkyl.
- a compound according to numbered embodiment 16, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding numbered embodiments, or a compound of formula (lb) and R23 is C( O)(CH2)1-2cycloalkyl.
- R16 is H.
- R16 and R17 are both H.
- R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22,
- R19 is selected from (CH2)1-2-cycloalkyl, (CH 2 )0-1-polycycloalkyl, heterocycloalkyl a , (CH 2 )1-2-heterocycloalkyl b , (CH 2 )0-2-R22, (C(R2O)(R21))-(CH 2 )0-1-phenyl, (C(R20)(R21))-R22, and (CH 2 ) 3 -O-(CH 2 )-phenyl. 23.
- heterocycloalkyl a is a 4-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyl a may optionally be substituted with 1 or 2 substituents independently selected from alkyl, aryl, halo, and heterocycloalkyl; wherein when heterocycloalkyl a is a bicyclic ring system, the bicyclic ring system is spiro.
- heterocycloalkyl a is selected from:
- a compound according to any of numbered embodiments 1 to 22, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein heterocycloalkyl b is a 4-6 membered non-aromatic carbon-containing monocyclic ring system which may be saturated or, where possible, unsaturated with 1 or 2 double bonds; heterocycloalkyl b contains one or two ring members independently selected from N, N(C( O)CH3) and O; heterocycloalkyl b may optionally be substituted with 1 or 2 substituents independently selected from alkyl, phenyl and oxo; wherein the point of attachment of heterocycloalkyl b is not at a ring nitrogen.
- heterocycloalkyl b is a 4-6 membered non-aromatic carbon-containing monocycl
- R22 is a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
- R22 is a fused 6,5- or 6,6- bicyclic ring containing a 6-membered aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
- R20 and R21 together with the carbon atom to which they are attached form a carbon-containing 3-, 4- or 6-membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H.
- R20 or R21 are independently selected from H, (C1-3)alkyl and CF3, wherein R20 and R21 are not both H.
- a compound according to numbered embodiment 35 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
- R20 or R21 are independently selected from H, methyl and CF3, wherein R20 and R21 are not both H. 37.
- R18 can be selected from:
- R18 can be selected from:
- R18 is selected from:
- a compound according to numbered embodiment 39 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
- R18 is selected from:
- R18 is selected from:
- R18 is selected from:
- R18 is selected from:
- R18 is selected from:
- A is substituted, where possible, with 1, 2 or 3 substituents independently selected from alkyl and oxo.
- A is selected from: 50.
- V is -O-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
- V is selected from -CH 2 -C(R16)(R17)- and -C(R16)(R17)-, and Z is -O-.
- R16 is H.
- R16 and R17 are both H.
- A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
- A' is selected from
- A' is selected from: 58.
- AW- is selected from
- AW- is selected from -(CH 2 )0-3-A, and -(CH 2 )0-3-0-(CH 2 )0-3-A .
- AW- is selected from -(CH 2 )0-1-A, and -(CH 2 )0-1-0-A
- AW- is selected from -(CH 2 )0-1-A, and -(CH 2 )-O-A.
- AW- is -(CH 2 )0-1-O-A.
- 63 A compound according to numbered embodiment 62, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
- AW- is -(CH 2 )-O-A.
- A'W- is -(CH 2 )0-1-A'.
- Y is -N(R12)-.
- Y is -NH- or N(CH 3 ).
- Y is -NH-. 69.
- B is aryl; or B is a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B is phenyl substituted as for aryl; or B is a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B is phenyl substituted as for aryl; or B is a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryl a .
- B is phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B is a 6- membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B is phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B is a 6- membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryl a .
- B is phenyl optionally substituted as for aryl, or B is pyridyl or isoquinolinyl, optionally substituted as for heteroaryl a .
- B is unsubstituted; or wherein B is aryl, B is substituted with CN and optionally 1 or 2 further substituents as for aryl; or wherein B is heteroaryl a , B is substituted with alkyl, halo, OH, or NH2, and optionally 1 or 2 further substituents as for heteroaryl a .
- B is selected from optionally further substituted with 1 or 2 substituents as for heteroaryl a ; or each optionally further substituted with 1 or 2 substituents as for heteroaryl a ; with no substituents ; or with no further substituents.
- Y is attached to B at a carbon atom on the heteroaryl a ring, and the two ring atoms adjacent to the carbon atom on the heteroaryl a ring to which Y attaches are both carbon.
- a pharmaceutical composition comprising: a compound, or a pharmaceutically acceptable salt and/or solvate thereof, according to any of numbered embodiments 1 to 99, and at least one pharmaceutically acceptable excipient.
- the compounds of the present invention can be prepared according to the procedures of the following schemes and examples, using appropriate materials, and are further exemplified by the specific examples provided herein below. Moreover, by utilising the procedures described herein, one of ordinary skill in the art can readily prepare additional compounds that fall within the scope of the present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. Those skilled in the art will readily understand that known variations of the conditions, processes and order in which the synthetic steps are performed in the following preparative procedures can be used to prepare these compounds.
- the compounds and intermediates of the invention may be isolated in the form of their pharmaceutically acceptable salts, such as those described previously herein above.
- the interconversion between free form and salt form would be readily known to those skilled in the art.
- reactive functional groups e.g. hydroxy, amino, thio or carboxy
- Conventional protecting groups for example those described by T. W. Greene and P. G. M. Wuts in "Protective groups in organic chemistry” John Wiley and Sons, 4 th Edition, 2006, may be used.
- a common amino protecting group suitable for use herein is tert-butoxy carbonyl (boc), which is readily removed by treatment with an acid such as trifluoroacetic acid or hydrogen chloride in an organic solvent such as dichloromethane.
- the amino protecting group may be a benzyloxycarbonyl (Cbz or Z) group which can be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere or 9- fluorenylmethyloxycarbonyl (Fmoc) group which can be removed by solutions of secondary organic amines such as diethylamine or piperidine in an organic solvent.
- Carboxyl groups are typically protected as esters such as methyl, ethyl, benzyl or tert-butyl which can all be removed by hydrolysis in the presence of bases such as lithium or sodium hydroxide.
- Benzyl protecting groups can also be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere whilst tert-butyl groups can also be removed by trifluoroacetic acid. Alternatively, a trichloroethyl ester protecting group is removed with zinc in acetic acid.
- a common hydroxy protecting group suitable for use herein is a methyl ether, deprotection conditions comprise refluxing in 48% aqueous HBr, or by stirring with borane tribromide in an organic solvent such as DCM. Alternatively, where a hydroxy group is protected as a benzyl ether, deprotection conditions comprise hydrogenation with a palladium catalyst under a hydrogen atmosphere.
- Palladium catalysed cross coupling reactions to form carbon-carbon, carbon-nitrogen and carbon-oxygen bonds typically require a palladium catalyst and ligand capable of forming an in situ catalytically active LnPd (0) species.
- precatalysts have been identified that contain the desired ligand and a labile group capable of eliminating to rapidly generate the active L n Pd (0) catalyst species in the reaction mixture (see, for example http://dx.doi.org/10.1039/c2sc20903a, http://dx.doi.org/10.1002/ange.201207750, http://dx.doi.org/10.1021/jo500355k, http://dx.doi.org/10.1021/ol401208t, http://dx.doi.org/10.1021/acs.orglett.8b00325).
- the choice of catalyst and ligand or precatalyst can be determined by literature or catalyst screening, by the skilled person.
- a depiction including wedges or broken lines eg. or indicates that the structure encompasses purity of that relative or absolute configuration of at least 80% ee, preferably >90% ee.
- references to the use of a phase separator refer to columns fitted with a selectively permeable, optimized frit material that separates aqueous phase from an organic phase under gravity.
- Acidic mobile phases used a linear gradient of 5-95% 10 mM aq. NH 4 HCO 2 /MeCN and basic mobile phases used a linear gradient of 5-95% 10 mM aq. NI-UHCOa/MeCN.
- Samples were run over 3 minutes, using a flow rate of 2.2 mL/min, and a pressure range of 0-200 bar. Data was collected using a Waters 3100 Mass Detector with single high resolution quadrupole and photomultiplier detectors and High Performance ZsprayTM dual- orthoganal API sources for standard ESI, or multimode ESI/APCI/ESCi®.
- Flash chromatography was typically carried out over 'silica' (silica gel for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g. Merck silica gel 60)), and an applied pressure of nitrogen up to 10 p.s.i accelerated column elution.
- pre-prepared cartridges of silica gel were used, for example pre-packed SiliaSepTM columns from Silicycle or Sfar C18 D - Duo 100 A 30 pm columns from Biotage.
- Typical conditions included, for example, flow rate range of 18-200 mL/min, with an applied pressure range of 0-225 PSI. Hexanes, EtOAc, DCM, MeOH, were used as mobile phases for normal-phase chromatography purifications.
- MeOH, MeCN, lOmM Ammonium Formate pH 4 in H2O and lOmM Ammonium Bicarbonate pH 10 in H2O buffers were used as mobile phases for reverse-phase chromatography. It will be understood that alternative conditions (such as flow rate ranges, applied pressures, solvents and pH) may be used for flash chromatography in order to separate and purify compounds synthesised herein.
- pre HPLC refers to reverse phase preparative HPLC purifications.
- Typical instrumentation and conditions include, for example, Waters Fraction Lynx Prep-HPLC with MWD/DAD & MSD using
- lyophilisation or freeze drying
- the procedure of lyophilisation is generally well known in the art.
- the substance is taken up in water, if necessary, with the addition of a minimum amount of MeCN to aid dissolution, and frozen, typically by rapid cooling in a cold bath at -78 °C.
- the resulting frozen solid mixture is evaporated to dryness in vacuo.
- Concentrated refers to evaporation of solvent under reduced pressure using a rotary evaporator, heating where necessary.
- IUPAC chemical names were generated using automated software such as Dotmatics Studies Notebook or ChemDraw (PerkinElmer). Compounds produced by the methods below may be isolated in salt forms. However, compound naming used herein typically refers to the compound without any salt counter ion.
- example compounds described herein can be prepared using conventional synthetic methods for example, but not limited to, the routes outlined in the General Schemes below, using, for example, the General Methods below.
- a biaryl ring (1.0 eq) was dissolved in EtOH and subjected to hydrogenation in the H-Cube® at 70 °C, 50 bar, 1 mL/min using a 10% Pd/C CatCart, recirculating when necessary. The solvent was removed in vacuo to afford the product which was used without purification.
- GM4 Buchwald coupling A suspension of amine or alcohol (1.0 eq), aryl halide (1.1 eq) and a base such as CS2CO3, NaOtBu (2.0 eq) or LiHMDS (2.0 eq) in a degassed solvent such as THF or 1,4-dioxane was purged with N2 (g).
- a Buchwald palladium precatalyst, such as BrettPhos Pd G3, (0.11 eq) was added and the mixture degassed and purged with N2 (g) for 5 min. The reaction was heated in a sealed vial at rt - 60°C for 30 min - 3 days as required.
- the product was isolated and purified using one of the following methods: i) The reaction was quenched with AcOH (2.0 eq) and concentrated. The crude was purified by SCX, loading and washing with MeOH then eluting the product with NH3 in MeOH followed by purification by flash chromatography or prep HPLC. ii) The reaction was quenched with AcOH (2.0 eq), filtered through Celite®, washing with EtOAc and the filtrate concentrated. The crude product was purified by flash chromatography. iii) The reaction mixture was acidified with AcOH (2.0 eq) and stirred for 5 min, IM NH3 in MeOH was added and the reaction mixture was concentrated on to silica and purified by flash chromatography. iv) The reaction mixture was dry loaded on to silica and purified by flash chromatography. v) The reaction was concentrated, and the product taken forward to deprotection without purification.
- a mixture of boc protected amine (1.0 eq) in DCM was treated with TFA (10.0 eq) and stirred at rt for 2 h.
- the product was isolated and purified using one of the following methods: i) The mixture was passed directly through an SCX column and washed with MeOH. The product was eluted with a solution of 7M NH3 in MeOH and concentrated. The crude product was purified by flash chromatography or prep HPLC. ii) The mixture was concentrated and loaded onto a PL-HCO3 MP SPE cartridge eluting with a mixture of MeCN and MeOH (1:1 v/v, 3 x 2 mL). The crude product was purified by flash chromatography or prep HPLC.
- the product was isolated and purified using one of the following methods: i) The reaction mixture was concentrated. The resulting residue was suspended in MeOH (2 mL) and loaded onto SCX, which was flushed with MeOH. The product was eluted with a solution of 7M NH3 in MeOH. The solvent was concentrated and the product was purified by flash chromatography or prep HPLC. ii) The mixture was concentrated and loaded onto a PL-HCO3 MP SPE cartridge eluting with a mixture of MeCN and MeOH (1:1 v/v, 3 x 2 mL). The crude product was purified by flash chromatography or prep HPLC.
- Part 1 A mixture of amine (1.6 eq) in anhydrous THF was added to a mixture of triphosgene (0.65 eq) and pyridine (2.2 eq) in anhydrous THF at rt. The mixture was stirred for 18-72 h.
- Alcohols such as la are typically reacted to form a suitable leaving group, such as halide or mesylate and can be generated using conditions well known in the art such as, for example; chlorination via a mesylate, bromination with PBr3, or bromination with CBr 4 and PPh3, using a suitable solvent such as DCM, THF or CCL (General Method 1), to give compound 2a.
- a suitable solvent such as DCM, THF or CCL (General Method 1)
- Compound 2a is subsequently reacted with an alcohol or amine 3 under typical alkylation conditions (General Method 2, eg KCtBu or NaH in DMF or CS2CO3 or K2CO3 in MeCN or DMSO, with heating as necessary).
- the nitrile 4 can be reduced to amine 5a under a variety of standard literature conditions well known in the art (General Method 3); for example under hydrogenation in the presence of Raney Ni, alternatively hydrogenation in the presence of Pd/C, or alternatively with NiCL and sodium borohydride (NaBH4) in the presence of BOC2O, or alternatively with borane.
- the amine 5a is reacted with aryl bromide or chloride 6 under Buchwald coupling conditions (General Method 4).
- This Buchwald coupling is carried out for example using a Buchwald pre catalyst, such as BrettPhos Pd G3, BrettPhos Pd G4 or Pd-PEPPSI-lpent, in the presence of a base such a sodium tert- butoxide, CS2CO3, or lithium hexamethyldisilazide (LiHMDS), in a solvent such as 1,4-dioxane or THF.
- a base such as sodium tert- butoxide, CS2CO3, or lithium hexamethyldisilazide (LiHMDS)
- LiHMDS lithium hexamethyldisilazide
- the aryl bromide or chloride 6 can be prepared from readily available starting materials using methods known in the art, or as described herein.
- a deprotection step (detailed below) may be required to obtain the example compound.
- the amine is protected, for example with a tert-butoxy carbamate protecting group, using standard conditions such as TEA and BOC2O in DCM or THF.
- a tert-butoxy carbamate protecting group is removed from compound 8a using standard conditions such as TFA, or HCI in 1,4-dioxane (General Method 5).
- Buchwald coupling completes the route.
- a protected alcohol is in the form of an ester such as Id.
- the ester 8b is reduced using standard conditions such as LiAIH4 (General Method 3) to reveal the alcohol.
- Buchwald coupling (General Method 4) of alcohol 5b completes the route. This typically requires an elevated temperature, for example 90 °C or above and in some cases alternative catalysts, such as RockPhos Pd G3, are more suitable.
- the alcohol such as Id can undergo a Buchwald (General Method 4), followed by reduction of the ester, formation of a leaving group (General Method 1) and finally alkylation with compound 3 (General Method 2).
- RgA contains a bicyclic aromatic
- it can be partially saturated during the synthesis, as shown in General Scheme 6.
- the aromatic ring such as 12 is subjected to hydrogenation at elevated temperature (General Method 3) using H2, 10% Pd/C to give compound 13. This transformation can take place on the free or protected amine.
- a protecting group strategy may be required.
- Alternative protecting groups can be used with different deprotection conditions, that is, an orthogonal protecting group strategy can be applied.
- General Schemes 7-12 outline possible protecting group strategies that may be used for the synthesis of the examples.
- a protected amine can be installed.
- the pyridone 14 may be chlorinated, typically using phosphorous oxychloride (General method 6).
- the resulting chloride 15 may be reacted with 2,4- dimethoxybenzylamine using General Method 7, for example using basic conditions such as K2CO3, CS2CO3, or pyridine in a solvent such as NMP or MeCN, either thermally and/or under microwave conditions.
- RgT refers to various substituents as required by the example compounds.
- the 2,4-dimethoxybenzyl protecting group is removed using TFA at 50 °C, either undiluted or diluted in DCM (General Scheme 8, General Method 8).
- RgT, RjA and RjB refer to various substituents as required by the examples.
- a carbamate protecting group can be used.
- the amine is reacted with methyl chloroformate under basic conditions with organic bases such as TEA or DIPEA in a solvent such as DCM to afford the methyl carbamate 21 (General Method 9).
- RjC refers to various substituents as required by the examples.
- the methyl carbamate protecting group is deprotected using basic conditions, such as KOH or LiOH in solvents such as 1,4-dioxane, MeCN, THF and optionally 10% water, at elevated temperature, typically 50 °C (General Scheme 10, General Method 10).
- basic conditions such as KOH or LiOH in solvents such as 1,4-dioxane, MeCN, THF and optionally 10% water, at elevated temperature, typically 50 °C (General Scheme 10, General Method 10).
- RjC and RjD refer to various substituents as required by the examples.
- Another protecting group that may be used where example compounds described herein contain a 6,6 ring system is boc.
- example compounds described herein contain a 5,6 ring system
- SEM, boc and sulfonyl protecting groups may typically be used.
- Protecting groups may subsequently be deprotected using standard literature procedures, for example those described by T. W. Greene and P. G. M. Wuts in "Protective groups in organic chemistry” John Wiley and Sons, 4 th Edition, 2006.
- RgA contains an aromatic or heteroaromatic bicycle they can be synthesised using procedures described in the literature and, for example, as depicted in General Scheme 13.
- Amino pyridines such as 3a can be reacted with chloromethyl aldehydes and ketones 28 by refluxing in a solvent such as ethanol (General Method 12).
- Hydroxylation of the aryl bromide 3b to the corresponding aryl alcohol 3c is typically completed in a one-pot tandem process via Miyaura borylation (Palladium(O)- Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters. T. Ishiyama, M. Murata, N. Miyaura, J. Org. Chem., 1995, 60, 7508-7510) and subsequent hydroxylation using hydrogen peroxide (General Method 13).
- azabicyclohexyl rings When azabicyclohexyl rings are used they may be protected with a suitable nitrogen protecting group such as Boc or Cbz (General Scheme 15). Alternatively, the nitrogen can be reacted using methods generally known in the art and detailed herein below, to provide amide, urea, thiourea, alkyl, heteroaryl and sulfonamide analogues as shown in General Schemes 15 and 17.
- a suitable nitrogen protecting group such as Boc or Cbz
- RgA can be installed by transforming the alcohol Id to a leaving group, such as a mesylate or halide 7b and reacting with aryl alcohols (General Method 2).
- the alcohol Id can be directly reacted with phenols under Mitsunobu conditions (General Method 15) using standard conditions such as DIAD and triphenylphosphine in THF.
- the alcohol Id can also be coupled with aryl halides under SNAr in the presence of NaH (General Method 7a), or under Buchwald conditions (General Method 4), typically using RockPhos Pd G3 as the catalyst and elevating the temperature to 100 °C.
- the ester 8b is then reduced to alcohol 5c under conditions well known in the art such as lithium borohydride (LiBH4) or lithium aluminium hydride (LiAIH4) or lithium triethylborohydride (LiEt3BH) (General Method 3b) depending on other functionality contained in the compound.
- Oxidation to aldehyde 5d is typically achieved using a reagent such as Dess Martin periodinane (General Method 16).
- reductive amination (General Method 17) with amine 6a completes the route.
- the alcohol 5c can be transformed to an amine using methods generally known in the art, such as via conversion to a leaving group (General Method 1) then via an azide or Gabriel synthesis to provide the primary amine and finally completing the route via a Buchwald coupling (General Method 4) as shown previously in General Scheme
- the nitrogen protecting group is removed using the appropriate conditions (for example boc deprotection via General Method 5, or Cbz deprotection via General Method 3e, 2,4-dimethoxybenzyl deprotection via General Method 8, or SEM deprotection via General Method 11).
- Manipulation of 7c using chemistry well known in the art can provide a variety of compound classes. For example, reductive alkylation with aldehydes (General Method 17) can give alkylated compounds such as 29a.
- Nl-(2,4-Dimethoxybenzyl)isoquinoline-l,5-diamine A mixture of 5-bromo-N-(2,4-dimethoxybenzyl)isoquinolin-l-amine (746 mg, 2.0 mmol), 2,2,2- trifluoroacetamide (339 mg, 3.0 mmol), Cul2 (38 mg, 0.2 mmol), K2CO3 (553 mg, 4.0 mmol) and N,N'- dimethylethylenediamine (35 mg, 0.4 mmol) were combined in a reaction vial. Anhydrous 1,4-dioxane (7 mL) was added, and the suspension purged with N2, before being capped and then heated to 75 °C for 24 h.
- the reaction was recharged with 2,2,2-trifluoroacetamide (339 mg, 3.0 mmol), Cul2 (38 mg, 0.2 mmol), K2CO3 (553 mg, 4.0 mmol) and N,N'-dimethylethylenediamine (35 mg, 0.4 mmol).
- the mixture was degassed with N2 and heated at 70 °C for 18 h. Water was added (3 mL) and the reaction heated at 80 °C for 6 h. The mixture was partitioned between EtOAc (30 mL) and water (10 mL).
- 6-bromo-3-rnethylirnidazo[l,2-a]pyridine 525 mg, 2.49 mmol was reacted with B2Pin2 (1.42 g, 5.6 mmol)at 100 °C for 5 h.
- the mixture was cooled to rt before AcOH (285 ⁇ L, 4.97 mmol) and water (1 mL) were added.
- the mixture was stirred for 15 min before a solution of H2O2 in water (30% w/w, 508 ⁇ L, 4.97 mmol) was added dropwise at 0 °C.
- the product was prepared from 4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-l-carboxylic acid (CAS 1522098-73-2, Tetrahedron Letters 55 (2014) 466-468) following the procedure described in ChemistrySelect 2019, 4, 4933 - 493.
Abstract
The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, Y and B are as defined herein.
Description
2-AZA- AND 2-OXABICYCLO[2.1.1]HEXANE DERIVATIVES AS FACTOR XIIA ENZYME INHIBITORS
This invention relates to enzyme inhibitors that are inhibitors of Factor XI la (FXIIa), and to pharmaceutical compositions comprising, and uses of, such inhibitors.
Background to the invention
The compounds of the present invention are inhibitors of factor Xlla (FXIIa) and thus have a number of possible therapeutic applications, particularly in the treatment of diseases or conditions in which factor Xlla inhibition is implicated.
FXIIa is a serine protease (EC 3.4.21.38) derived from its zymogen precursor, factor XII (FXII), which is expressed by the F12 gene. Single chain FXII has a low level of amidolytic activity that is increased upon interaction with negatively charged surfaces and has been implicated in its activation (see Invanov et al., Blood. 2017 Mar 16;129(11):1527-1537. doi: 10.1182/blood-2016-10-744110). Proteolytic cleavage of FXII to heavy and light chains of FXIIa dramatically increases catalytic activity. FXIIa that retains its full heavy chain is aFXIIa. FXIIa that retains a small fragment of its heavy chain is PFXIIa. The separate catalytic activities of aFXIIa and PFXIIa contribute to the activation and biochemical functions of FXIIa. Mutations and polymorphisms in the F12 gene can alter the cleavage of FXII and FXIIa.
FXIIa has a unique and specific structure that is different from many other serine proteases. For instance, the Tyr99 in FXIIa points towards the active site, partially blocking the S2 pocket and giving it a closed characteristic. Other serine proteases containing a Tyr99 residue (e.g. FXa, tPA and FIXa) have a more open S2 pocket. Moreover, in several trypsin-like serine proteases the P4 pocket is lined by an "aromatic box" which is responsible for the P4-driven activity and selectivity of the corresponding inhibitors. However, FXIIa has an incomplete "aromatic box" resulting in more open P4 pocket. See e.g. "Crystal structures of the recombinant ^-factor Xlla protease with bound Thr-Arg and Pro-Arg substrate mimetics" M. Pathak et al., Acta. Cryst.2019, D75, 1-14; "Structures of human plasma ^-factor Xlla cocrystallized with potent inhibitors" A Dementiev et al., Blood Advances 2018, 2(5), 549-558; "Design of Small-Molecule Active-Site Inhibitors of theSlA Family Proteases as Procoagulant and Anticoagulant Drugs" P. M. Fischer, J. Med. Chem., 2018, 61(9), 3799-3822; "Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation" B. K. Hamad et al. Journal of Thrombosis and Haemostasis, 15: 1818-1828.
FXIIa converts plasma prekallikrein (PK) to plasma kallikrein (PKa), which provides positive feedback activation of FXII to FXIIa. FXII, PK, and high molecular weight kininogen (HK) together represent the contact system. FXIIa mediated conversion of plasma prekallikrein to plasma kallikrein can cause subsequent cleavage of HKto generate bradykinin, a potent inflammatory hormone that can also increase vascular permeability, which has been implicated in disorders such as hereditary angioedema (HAE). The contact system is activated via a number of mechanisms, including interactions with negatively charged surfaces, negatively charged molecules, unfolded proteins, artificial surfaces, foreign tissue (e.g. biological transplants, that include bio-prosthetic heart valves, and organ/tissue transplants), bacteria, and biological surfaces (including endothelium and extracellular matrix) that mediate assembly of contact system components. In addition, the contact system is activated by plasmin, and cleavage of FXII by other enzymes can facilitate its activation.
Activation of the contact system leads to activation of the kallikrein kinin system (KKS), complement system, and intrinsic coagulation pathway (see https://www.genome.jp/kegg- bin/show_pathway?map04610). In addition, FXIIa has additional substrates both directly, and indirectly via PKa, including Proteinase-activated receptors (PARs), plasminogen, and neuropeptide Y (NPY) which can contribute to the biological activity of FXIIa. Inhibition of FXIIa could provide clinical benefits by treating diseases and conditions associated with these systems, pathways, receptors, and hormones.
PKa activation of PAR2 mediates neuroinflammation and may contribute to neuroinflammatory disorders including multiple sclerosis (see Gbbel et al., Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):271-276. doi: 10.1073/pnas.1810020116). PKa activation of PARI and PAR2 on vascular smooth muscle cells has been implicated in vascular hypertrophy and atherosclerosis (see Abdallah et al., J Biol Chem. 2010 Nov 5;285(45):35206-15. doi: 10.1074/jbc.M110.171769). FXIIa activation of plasminogen to plasmin contributes to fibrinolysis (see Konings et al., Thromb Res. 2015 Aug;136(2):474-80. doi: 10.1016/j.thromres.2015.06.028). PKa proteolytically cleaves NPY and thereby alters its binding to NPY receptors (Abid et al., J Biol Chem. 2009 Sep ll;284(37):24715-24. doi: 10.1074/jbc.M109.035253). Inhibition of FXIIa could provide clinical benefits by treating diseases and conditions caused by PAR signaling, NPY metabolism, and plasminogen activation.
FXIIa-mediated activation of the KKS results in the production of bradykinin (BK), which can mediate, for example, angioedema, pain, inflammation, vascular hyperpermeability, and vasodilatation (see Kaplan et al., Adv Immunol. 2014;121:41-89. doi: 10.1016/B978-0-12-800100-4.00002-7; and Hopp et al., J Neuroinflammation. 2017 Feb 20;14(1):39. doi: 10.1186/sl2974-017-0815-8). Garadacimab (CSL-312), a monoclonal antibody inhibitory against FXIIa, recently completed a phase 3 study where monthly
prophylactic subcutaneous treatment was reported to reduce attacks in patients with type l/ll hereditary angioedema (HAE), which results in intermittent swelling of face, hands, throat, gastro-intestinal tract and genitals (see https://www.clinicaltrials.gov/ct2/show/NCT04656418 and Craig et al., The Lancet. 2023;401(10382):1079-1090. doi: 10.1016/50140-6736(23)00350-1). Mutations in FXII that facilitate its activation to FXIIa have been identified as a cause of HAE (see Bjbrkqvist et al., J Clin Invest. 2015 Aug 3;125(8):3132-46. doi: 10.1172/JCI77139; and de Maat et al., J Allergy Clin Immunol. 2016 Nov;138(5):1414-1423.e9. doi: 10.1016/j.jaci.2016.02.021). Since FXIIa mediates the generation of PK to PKa, inhibitors of FXIIa could provide protective effects of all form of BK-mediated angioedema, including HAE and non-hereditary bradykinin-mediated angioedema (BK-AEnH).
"Hereditary angioedema" can be defined as any disorder characterised by recurrent episodes of bradykinin-mediated angioedema (e.g. severe swelling) caused by an inherited genetic dysfunction/fault/mutation. There are currently three known categories of HAE: (i) HAE type 1, (ii) HAE type 2, and (iii) normal Cl inhibitor HAE (normal Cl-lnh HAE). However, work on characterizing the etiologies of HAE is ongoing so it is expected that further types of HAE might be defined in the future.
Without wishing to be bound by theory, it is thought that HAE type 1 is caused by mutations in the SERPING1 gene that lead to reduced levels of Cl inhibitor in the blood. Without wishing to be bound by theory, it is thought that HAE type 2 is caused by mutations in the SERPING1 gene that lead to dysfunction of the Cl inhibitor in the blood. Without wishing to be bound by theory, the cause of normal Cl-lnh HAE is less well defined and the underlying genetic dysfunction/fault/mutation can sometimes remain unknown. What is known is that the cause of normal Cl-lnh HAE is not related to reduced levels or dysfunction of the Cl inhibitor (in contrast to HAE types 1 and 2). Normal Cl-lnh HAE can be diagnosed by reviewing the family history and noting that angioedema has been inherited from a previous generation (and thus it is hereditary angioedema). Normal Cl-lnh HAE can also be diagnosed by determining that there is a dysfunction/fault/mutation in a gene other than those related to Cl inhibitor. For example, it has been reported that dysfunction/fault/mutation with plasminogen can cause normal Cl-lnh HAE (see e.g. Veronez et al., Front Med (Lausanne). 2019 Feb 21;6:28. doi: 10.3389/fmed.2019.00028; or Recke et al., Clin Transl Allergy. 2019 Feb 14;9:9. doi: 10.1186/sl3601-019- 0247-x.). It has also been reported that dysfunction/fault/mutation with Factor XII can cause normal Cl- lnh HAE (see e.g. Mansi et al. 2014 The Association for the Publication of the Journal of Internal Medicine Journal of Internal Medicine, 2015, 277; 585-593; or Maat et al. J Thromb Haemost. 2019 Jan;17(1):183- 194. doi: 10.1111/jth.14325).
However, angioedemas are not necessarily inherited. Indeed, another class of angioedema is bradykinin mediated angioedema non-hereditary (BK-AEnH), which is not caused by an inherited genetic dysfunction/fault/mutation. Often the underlying cause of BK-AEnH is unknown and/or undefined. However, the signs and symptoms of BK-AEnH are similar to those of HAE, which, without being bound by theory, is thought to be on account of the shared bradykinin mediated pathway between HAE and BK-AEnH. Specifically, BK-AEnH is characterised by recurrent acute attacks where fluids accumulate outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues such as in the hands, feet, limbs, face, intestinal tract, airway or genitals.
Specific types of BK-AEnH include: non hereditary angioedema with normal Cl Inhibitor (AE-nCl Inh), which can be environmental, hormonal, or drug induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE) inhibitor induced angioedema; dipeptidyl peptidase 4 inhibitor induced angioedema; and tPA induced angioedema (tissue plasminogen activator induced angioedema). However, reasons why these factors and conditions cause angioedema in only a relatively small proportion of individuals are unknown.
Environmental factors that can induce AE-nCl Inh include air pollution (Kedarisetty et al, Otolaryngol Head Neck Surg. 2019 Apr 30:194599819846446. doi: 10.1177/0194599819846446) and silver nanoparticles such as those used as antibacterial components in healthcare, biomedical and consumer products (Long et al., Nanotoxicology. 2016;10(4):501-ll. doi: 10.3109/17435390.2015.1088589).
Various publications suggest a link between the bradykinin and contact system pathways and BK-AEnHs, and also the potential efficacy of treatments, see e.g.: Bas et al. (N Engl J Med 2015; Leibfried and Kovary. J Pharm Pract 2017); van den Elzen et al. (Clinic Rev Allerg Immunol 2018); Han et al (JCI 2002).
For instance, BK-medicated AE can be caused by thrombolytic therapy. For example, tPA induced angioedema is discussed in various publications as being a potentially life threatening complication following thrombolytic therapy in acute stroke victims (see e.g. Simao et al., Blood. 2017 Apr 20;129(16):2280-2290. doi: 10.1182/blood-2016-09-740670; Frohlich et al., Stroke. 2019 Jun 11:STROKEAHA119025260. doi: 10.1161/STROKEAHA.119.025260; Rathbun, Oxf Med Case Reports. 2019 Jan 24;2019(1):omyll2. doi: 10.1093/omcr/omyll2; Lekoubou et al., Neurol Res. 2014 Jul;36(7):687-94. doi: 10.1179/1743132813Y.0000000302; Hill et al., Neurology. 2003 May 13;60(9):1525-7).
Stone et al. (Immunol Allergy Clin North Am. 2017 Aug;37(3):483-495.) reports that certain drugs can cause angioedema.
Scott et al. (Curr Diabetes Rev. 2018;14(4):327-333. doi: 10.2174/1573399813666170214113856) reports cases of dipeptidyl Peptidase-4 Inhibitor induced angioedema.
Hermanrud et al., (BMJ Case Rep. 2017 Jan 10;2017. pii: bcr2016217802) reports recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV and also discusses acquired angioedema related to angiotensin-converting enzyme inhibitors (ACEI-AAE). Kim et al. (Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):115-122. doi: 10.1111/bcpt.l3097) reports angiotensin II receptor blocker (ARB)-related angioedema. Reichman et al., (Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1190- 1196. doi: 10.1002/pds.4260) also reports angioedema risk for patients taking ACE inhibitors, ARB inhibitors and beta blockers. Diestro et al. (J Stroke Cerebrovasc Dis. 2019 May;28(5):e44-e45. doi: 10.1016/j.jstrokecerebrovasdis.2019.01.030) also reports a possible association between certain angioedemas and ARBs.
Giard et al. (Dermatology. 2012;225(1):62-9. doi: 10.1159/000340029) reports that bradykinin mediated angioedema can be precipitated by estrogen contraception, so called "oestrogen associated angioedema".
Contact system mediated activation of the KKS has also been implicated in retinal edema and diabetic retinopathy (see Liu et al., Biol Chem. 2013 Mar;394(3):319-28. doi: 10.1515/hsz-2012-0316). FXIIa concentrations are increased in the vitreous fluid from patients with advance diabetic retinopathy and in Diabetic Macular Edema (DME) (see Gao et al., Nat Med. 2007 Feb;13(2):181-8. Epub 2007 Jan 28 and Gao et al., J Proteome Res. 2008 Jun;7(6):2516-25. doi: 10.1021/pr800112g). FXIIa has been implicated in mediating both vascular endothelial growth factor (VEGF) independent DME (see Kita et al., Diabetes. 2015 Oct;64(10):3588-99. doi: 10.2337/dbl5-0317) and VEGF mediated DME (see Clermont et al., Invest Ophthalmol Vis Sci. 2016 May l;57(6):2390-9. doi: 10.1167/iovs.15-18272). FXII deficiency is protective against VEGF induced retinal edema in mice (Clermont et al., ARVO talk 2019). Therefore, it has been proposed that FXIIa inhibition will provide therapeutic effects for diabetic retinopathy and retinal edema caused by retinal vascular hyperpermeability, including DME, retinal vein occlusion, age-related macular degeneration (AMD).
As noted above, the contact system can be activated by interaction with bacteria, and therefore FXIIa has been implicated in the treatment of sepsis and bacterial sepsis (see Morrison et al., J Exp Med. 1974 Sep l;140(3):797-811). Therefore, FXIIa inhibitors could provide therapeutic benefits in treating sepsis, bacterial sepsis and disseminated intravascular coagulation (DIC).
FXIIa mediated activation of the KKS and production of BK have been implicated in neurodegenerative diseases including Alzheimer's disease, multiple sclerosis, epilepsy and migraine (see Zamolodchikov et al., Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):4068-73. doi: 10.1073/pnas.l423764112; Simoes et al., J Neurochem. 2019 Aug;150(3):296-311. doi: 10.1111/jnc.14793; Gobel et al., Nat Commun. 2016 May 18;7:11626. doi: 10.1038/ncommsll626; and https://clinicaltrials.gov/ct2/show/NCT03108469). Therefore, FXIIa inhibitors could provide therapeutic benefits in reducing the progression and clinical symptoms of these neurodegenerative diseases.
FXIIa has also been implicated in anaphylaxis (see Bender et al., Front Immunol. 2017 Sep 15;8:1115. doi: 10.3389/fimmu.2017.01115; and Sala-Cunill et al., J Allergy Clin Immunol. 2015 Apr;135(4):1031-43.e6. doi: 10.1016/j.jaci.2014.07.057). Therefore, FXIIa inhibitors could provide therapeutic benefits in reducing the clinical severity and incidence of anaphylactic reactions.
The role of FXIIa in coagulation was identified over 50 years ago, and has been extensively documented in publications using biochemical, pharmacological, genetic and molecular studies (see Davie et al., Science. 1964 Sep 18;145(3638):1310-2). FXIIa mediated activation of factor XI (FXI) triggers the intrinsic coagulation pathway. In addition, FXIIa can increase coagulation in a FXI independent manner (see Radcliffe et al., Blood. 1977 Oct;50(4):611-7; and Puy et al., J Thromb Haemost. 2013 Jul;ll(7):1341-52. doi: 10.1111/jth.12295). Studies on both humans and experimental animal models have demonstrated that FXII deficiency prolongs activated partial prothrombin time (APTT) without adversely affecting hemostasis (see Renne et al., J Exp Med. 2005 Jul 18;202(2):271-81; and Simao et al., Front Med (Lausanne). 2017 Jul 31;4:121. doi: 10.3389/fmed.2017.00121). Pharmacological inhibition of FXIIa also prolongs APTT without increasing bleeding (see Worm et al., Ann Transl Med. 2015 Oct;3(17):247. doi: 10.3978/j.issn.2305-5839.2015.09.07). These data suggest that inhibition of FXIIa could provide therapeutic effects against thrombosis without inhibiting bleeding. Therefore, FXIIa inhibitors could be used to treat a spectrum of prothrombotic conditions including venous thromboembolism (VTE); cancer associated thrombosis; complications caused by mechanical and bioprosthetic heart valves, catheters, extracorporeal membrane oxygenation (ECMO), left ventricular assisted devices (LVAD), dialysis, cardiopulmonary bypass (CPB); sickle cell disease, joint arthroplasty, thrombosis induced by tPA, Paget-Schroetter syndrome and Budd-Chari syndrome. FXIIa inhibitor could be used for the treatment and/or prevention of thrombosis, edema, and inflammation associated with these conditions.
Surfaces of medical devices that come into contact with blood can cause thrombosis. FXIIa inhibitors may also be useful for treating or preventing thromboembolism by lowering the propensity of devices that
come into contact with blood to clot blood. Examples of devices that come into contact with blood include vascular grafts, stents, in-dwelling catheters, external catheters, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.
Preclinical studies have shown that FXIIa has been shown to contribute to stroke and its complications following both ischemic stroke, and hemorrhagic accidents (see Barbieri et al., J Pharmacol Exp Ther. 2017 Mar;360(3):466-475. doi: 10.1124/jpet.ll6.238493; Krupka et al., PLoS One. 2016 Jan 27;ll(1):e0146783. doi: 10.1371/journal.pone.0146783; Leung et al., Transl Stroke Res. 2012 Sep;3(3):381-9. doi: 10.1007/S12975-012-0186-5; Simao et al., Blood. 2017 Apr 20;129(16):2280-2290. doi: 10.1182/blood- 2016-09-740670; and Liu et al., Nat Med. 2011 Feb;17(2):206-10. doi: 10.1038/nm.2295). Therefore, FXIIa inhibition may improve clinical neurological outcomes in the treatment of patients with stroke.
FXII deficiency has been shown to reduce the formation of atherosclerotic lesions in Apoe_/_ mice (Didiasova et al., Cell Signal. 2018 Nov;51:257-265. doi: 10.1016/j.cellsig.2018.08.006). Therefore, FXIIa inhibitors could be used in the treatment of atherosclerosis.
FXIIa, either directly, or indirectly via PKa, has been shown to activate the complement system (Ghebrehiwet et al., Immunol Rev. 2016 Nov;274(1):281-289. doi: 10.1111/imr.l2469). BK increases complement C3 in the retina, and an in vitreous increase in complement C3 is associated with DME (Murugesan et al., Exp Eye Res. 2019 Jul 24;186:107744. doi: 10.1016/j.exer.2019.107744). Both FXIIa and PKa activate the complement system (see Irmscher et al., J Innate Immun. 2018;10(2):94-105. doi: 10.1159/000484257; and Ghebrehiwet et al., J Exp Med. 1981 Mar l;153(3):665-76).
A phase 2 study to assess the safety and efficacy of CSL312, a FXIIa inhibitor, in the treatment of COVID-19 has been assigned clinicaltrials.gov identifier NCT04409509. Shatzel et al. (Res Pract Thromb Haemost, 2020 May 15;4(4):500-505. doi: 10.1002/rth2.12349) also relates to investigating the contact system's role in COVID-19.
Wygrecka et al. ("Coagulation factor XII regulates inflammatory responses in human lungs", European Respiratory Journal 2017 50: PA339; DOI: 10.1183/1393003. congress-2017. PA339) relates to the effect of an accumulation of FXII in acute respiratory distress syndrome (ARDS) lungs.
Wong et al. ("CSL312, a Novel Anti-FXII Antibody, Blocks FXII-lnduced IL-6 Production from Primary Non- Diseased and Idiopathic Pulmonary Fibrosis Fibroblasts", American Journal of Respiratory and Critical Care
Medicine 2020;201:A6363) reports that activated FXII may contribute to lung fibrosis (e.g. idiopathic
Pulmonary Fibrosis) through direct stimulation of fibroblasts to produce pro-fibrotic cytokine IL-6.
Gbbel et al. (The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders— A Systematic Review, Front. Immunol., 26 July 20181 https://doi.org/10.3389/fimmu.2018.01731) relates to FXII's role in the rheumatoid arthritis (RA).
Scheffel et al. (Cold-induced urticarial autoinflammatory syndrome related to factor XII activation, Nature Communications volume 11, Article number: 179 (2020)) reports that there is a link between contact system activation and cytokine-mediated inflammation, such as cold-induced urticarial autoinflammatory syndrome.
Peyrou et al. (The kallikrein— kinin pathway as a mechanism for auto-control of brown adipose tissue activity, NATURE COMMUNICATIONS, (2020) 11:2132, https://doi.org/10.1038/s41467-020-16009-x), reports a pathway for controlling brown adipose tissue (BAT) thermogenic activity mediated by the kallikrein— kinin system, which may contribute to expanding the range of potential pharmacological candidates in therapeutic strategies against obesity and associated diseases designed to improve energy expenditure and remove excess blood metabolites through activation of BAT. Impaired BAT activity is associated with obesity and insulin resistance.
Wygrecka et al. ("Use of a FXIIa-lnhibitor in the treatment of renal fibrosis and/or kidney disease" WO2019/113642) relates to an inhibitor of Factor XII for use in treating or preventing kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys and/or acute kidney injury.
Compounds that are said to be FXIIa inhibitors have been described by Rao et al. ("Factor XI la Inhibitors" WO2018/093695), Hicks et al. ("Factor XI la Inhibitors" WO2018/093716), Breslow et al. ("Aminotriazole immunomodulators for treating autoimmune diseases" WO2017/123518) and Ponda et al. ("Aminacylindazole immunomodulators for treatment of autoimmune diseases" WO2017/205296 and "Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases" WO2019/108565). FXII/FXIIa inhibitors are said to have been described by Nolte et al. ("Factor XII inhibitors for the administration with medical procedures comprising contact with artificial surfaces" W02012/120128).
Compounds that are said to be modulators of FXIIa have been described by Philippou et al. ("Factor XI la Inhibitors" WO 2019/211585 and WO 2019/186164). Macrocylic peptides that are said to be inhibitors of FXIIa have been described by Wilbs et al. (Nat Commun 11, 3890 (2020). Doi: 10.1038/s41467-020-17648- w).
To date, no FXIIa inhibitors have been approved for medical use, and there are no small molecule FXIIa inhibitors in clinical development. Although certain known compounds are said to be modulators or inhibitors of FXIIa, these compounds can suffer from limitations such as being non-reversible or covalent binders, being poorly selective for FXIIa over other related enzymes, or not having pharmacokinetic properties suitable for oral therapy. For example, compounds with acylating reactivity e.g. acylated aminotriazoles, are typically non-reversible covalent binders, and can sometimes also be unstable in water and/or blood plasma due to their inherent reactivity. Poor selectivity for FXIIa over other serine proteases (such as thrombin, FXa, FXIa, KLK1, plasmin, trypsin) increases the risk of off-target effects, which can be made even worse (i.e. there is typically a higher likelihood of poor selectivity and off-target effects) if the inhibitor is a covalent binder. Therefore, there remains a need to develop new FXIIa inhibitors that are not covalent inhibitors and/or are highly selective for FXIIa in order to e.g. mitigate the risks of non- selectivity and cytotoxicity. There is a particular need to develop a small molecule FXIIa inhibitors, particularly as an oral therapy.
In view of the above, there also remains a need to develop new FXIIa inhibitors that will have utility to treat a wide range of disorders, in particular angioedema; HAE, including : (i) HAE type 1, (ii) HAE type 2, and (iii) normal Cl inhibitor HAE (normal Cl-lnh HAE); BK-AEnH, including AE-nCl Inh, ACE and tPA induced angioedema; vascular hyperpermeability; stroke including ischemic stroke and haemorrhagic accidents; retinal edema; diabetic retinopathy; impaired visual acuity; DME; retinal vein occlusion; AMD; neuroinflammation; neuroinflammatory/neurodegenerative disorders such as MS (multiple sclerosis); other neurodegenerative diseases such as Alzheimer's disease, epilepsy and migraine; sepsis; bacterial sepsis; inflammation; anaphylaxis; thrombosis; thromboembolism caused by increased propensity of medical devices that come into contact with blood to clot blood; prothrombotic conditions including disseminated intravascular coagulation (DIC), venous thromboembolism (VTE), cancer associated thrombosis, complications caused by mechanical and bioprosthetic heart valves, complications caused by catheters, complications caused by ECMO, complications caused by LVAD, complications caused by dialysis, complications caused by CPB, sickle cell disease, joint arthroplasty, thrombosis induced to tPA, Paget-Schroetter syndrome and Budd-Chari syndrome; atherosclerosis; COVID-19; acute respiratory distress syndrome (ARDS); idiopathic pulmonary fibrosis (IPF); rheumatoid arthritis (RA); cold-induced urticarial autoinflammatory syndrome; obesity; diabetes; kidney disease; renal fibrosis;
glomerulosclerosis; renal scarring; ischemia/reperfusion injury in native or transplant kidneys; and acute kidney injury. In particular, there remains a need to develop new FXIIa inhibitors.
Description of the Invention
The present invention relates to a series of inhibitors of Factor Xlla (FXIIa). The compounds of the invention are potentially useful in the treatment of diseases or conditions in which factor Xlla inhibition is implicated. The invention further relates to pharmaceutical compositions of the inhibitors, to the use of the compositions as therapeutic agents, and to methods of treatment using these compositions.
Formula (I), wherein:
V is selected from -O- and -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is selected from -O- and -N(R18)-; wherein R18 or R23 are selected from C(=S)NH-aryl; C(=S)NH-R19; C(=S)N(alkyl)R19; C(=S)NR13R14; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one substituent selected from cycloalkyl and heterocycloalkylb, and optionally one or two further substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
R19 is selected from (CH2)i.3-cycloalkyl, (CH2)o-3-polycycloalkyl, heterocycloalkyla, (CH2)i-3-heterocycloalkylb, (CH2)0-3-R22, (C(R2O)(R21))-(CH2)o.3-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)i.3-O-(CH2)-phenyl;
R20 and R21 are independently selected from H, alkyl and CF3, or R20 and R21 together with the carbon atom to which they are attached form a carbon-containing 3-, 4-, 5- or 6- membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H;
R22 is a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6bicyclic ring is not aryl substituted with ethylenedioxy;
Y is selected from -O- and -N(R12)-;
B is selected from:
(i) heteroaryla; and
(ii) aryl;
AW- is selected from:
-(CH2)O-6-(CHR15)-(CH2)0-6-A, -(CHR12)-A, -O-(CHR12)-A, -(CH2)O.6-A, -(CH2)0-6-O-(CH2)0-6-A, -(CH2)0-6-NH-(CH2)0-6-A, -(CH2)O-6-N(R12)-(CH2)I.6-C(=0)-A, -(CH2)0-6-NH-C(=O)-(CH2)0-6-A,
-C(=0)N(R12)-(CH2)0-6-A, -(CH2)O-6-C(=0)-(CH2)0-6-A, -(CH2)0-6-(phenyl)-(CH2)0-6-A, -NH-SO2-A and -SO2-NH-A;
A is a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from N, O and S, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro;
wherein when A is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system; wherein when:
(i) V is -O-, or
(ii) Z is -O-,
A is A', wherein A' is a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from N, O and S, wherein the ring system is substituted with phenyl and optionally, where possible, 1, 2, or 3 further substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl; wherein when A' is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro; wherein when A' is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system; alkoxy is OCF3, a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted, where possible, with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro; alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, -NR13R14, -C(=O)OR13, -C(=O)NR13R14, CN, CF3, halo; alkylb is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkylb may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, CN, CF3, halo; small alkyl is a linear saturated hydrocarbon having up to 4 carbon atoms (C1-C4) or a branched saturated hydrocarbon of between 3 and 4 carbon atoms (C3-C4); small alkyl may optionally be substituted with 1 or 2 substituents independently selected from alkoxy, OH, NR13R14, C(=O)OR13, C(=O)NR13R14, CN, CF3, halo;
aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, methylenedioxy, ethylenedioxy, OH, halo, CN, -(CH2)0-3- O-heteroaryla, arylb, -O-arylb, -(CH2)1-3-arylb, -(CH2)0-3-heteroaryla, -C(=O)OR13, -C(=O)NR13R14, -(CH2)0-3-NR13R14, OCF3 and CF3; a ry I b is phenyl, biphenyl or naphthyl; a ryl b may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, and CF3; cycloalkyl is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo; halo is F, Cl, Br, or I; heteroaryl is a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3; heteroaryla is a 5-, 6-, 9- or 10- membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O; heteroaryla may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, arylb, -(CH2)o-3-NR13R14, heteroaryl”, -C(=O)OR12, -C(=O)NR13R14 and CF3; heteroarylb is a 5-, 6-, 9- or 10- membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, N(R12), S and O; wherein heteroarylb may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, arylb, -(CH2)1-3-arylb, and CF3; heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N, N(R12), S, and O; heterocycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo;
heterocycloalkyla is a 3-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, aryl, halo, OH, CN, CF3, and heterocycloalkyl; wherein when heterocycloalkyla is a bicyclic ring system, the bicyclic ring system is spiro; heterocycloalkylb is a 3-6 membered non-aromatic carbon-containing monocyclic ring system which may be saturated or, where possible, unsaturated with 1 or 2 double bonds; heterocycloalkylb contains one or two ring members independently selected from N, N(C(=O)CH3) and O; heterocycloalkylb may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, halo, OH, CN, CF3, phenyl and oxo; wherein the point of attachment of heterocycloalkylb is not at a ring nitrogen; polycycloalkyl is a bi- or tri-cyclic saturated hydrocarbon ring system of between 5 and 10 carbon atoms (C5-C10), wherein the bi- or tri-cyclic ring system is bridged or spiro;
R8 is independently selected from H, alkyl, cycloalkyl, and heterocycloalkyl;
R12 is independently selected from H, alkyl, and cycloalkyl;
R13 and R14 are independently selected from H, alkylb, arylb and heteroarylb or R13 and R14 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkylb, alkoxy, OH, halo and CF3;
R15 is selected from alkyl, halo, CF3, CN, OH, alkoxy, NR13R14, and CONR13R14;
R16 and R17 are independently selected from H and small alkyl; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated analogues, and pharmaceutically acceptable salts and/or solvates thereof.
The compounds of formula (I) have been developed to be inhibitors of FXIIa, which as noted above, has a unique and specific binding site. The compounds of formula (I) aim to address the need for small molecule FXIIa inhibitors, particularly with pharmacokinetic properties suitable for use as oral therapies. The compounds of formula (I) can also avoid including groups associated with covalent binding properties e.g. groups with acylating reactivity such as acylated aminotriazoles, and thus can provide compounds that are reversible inhibitors, to further reduce the risk of off-target effects and cytotoxicity.
The present invention also provides a prodrug of a compound as herein defined, or a pharmaceutically acceptable salt and/or solvate thereof.
The present invention also provides an N-oxide of a compound as herein defined, or a prodrug or pharmaceutically acceptable salt and/or solvate thereof.
It will be understood that "methylenedioxy" refers to -O-CH2-O- only, wherein "methylenedioxy" cannot be substituted.
It will be understood that "ethylenedioxy" refers to -O-CH2-CH2-O- only, wherein "ethylenedioxy" cannot be substituted.
It will be understood that "aryl substituted with methylenedioxy" refers to aryl as defined above, wherein aryl is substituted with -O-CH2-O-. For example,
.
It will be understood that "aryl substituted with ethylenedioxy" refers to aryl as defined above, wherein aryl is substituted with -O-CH2-CH2-O-. For example,
It will be understood that, as noted above R22 is not aryl substituted with methylenedioxy, which as mentioned above excludes
; and R22 is not aryl substituted with ethylenedioxy which as mentioned above excludes
R22 can include fused 6,5- or 6,6- bicyclic rings containing an
aryl ring fused to a non-aromatic ring, wherein the non-aromatic ring contains two O ring members, positioned as for
but wherein the non-aromatic ring is substituted as for
It will be understand that A and A', as defined above, contain at least one N ring member. Other than optional non-carbon ring members, it will be understood that the remaining ring members are carbon.
It will be understood that "pharmaceutically acceptable salts and/or solvates thereof" means "pharmaceutically acceptable salts thereof", "pharmaceutically acceptable solvates thereof", and "pharmaceutically acceptable solvates of salts thereof".
The compounds of the present invention can be provided as mixtures of more than one stereoisomer. When provided as a mixture of stereoisomers, one stereoisomer can be present at a purity >90 % relative to the remaining stereoisomers. More specifically, when provided as a mixture of stereoisomers, one stereoisomer can be present at a purity >95 % relative to the remaining stereoisomers.
It will be understood that substituents may be named as its free unbonded structure (e.g. piperidine) or by its bonded structure (e.g. piperidinyl). No difference is intended.
It will be understood that the compounds of the invention comprise several substituents. When any of these substituents is defined more specifically herein, the substituents/optional substituents to these groups described above also apply, unless stated otherwise. For example, B can be heteroaryla, which more specifically can be isoquinolinyl. In this case, isoquinolinyl can be optionally substituted in the same manner as "heteroaryla".
It will be understood that the term "where possible" means that the group, atom, or substituent in question may be present if it is chemically possible to do so, e.g. does not exceed the valencies of chemically stable compounds.
It will be understood that a fused ring system refers to a ring system where two rings in the ring system share two adjacent atoms (i.e., one common covalent bond). For example,
is a fused ring system (specifically a fused bicyclic ring system) which can be considered as a benzene ring and a piperidine ring sharing a common bond.
It will be understood that a bridged ring system refers to a ring system having two rings sharing three or more atoms. For example,
is a bridged ring system (specifically a bridged bicyclic ring system) which can be considered as a cyclopentane ring and a second cyclopentane ring joined at a bridge and sharing three common atoms.
It will be understood that a spiro ring system refers to a ring system where two rings in the ring system share one common atom. For example,
is a spiro ring system (specifically a spiro bicyclic ring system) which can be considered as a cyclobutane ring and an azetidine ring sharing a common carbon atom.
It will be understood that the ring system A, as defined in formula (I), can be fully saturated, or have any degree of unsaturation. For example, the ring system can be fully saturated, partially unsaturated, aromatic, non-aromatic, or have an aromatic ring bridged, fused or spiro to a non-aromatic ring.
It will be understood that ring system A can contain non-carbon ring members, and that these non-carbon ring members can, where possible, be optionally substituted themselves (as well, or as opposed to the carbon ring members), with the optional substituents included in the definition of A.
It will be understood that when any variable (e.g. alkyl) occurs more than once, its definition on each occurrence is independent of every other occurrence.
It will be understood that combinations of substituents and variables are permissible only if such combinations result in stable compounds.
As used herein the term "bradykinin-mediated angioedema" means hereditary angioedema, and any non- hereditary bradykinin-mediated angioedema. For example, "bradykinin-mediated angioedema" encompasses hereditary angioedema and acute bradykinin-mediated angioedema of unknown origin.
As used herein, the term "hereditary angioedema" means any bradykinin-mediated angioedema caused by an inherited genetic dysfunction, fault, or mutation. As a result, the term "HAE" includes at least HAE type 1, HAE type 2, and normal Cl inhibitor HAE (normal Cl-lnh HAE).
More specifically, the invention provides compounds of formula (I) wherein the compound is a compound of formula (la), formula (lb), or formula (Ic),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
The invention provides compounds of formula (I) wherein the compound is a compound of formula (la),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
The invention provides compounds of formula (I) wherein the compound is a compound of formula (lb),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
The invention provides compounds of formula (I) wherein the compound is a compound of formula (Ic),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
As noted above, B can be selected from:
(i) heteroaryla; and
(ii) aryl.
B can be aryl; or B can be a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
B can be aryl; or B can be 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
B can be aryl; or B can be 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
B can be phenyl substituted as for aryl; or B can be a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
B can be phenyl substituted as for aryl; or B can be a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
B can be phenyl substituted as for aryl; or B can be a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be a 6- membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be a 6- membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be a 6- membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
B can be phenyl optionally substituted as for aryl, or B can be pyridyl or isoquinolinyl, optionally substituted as for heteroaryla.
B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl, or B can be pyridyl or isoquinolinyl, optionally substituted as for heteroaryla.
or
optionally substituted as for heteroaryla, or B can be phenyl optionally substituted as for aryl. B can be optionally substituted as for heteroaryla. B can be
optionally substituted as for heteroaryla. B can be phenyl optionally substituted as for aryl.
B can be
or
optionally substituted as for heteroaryla, or B can be phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl. B can be phenyl substituted with
CN and optionally 1 or 2 further substituents as for aryl.
B can be unsubstituted; or B can be aryl, wherein B can be substituted with CN and optionally 1 or 2 further substituents as for aryl; or B can be heteroaryla, wherein B can be substituted with alkyl, halo, OH, or NH2, and optionally 1 or 2 further substituents as for heteroaryla.
B can be selected from
optionally further substituted with 1 or 2 substituents as for heteroaryla;
or
each optionally further substituted with 1 or 2 substituents as for heteroaryla;
with no substituents; or
no further substituents. B can be
, optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be
optionally further substituted with 1 or 2 substituents as for
heteroaryla. B can be
optionally further substituted with 1 or 2 substituents as for heteroaryla.
B can be
optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be
optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be
B can be selected from the following groups:
optionally further substituted with 1 or 2 substituents as for heteroaryla; or B can be
with no substituents; or B can be
with no further substituents. B can be
optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be
, optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be
optionally further substituted with 1 or 2 substituents as for heteroaryla. B can be
with no substituents. B can be
with no further substituents.
Preferably, B is heteroaryla.
B can be heteroaryla and Y can be attached to B at a carbon atom on the heteroaryla ring.
B can be heteroaryla and Y can be attached to B at a carbon atom on the heteroaryla ring, and the two ring atoms adjacent to the carbon atom on the heteroaryla ring to which Y attaches are both carbon.
It will be understood that, in the instance when Y is attached to B at a carbon atom on the heteroaryla ring, the attachment of Y to B can be at any carbon on the heteroaryla ring, so long as the remainder of the ring is still a heteroaryl ring.
It will be understood that, in the instance when Y is attached to B at a carbon atom on the heteroaryla ring, and the two ring atoms adjacent to the carbon atom on the heteroaryla ring to which Y attaches are both carbon, these adjacent ring atoms can be, where possible, substituted or unsubstituted as defined
in the embodiment or claim. Further, for example, if B is isoquinolinyl, the attachment to Y can be at any of the following ring atoms:
When B is heteroaryla, B can be a 9 or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla. B can be a 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla. B can be a 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
When B is heteroaryla, B is preferably isoquinolinyl, optionally substituted as for heteroaryla.
When B is heteroaryla, B is preferably isoquinolinyl, wherein Y is attached to B at a carbon atom on the heteroaryla ring, and the two ring atoms adjacent to the carbon atom on the heteroaryla ring to which Y attaches are both carbon.
When B is heteroaryla, B is preferably substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla.
When B is isoquinolinyl, B is preferably substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla.
When B is isoquinolinyl, B can be substituted with NH2 at the 1- position and optionally
further substituted with 1 or 2 substituents as for heteroaryla.
When B is isoquinolinyl, B can be
optionally further substituted with 1 or 2 substituents as for heteroaryla.
Y can be as defined above. Preferably, Y is -N(R12)-. Preferably, Y is -NH- or -N(CH3)-. Yet more preferably,
Y is -NH-.
Preferably, B is heteroaryla and Y is -NH-.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; and Y is -NH-.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; and Y is -NH-.
AW- can be as defined above. AW- can be selected from
-(CH2)0-3-(CHR15)-(CH2)0-3-A, -(CHR12)-A, -O-(CHR12)-A, -(CH2)O.3-A, -(CH2)0-3-0-(CH2)O.3-A,
-(CH2)0-3-NH-(CH2)0-3-A, -(CH2)0-3-N(R12)-(CH2)I.3-C(=0)-A, -(CH2)0-3-NH-C(=0)-(CH2)0-3-A,
-C(=0)N(R12)-(CH2)0-3-A, -(CH2)0-3-C(=0)-(CH2)0-3-A, -(CH2)0-3-(phenyl)-(CH2)0-3-A, -NH-SO2-A and -SO2-NH-A.
AW- can be selected from -(CH2)0-3-A, and -(CH2)0-3-0-(CH2)0-3-A.
AW- can be selected from -(CH2)0-1-A, and -(CH2)0-1-O-A.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and Y is -NH-.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and B is heteroaryla.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; and B is isoquinolinyl, optionally substituted as for heteroaryla.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; B is heteroaryla; and Y is -NH-.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; and Y is -NH-.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; B is isoquinolinyl, optionally substituted as for heteroaryla; and Y is -NH-.
Preferably, AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A; B is and Y is -NH-.
The invention provides compounds of formula (I), wherein
V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-.
More specifically, the invention provides compounds of formula (I) wherein the compound is a compound of formula (la) or formula (lb),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
R16 can be H. R16 and R17 can both be H.
Preferably, R16 and R17 are both H; and B is heteroaryla.
Preferably, R16 and R17 are both H; and B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla.
Preferably, R16 and R17 are both H; and B is isoquinolinyl, optionally substituted as for heteroaryla.
Preferably, R16 and R17 are both H; and Y is -NH-.
Preferably, R16 and R17 are both H; B is heteroaryla; and Y is -NH-.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; and Y is -NH-.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; and Y is - NH-.
R18 or R23 can be selected from C(=S)NH-aryl; C(=S)NH-R19; C(=S)N(alkyl)R19; C(=S)NR13R14; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one substituent selected from cycloalkyl and heterocycloalkylb, and optionally one or two further substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
wherein R13 and R14 together with the nitrogen atom to which they are attached form a carbon- containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkylb, alkoxy, OH, halo and CF3.
R18 or R23 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic
one cycloalkyl substituent;
R18 or R23 can be selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2, heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
Preferably, R18 or R23 can be selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19);
C(=O)NH2; heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing one or two N ring members substituted with one cycloalkyl substituent;
Yet more preferably, R18 or R23 can be selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- or 6- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing one or two N ring members substituted with one cycloalkyl substituent;
Yet more preferably, R18 or R23 can be selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing one or two N ring members substituted with one cycloalkyl substituent;
Yet more preferably, R18 or R23 can be selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing one or two N ring members
substituent;
Yet more preferably, R18 or R23 can be selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing two N ring members
substituted with one
substituent;
and
The compound of the invention can be a compound of formula (la), wherein R18 is as described as above, or a compound of formula (lb) and R23 is C(=O)R19.
The compound of the invention can be a compound of formula (la), wherein R18 is as described as above, or a compound of formula (lb) and R23 is C(=O)(CH2)1-3cycloalkyl.
The compound of the invention can be a compound of formula (la), wherein R18 is as described above, or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
The compound of the invention can be a compound of formula (la), wherein R18 is as described above, or a compound of formula (lb) and R23 is selected from
Preferably, R16 and R17 are both H; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, B is heteroaryla; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, B is
and the compound of the invention is a compound formula (la), wherein
R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, B is heteroaryla; Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl. preferably, B is
Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; B is heteroaryla; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with
1 or 2 further substituents as for heteroaryla; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon- containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; B is
and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19);
C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
and
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with
1 or 2 further substituents as for heteroaryla; Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; and the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
Preferably, R16 and R17 are both
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19;
C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
R19 can be selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22,
(C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R19 can be selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, and
(CH2)3-O-(CH2)-phenyl.
Heterocycloalkyla can be a 4-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, aryl, halo, and heterocycloalkyl; wherein when heterocycloalkyla is a bicyclic ring system, the bicyclic ring system is spiro.
Heterocycloalkyla can be selected from:
Heterocycloalkyla can be selected from:
Heterocycloalkylb can be a 4-6 membered non-aromatic carbon-containing monocyclic ring system which may be saturated or, where possible, unsaturated with 1 or 2 double bonds; heterocycloalkylb contains one or two ring members independently selected from N, N(C(=O)CH3) and O; heterocycloalkylb may optionally be substituted with 1 or 2 substituents independently selected from alkyl, phenyl and oxo; wherein the point of attachment of heterocycloalkylb is not at a ring nitrogen.
R22 can be a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
R22 can be a fused 6,5- or 6,6- bicyclic ring containing a 6-membered aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
R22 can be selected from:
R20 and R21 together with the carbon atom to which they are attached can form a carbon-containing 3-, 4- or 6-membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H.
Alternatively, R20 or R21 can be independently selected from H, (Ci-sjalkyl and CF3, wherein R20 and R21 are not both H.
More specifically, R20 or R21 can be independently selected from H, methyl and CF3, wherein R20 and R21 are not both H.
Preferably, R16 and R17 are both H; and R19 is selected from (CH2h-z-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O- phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably,
selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla; Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1- polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl. preferably,
selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb,
(CH2)O.2-R22, (C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and
(CH2)3-O-(CH2)-phenyl.
(CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0.2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22,
(C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both
selected from (CH2)I.2- cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
0 v . ... TH n
° ; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted
one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably,
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
0 v A L.
X LM if
0 ; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
preferably,
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic tuent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2;
heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon- containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-
containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with
1 or 2 further substituents as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
and
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH- aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
Preferably, R16 and R17 are both
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; and R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
When V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-; AW- can be -(CH2)-O-A.
When V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-; AW- can be -(CH2)-O-A.
When V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-; A can be a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from N, O and S, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, and CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro;
wherein when A is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system.
When V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-; A can be a 6 to 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro.
When V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-; A can be a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused.
When V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-; A can be substituted, where possible, with 1, 2 or 3 substituents independently selected from alkyl and oxo.
When V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
Preferably, R16 and R17 are both H; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl,
heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably,
membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl,
C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22,
(C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla; Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-0-A.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably,
membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both
membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-0-A.
Preferably, R16 and R17 are both
membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-0-A.
Preferably, R16 and R17 are both H; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted
one cycloalkyl substituent;
0 v . ... TH n
° ; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and
AW- is -(CH2)-O-A.
Preferably, B is heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
0 v A L
X LM if
° ; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably,
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH,
oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
0 A JL 'h f if c ; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is
substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14,
NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and
AW- is -(CH2)-O-A. preferably,
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring substituted with one cycloalkyl substituent;
and 'YHT ; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14,
NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and
AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19);
C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
and
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon- containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
NH, , 1 ' QQ
Preferably, R16 and R17 are both H; B is ; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=0)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=O)NH2;
heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19); C(=0)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with
1 or 2 further substituents as for heteroaryla; Y is -NH-; the compound of the invention is a compound
formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19; C(=0)N(alkyl)(R19);
C(=0)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is
; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=0)R19; C(=0)NHR19;
C(=0)N(alkyl)(R19); C(=0)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-0-A.
Preferably, Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22,
(C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=0)R12, C(=0)0R13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-0-A.
Preferably, B is heteroaryla; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
Preferably, B is R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl,
heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6-
membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla substituted with NH2, optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
Preferably, B is
Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl,
(C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)O-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and
(CH2)3-O-(CH2)-phenyl; A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
(CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1- polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13,
C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22,
(C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
(CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent; . and
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from
halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19;
C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
and
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13,
C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is the compound of the invention is a compound formula (la), wherein R18
can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2;
heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13,
C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring substituted with one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A. preferably, B is
Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
and
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-
containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring substituted with one cycloalkyl substituent;
and
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon- containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is
the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19);
C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent; and
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic one cycloalkyl substituent;
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R20)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with
1 or 2 further substituents as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon- containing aromatic ring is substituted with one cycloalkyl substituent;
and
; or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from
C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
and
or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22,
(C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13,
C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
Preferably, R16 and R17 are both H; B is
Y is -NH-; the compound of the invention is a compound formula (la), wherein R18 can be selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19;
C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
and or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl; R19 is selected from
(CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl; and A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused; and AW- is -(CH2)-O-A.
The invention also provides compounds wherein A is A'; wherein
V is -O-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -O-.
More specifically, the invention also provides compounds wherein A is A', wherein the compound is a compound of formula (Ic),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
When V is -O-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or, V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -O-; wherein A is A'; R16 can be H. Preferably, R16 and R17 can both be H.
When A is A', A' can be a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl and optionally, where possible, 1, 2, or 3 further substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl.
Preferably, A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
More preferably, A' is selected from:
When AW- is A'W-, A'W- can be -(CH2)0-3-A'.
More specifically, A'W- can be -(CH2)0-1-A'.
Preferably, A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, B is heteroaryla; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, B is
A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, B is heteroaryla; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl. preferably, B is
Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is
A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5- membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is heteroaryla substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla; Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is isoquinolinyl, optionally substituted as for heteroaryla; Y is -NH-; and A'W- can be -(CH2)0-1-A'; and A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
Preferably, R16 and R17 are both H; B is Y is -NH-; A'W- can be -(CH2)0-1-A'; and A' is a 5-
membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
More specifically, the invention provides compounds of formula (I), selected from Table 1, Table 2, Table 3, Table 4, and Table 5, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
More specifically, the invention provides compounds of formula (I), selected from Table 1; Table 2; compounds 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92 of Table 3; compounds 93, 94, 95, 96, 97, 98, 99, and 101 of Table 4; and Table 5, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
For the compounds provided in Table 1, Table 2, Table 3, Table 4, and Table 5 below, where stereochemistry is indicated, the compound is intended to cover all possible stereoisomers thereof.
The present invention therefore provides the compounds below in Table 1, and pharmaceutically acceptable salts and/or solvates thereof. The present invention therefore also provides stereoisomers of the compounds below in Table 1, and pharmaceutically acceptable salts and/or solvates thereof.
The present invention therefore provides the compounds below in Table 2, and pharmaceutically acceptable salts and/or solvates thereof. The present invention therefore also provides stereoisomers of the compounds below in Table 2, and pharmaceutically acceptable salts and/or solvates thereof.
The present invention therefore provides the compounds below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof. The present invention therefore also provides stereoisomers of the compounds below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof.
The present invention therefore provides compounds 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92 below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof. The present invention therefore also provides stereoisomers of compounds 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, and 92 below in Table 3, and pharmaceutically acceptable salts and/or solvates thereof.
The present invention therefore provides the compounds below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof. The present invention therefore also provides stereoisomers of the compounds below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof.
The present invention therefore provides compounds 93, 94, 95, 96, 97, 98, 99, and 101 below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof. The present invention therefore also provides stereoisomers of compounds 93, 94, 95, 96, 97, 98, 99, and 101 below in Table 4, and pharmaceutically acceptable salts and/or solvates thereof.
The present invention therefore provides the compounds below in Table 5, and pharmaceutically acceptable salts and/or solvates thereof. The present invention therefore also provides stereoisomers of the compounds below in Table 5, and pharmaceutically acceptable salts and/or solvates thereof.
It will be understood that, when reading the compounds in Table 1, Table 2, Table 3, Table 4, and Table 5 below, the substituents are to be read from left to right. For example, example compound 93 in Table 4 has a Q1 group:
and a Q.2 group "OCH2". Therefore, the Qi group is attached to the
Preferably, the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 , 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 102, 103, 104, or 105, and pharmaceutically acceptable salts and/or solvates thereof. Preferably, the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 , 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 102, or 103, and pharmaceutically acceptable salts and/or solvates thereof. More preferably, the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 , 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66,
69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 102,
104, or 105, and pharmaceutically acceptable salts and/or solvates thereof.
More preferably, the compound of formula (I) is a compound selected from example numbers: 3, 4, 5, 6,
7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 , 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66,
69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, or
102, and pharmaceutically acceptable salts and/or solvates thereof.
Even more preferably, the compound of formula (I) is a compound selected from example numbers: 3, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 97, 104, or 105, and pharmaceutically acceptable salts and/or solvates thereof.
Even more preferably, the compound of formula (I) is a compound selected from example numbers: 3, 5, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 38, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 57, 59, 60, 61, 62, 63, 64, 65, 66, 69, 70, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 97, and pharmaceutically acceptable salts and/or solvates thereof.
Yet more preferably, the compound of formula (I) is a compound selected from example numbers: 3, 15, 17, 30, 38, 43, 44, 45, 52, 57, 59, 60, 62, 65, 66, 69, 90, or 105, and pharmaceutically acceptable salts and/or solvates thereof.
Yet more preferably, the compound of formula (I) is a compound selected from example numbers: 3, 15, 17, 30, 38, 43, 44, 45, 52, 57, 59, 60, 62, 65, 66, 69, or 90, and pharmaceutically acceptable salts and/or solvates thereof. Preferably, the compound of formula (I) is a compound selected from example numbers 104 or 105, and pharmaceutically acceptable salts and/or solvates thereof.
Therapeutic Applications
As noted above, the compounds (or pharmaceutically acceptable salts and/or solvates thereof), and pharmaceutical compositions comprising the compounds (or pharmaceutically acceptable salts and/or solvates thereof) of the present invention are inhibitors of FXIIa. They are therefore useful in the treatment of disease conditions for which FXIIa is a causative factor.
Accordingly, the present invention provides a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), or a pharmaceutical composition comprising a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), for use in medicine.
The present invention also provides for the use of a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), or a pharmaceutical composition comprising the compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), in the manufacture of a medicament for the treatment or prevention of a disease or condition in which FXIIa activity is implicated.
The present invention also provides a method of treatment of a disease or condition in which FXIIa activity is implicated comprising administration to a subject in need thereof a therapeutically effective amount of a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof), or a pharmaceutical composition comprising the compound of the invention (ora pharmaceutically acceptable salt and/or solvate thereof).
As discussed above, FXIIa can mediate the conversion of plasma kallikrein from plasma prekallikrein. Plasma kallikrein can then cause the cleavage of high molecular weight kininogen to generate bradykinin, which is a potent inflammatory hormone. Inhibiting FXIIa has the potential to inhibit (or even prevent) plasma kallikrein production. Thus, the disease or condition in which FXIIa activity is implicated can be a bradykinin-mediated angioedema.
The bradykinin-mediated angioedema can be non-hereditary. For example, the non-hereditary bradykinin-mediated angioedema can be selected from non-hereditary angioedema with normal Cl Inhibitor (AE-nCl Inh), which can be environmental, hormonal, or drug-induced; acquired angioedema; anaphylaxis associated angioedema; angiotensin converting enzyme (ACE or ace) inhibitor-induced angioedema; dipeptidyl peptidase-4 inhibitor-induced angioedema; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema).
Alternatively, and preferably, the bradykinin-mediated angioedema can be hereditary angioedema (HAE), which is angioedema caused by an inherited dysfunction/fault/mutation. Types of HAE that can be treated with compounds according to the invention include HAE type 1, HAE type 2, and normal Cl inhibitor HAE (normal Cl Inh HAE).
The disease or condition in which FXIIa activity is implicated can be selected from vascular hyperpermeability, stroke including ischemic stroke and haemorrhagic accidents; retinal edema; diabetic
retinopathy; impaired visual acuity; DME; retinal vein occlusion; and AMD. These conditions can also be bradykinin-mediated.
As discussed above, FXIIa can activate FXIa to cause a coagulation cascade. Thrombotic disorders are linked to this cascade. Thus, the disease or condition in which FXIIa activity is implicated can be a thrombotic disorder. More specifically, the thrombotic disorder can be thrombosis; thromboembolism caused by increased propensity of medical devices that come into contact with blood to clot blood; prothrombotic conditions such as disseminated intravascular coagulation (DIC), Venous thromboembolism (VTE), cancer associated thrombosis, complications caused by mechanical and bioprosthetic heart valves, complications caused by catheters, complications caused by ECMO, complications caused by LVAD, complications caused by dialysis, complications caused by CPB, sickle cell disease, joint arthroplasty, thrombosis induced to tPA, Paget-Schroetter syndrome and Budd-Chari syndrome; atherosclerosis; COVID-19; acute respiratory distress syndrome (ARDS); idiopathic pulmonary fibrosis (IPF); rheumatoid arthritis (RA); and cold-induced urticarial autoinflammatory syndrome.
Surfaces of medical devices that come into contact with blood can cause thrombosis. The compounds (or pharmaceutically acceptable salts and/or solvates thereof) and pharmaceutical compositions of the present invention can be coated on the surfaces of devices that come into contact with blood to mitigate the risk of the device causing thrombosis. For instance, they can lower the propensity these devices to clot blood and therefore cause thrombosis. Examples of devices that come into contact with blood include vascular grafts, stents, in dwelling catheters, external catheters, orthopedic prosthesis, cardiac prosthesis, and extracorporeal circulation systems.
Other disease conditions for which FXIIa is a causative factor include: neuroinflammation; neuroinflammatory/neurodegenerative disorders such as MS (multiple sclerosis); other neurodegenerative diseases such as Alzheimer's disease, epilepsy and migraine; sepsis; bacterial sepsis; inflammation; vascular hyperpermeability; and anaphylaxis.
Brown adipose tissue (BAT) thermogenic activity can be mediated by the kallikrein-kinin system, and impaired BAT activity is associated with obesity and insulin resistance. Inhibiting FXIIa has the potential to inhibit (or even prevent) BAT activity mediated by the kallikrein-kinin system. The compounds or pharmaceutically acceptable salts and/or solvates thereof) and pharmaceutical compositions of the invention can therefore treat disease conditions such as obesity and diabetes.
Factor XII inhibition is further implicated in the treatment of disease conditions such as kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, and acute kidney injury.
Combination Therapy
The compounds of the present invention (or pharmaceutically acceptable salts and/or solvates thereof) may be administered in combination with other therapeutic agents. Suitable combination therapies include any compound of the present invention (or a pharmaceutically acceptable salt and/or solvate thereof) combined with one or more agents selected from agents that inhibit platelet-derived growth factor (PDGF), endothelial growth factor (VEGF), integrin alpha5betal, steroids, other agents that inhibit FXIIa and other inhibitors of inflammation.
Some specific examples of therapeutic agents that may be combined with the compounds of the present invention include those disclosed in EP2281885A1 and by S. Patel in Retina, 2009 Jun;29(6 Suppl):S45-8.
Other suitable combination therapies include a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof) combined with one or more agents selected from agents that treat HAE (as defined generally herein), for example bradykinin B2 antagonists such icatibant (Firazyr®); plasma kallikrein inhibitors such as ecallantide (Kalbitor®), lanadelumab (Takhzyro®) and berotralstat (ORLADEYO™); or Cl esterase inhibitor such as Cinryze® and Haegarda® and Berinert® and Ruconest®.
Other suitable combination therapies include a compound of the invention (or a pharmaceutically acceptable salt and/or solvate thereof) combined with one or more agents selected from agents that are antithrombotics (as outlined above), for example other Factor Xlla inhibitors, thrombin receptor antagonists, thrombin inhibitors, factor Vila inhibitors, factor Xa inhibitors, factor Xia inhibitors, factor IXa inhibitors, adenosine diphosphate antiplatelet agents (e.g., P2Y12 antagonists), fibrinogen receptor antagonists (e.g. to treat or prevent unstable angina or to prevent reocclusion after angioplasty and restenosis) and aspirin) and platelet aggregation inhibitors.
When combination therapy is employed, the compounds of the present invention and said combination agents may exist in the same or different pharmaceutical compositions, and may be administered separately, sequentially or simultaneously.
The compounds of the present invention can be administered in combination with laser treatment of the retina. The combination of laser therapy with intravitreal injection of an inhibitor of VEGF for the
treatment of diabetic macular edema is known (Elman M, Aiello L, Beck R, et al. "Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema" Ophthalmology. 27 April 2010).
Definitions
As noted above, the term "alkyl" is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy,
OH, -NR13R14, -C(=O)OR13, -C(=O)NR13R14, CN, CF3, halo. As noted above "alkylb" is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkylb may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, CN, CF3, halo. Examples of such alkyl or alkylb groups include, but are not limited, to C1 - methyl, C2 - ethyl, C3 - propyl and C4-n-butyl, C3 - iso-propyl, C4 - sec-butyl, C4 - iso- butyl, C4 - tert-butyl and C5 - neo-pentyl, optionally substituted as noted above. More specifically, "alkyl" or "alkylb" can be a linear saturated hydrocarbon having up to 6 carbon atoms (C1-C6) or a branched saturated hydrocarbon of between 3 and 6 carbon atoms (C3-C6), optionally substituted as noted above. Even more specifically, "alkyl" or "alkylb" can be a linear saturated hydrocarbon having up to 4 carbon atoms (C1-C4) or a branched saturated hydrocarbon of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above, which is herein called "small alkyl" or "small alkylb", respectively. Preferably, "alkyl" or "alkylb" can be defined as a "small alkyl" or "small alkylb".
"Aryl" and "arylb" are as defined above. Typically, "aryl" or "arylb" will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable aryl or arylb groups include phenyl, biphenyl and naphthyl (each optionally substituted as stated above). Preferably "aryl" is selected from phenyl, substituted phenyl (wherein said substituents are selected from those stated above) and naphthyl. Most preferably "aryl" is selected from phenyl and substituted phenyl (wherein said substituents are selected from those stated above).
As noted above, the term "cycloalkyl" is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo. Examples of suitable monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, optionally substituted as noted above. More
specifically, "cycloalkyl" can be a monocyclic saturated hydrocarbon ring of between 3 and 5 carbon atoms, more specifically, between 3 and 4 carbon atoms, optionally substituted as noted above.
As noted above, the term "alkoxy" is -OCF3, a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted, where possible, with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro. Examples of such alkoxy groups include, but are not limited to, C1 - methoxy, C2 - ethoxy, C3 - n-propoxy and C4 - n-butoxy for linear alkoxy, and C3 - iso-propoxy, and C4 - sec-butoxy and tert-butoxy for branched alkoxy, optionally substituted as noted above. More specifically, "alkoxy" can be linear groups of between 1 and 4 carbon atoms (C1-C4), more specifically, between 1 and 3 carbon atoms (C1- C3). More specifically, "alkoxy" can be branched groups of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above.
"Alkoxy" can be defined as above. Specifically, "alkoxy" is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro. Examples of such alkoxy groups include, but are not limited to, C1 - methoxy, C2 - ethoxy, C3 - n-propoxy and C4 - n-butoxy for linear alkoxy, and C3 - iso-propoxy, and C4 - sec-butoxy and tert-butoxy for branched alkoxy, optionally substituted as noted above. More specifically, "alkoxy" can be linear groups of between 1 and 4 carbon atoms (C1-C4), more specifically, between 1 and 3 carbon atoms (C1- C3). More specifically, "alkoxy" can be branched groups of between 3 and 4 carbon atoms (C3-C4), optionally substituted as noted above.
"Halo" can be selected from Cl, F, Br and I. More specifically, halo can be selected from Cl and F.
As noted above, "heteroaryl" is a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3. For example, heteroaryl can be selected from thiophene, furan, pyrrole, pyrazole, imidazole, oxazole, isoxazole, thiazole, isothiazole, triazole, oxadiazole, thiadiazole, pyridine, pyridazine, pyrimidine, and pyrazine, optionally substituted as noted above.
"Heteroaryla" and "heteroarylb" are as defined above. Typically, "heteroaryla" or "heteroarylb" will be optionally substituted with 1, 2 or 3 substituents. Optional substituents are selected from those stated above. Examples of suitable heteroaryla or heteroarylb groups include thienyl, furanyl, pyrrolyl, pyrazolyl,
imidazoyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, benzimidazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 5-azathianaphthenyl, indolizinyl, isoindolyl, indazolyl, benzothiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-napthyridinyl and phthalazinyl (optionally substituted as stated above). More specifically, "heteroaryla" or "heteroarylb" can be a 9- or 10- membered bi-cyclic ring as defined, and optionally substituted as stated above. Examples of suitable 9- or 10- membered heteroaryla or heteroarylb groups include indolyl, benzimidazolyl, benzotriazolyl, quinolinyl, isoquinolinyl, 5-azathianaphthenyl, indolizinyl, isoindolyl, indazolyl, benzothiazolyl, cinnolinyl, quinazolinyl, quinoxalinyl, 1,8-napthyridinyl and phthalazinyl.
As noted above, "heterocycloalkyl" is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N, N(R12), S, and O; heterocycloalkyl may be optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo. More specifically, "heterocycloalkyl" can be a non-aromatic carbon- containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N(R12), and O; heterocycloalkyl may be optionally substituted with 1 or 2 substituents independently selected from alkyl alkoxy, OH, CN, CF3, halo.
As noted above, "polycycloalkyl" is a bi- or tri-cyclic saturated hydrocarbon ring system of between 5 and 10 carbon atoms (C5-C10), wherein the bi- or tri-cyclic ring system is bridged or spiro. Examples of such polycycloalkyls include, but are not limited to, adamantane, spiro[3.3]heptane, bicyclo[2.2.2]octane, bicyclo[2.2.1]heptane, and bicyclo[l.l.l]pentane.
As noted above, "heterocycloalkyla" is a 3-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, aryl, halo, OH, CN, CF3, and heterocycloalkyl; wherein when heterocycloalkyla is a bicyclic ring system, the bicyclic ring system is spiro. For example, "heterocycloalkyla" can be morpholine, tetrahydrofuran, piperidine, 2-azaspiro[3.3]heptane, and 2-azaspiro[4.4]nonane optionally substituted as noted above. More specifically, "heterocycloalkyla" can be a 4-10 membered non-aromatic carbon- containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O. More specifically, heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, aryl, halo, and heterocycloalkyl.
As noted above, "heterocycloalkylb" is a 3-6 membered non-aromatic carbon-containing monocyclic ring system which may be saturated or, where possible, unsaturated with 1 or 2 double bonds; heterocycloalkylb contains one or two ring members independently selected from N, N(C(=O)CH3) and O; heterocycloalkylbmay optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, halo, OH, CN, CF3, phenyl and oxo; wherein the point of attachment of heterocycloalkylb is not at a ring nitrogen. For example, "heterocycloalkylb" can be tetrahydro-2H-pyran, tetrahydrofuran, or oxetane, optionally substituted as noted above. Further, for example, "heterocycloalkylb" can be piperidine, wherein the point of attachment is not at the ring nitrogen. For example, if heterocycloalkylb is piperidine, the attachment of Y to the rest of compound of formula (I) can be at any of the following ring atoms:
refers to the point at which heterocycloalkylb is attached to the rest of the compound of formula (I), it does not refer to the position of any optional substituents. "Heterocycloalkylb" can be substituted at a ring nitrogen. For example, heterocycloalkylb can be
More specifically, "heterocycloalkylb" is a
4-6 membered non-aromatic carbon-containing monocyclic ring system. More specifically, "heterocycloalkylb" may optionally be substituted with 1 or 2 substituents independently selected from alkyl, phenyl and oxo.
The term "O-linked", such as in "O-linked hydrocarbon residue", means that the hydrocarbon residue is joined to the remainder of the molecule via an oxygen atom.
In groups such as -(CH2)0-6-A,
denotes the point of attachment of the substituent group to the remainder of the molecule.
As is clear from the definitions above, and for the avoidance of any doubt, it will be understood that "Y" is defined above, and does not encompass Yttrium.
As is clear from the definitions above, and for the avoidance of any doubt, it will be understood that "B" is defined above, and does not encompass Boron.
As is clear from the definitions above, and for the avoidance of any doubt, it will be understood that "W" is defined above, and does not encompass Tungsten.
As is clear from the definitions above, and for the avoidance of any doubt, it will be understood that "V" is defined above, and does not encompass Vanadium.
"Salt", as used herein (including "pharmaceutically acceptable salt") means a physiologically or toxicologically tolerable salt and includes, when appropriate, pharmaceutically acceptable base addition salts and pharmaceutically acceptable acid addition salts. For example (i) where a compound of the invention contains one or more acidic groups, for example carboxy groups, base addition salts (including pharmaceutically acceptable base addition salts) that can be formed include sodium, potassium, calcium, magnesium and ammonium salts, or salts with organic amines, such as, diethylamine, A/-methyl- glucamine, diethanolamine or amino acids (e.g. lysine) and the like; (ii) where a compound of the invention contains a basic group, such as an amino group, acid addition salts (including pharmaceutically acceptable acid addition salts) that can be formed include hydrochlorides, hydrobromides, sulfates, phosphates, acetates, citrates, lactates, tartrates, mesylates, succinates, oxalates, phosphates, esylates, tosylates, benzenesulfonates, naphthalenedisulphonates, maleates, adipates, fumarates, hippurates, camphorates, xinafoates, p-acetamidobenzoates, dihydroxybenzoates, hydroxynaphthoates, succinates, ascorbates, oleates, bisulfates, trifluoroacetates and the like.
Hemisalts of acids and bases can also be formed, for example, hemisulfate and hemicalcium salts.
For a review of suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection and Use" by Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).
"Prodrug" refers to a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis, reduction or oxidation) to a compound of the invention. Suitable groups for forming prodrugs are described in 'The Practice of Medicinal Chemistry, 2nd Ed. pp561-585 (2003) and in F. J. Leinweber, Drug Metab. Res., 1987, 18, 379.
The compounds of the invention can exist in both unsolvated and solvated forms. The term 'solvate1 is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term 'hydrate' is employed when the solvent is water.
Where compounds of the invention exist in one or more geometric, optical, enantiomeric, diastereomeric and tautomeric forms, including but not limited to cis- and trans-forms, E- and Z-forms, R-, S- and meso- forms, keto-, and enol-forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. Where appropriate such isomers can be separated from their mixtures by the application or adaptation of known methods (e.g. chromatographic techniques and recrystallisation techniques). Where appropriate such isomers can be prepared by the application or adaptation of known methods (e.g. asymmetric synthesis). For example, where compounds of the invention exist as a mixture of stereoisomers, one stereoisomer can be present at a purity of >90% relative to the remaining stereoisomers, or more specifically at a purity of >95% relative to the remaining stereoisomers, or yet more specifically at a purity of >99% relative to the remaining stereoisomers. For example, where compounds of the invention exists in enantiomeric forms, the compound can be >90% enantiomeric excess (ee), or more specifically >95% enantiomeric excess (ee), or yet more specifically, >99% ee.
Unless otherwise stated, the compounds of the invention include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds wherein hydrogen is replaced by deuterium or tritium, or wherein carbon is replaced by 13C or 14C, are within the scope of the present invention. Such compounds are useful, for example, as analytical tools or probes in biological assays.
Methods for the preparation of deuterated analogues will be readily apparent to those skilled in the art. For example, methods may include the use of deuterated starting materials in the synthesis of the compounds described herein. Deuterated starting materials will be readily available to the skilled person, from standard commercial sources. Methods for making deuterated analogues and deuterated starting materials may also include deuterium exchange. For example, deuterium exchange may be achieved by mixing the compounds with D2O.
In the context of the present invention, references herein to "treatment" include references to curative, palliative and prophylactic treatment. For instance, treatment includes preventing the symptoms of the disease conditions for which FXIIa is a causative factor.
Methods
The compounds of the invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term 'excipient' is used herein to describe any ingredient other than the compound(s) of the invention which may impart either a functional (i.e., drug release rate controlling) and/or a non-functional (i.e., processing aid or diluent) characteristic to the formulations. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
Compounds of the invention intended for pharmaceutical use may be administered as a solid or liquid, such as a tablet, capsule or solution. Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
Accordingly, the present invention provides a pharmaceutical composition comprising a compound of the invention and a pharmaceutically acceptable carrier, diluent or excipient.
For the treatment of conditions such as retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema, the compounds of the invention may be administered in a form suitable for injection into the ocular region of a patient, in particular, in a form suitable for intra-vitreal injection. It is envisaged that formulations suitable for such use will take the form of sterile solutions of a compound of the invention in a suitable aqueous vehicle. The compositions may be administered to the patient under the supervision of the attending physician.
The compounds of the invention may also be administered directly into the blood stream, into subcutaneous tissue, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous or oily solutions. Where the solution is aqueous, excipients such as sugars (including but not restricted to glucose, manitol, sorbitol, etc.), salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably
formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
Parenteral formulations may include implants derived from degradable polymers such as polyesters (i.e., polylactic acid, polylactide, polylactide-co-glycolide, polycapro-lactone, polyhydroxybutyrate), polyorthoesters and polyanhydrides. These formulations may be administered via surgical incision into the subcutaneous tissue, muscular tissue or directly into specific organs.
The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
The solubility of compounds of the invention used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of co-solvents and/or solubility-enhancing agents such as surfactants, micelle structures and cyclodextrins.
The compounds of the invention may be administered orally. Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid plugs, solid microparticulates, semi-solids and liquids (including multiple phases or dispersed systems). Exemplary formulations suitable for oral administration include tablets; soft or hard capsules containing multi- or nano-particulates, liquids, emulsions or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
Liquid (including multiple phases and dispersed systems) formulations include emulsions, solutions, syrups and elixirs. Such formulations may be presented as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 2001, 11 (6), 981-986.
The formulation of tablets is discussed in Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman (Marcel Dekker, New York, 1980).
For administration to human patients, the total daily dose of the compounds of the invention is typically in the range 0.1 mg and 10,000 mg, or between 1 mg and 5000 mg, or between 10 mg and 1000 mg depending, of course, on the mode of administration.
The total dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein. These dosages are based on an average human subject having a weight of about 60kg to 70kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
Numbered Embodiments:
Formula (I), wherein:
V is selected from -O- and -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-;
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is selected from -O- and -N(R18)-; wherein R18 or R23 are selected from C(=S)NH-aryl; C(=S)NH-R19; C(=S)N(alkyl)R19; C(=S)NR13R14; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one substituent selected from cycloalkyl and heterocycloalkylb, and optionally one or two further substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
R19 is selected from (CH2)1-3-cycloalkyl, (CH2)0-3-polycycloalkyl, heterocycloalkyla, (CH2)i-3-heterocycloalkylb, (CH2)0-3-R22, (C(R2O)(R21))-(CH2)o.3-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)i-3-O-(CH2)-phenyl;
R20 and R21 are independently selected from H, alkyl and CF3, or R20 and R21 together with the carbon atom to which they are attached form a carbon-containing 3-, 4-, 5- or 6- membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H;
R22 is a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6bicyclic ring is not aryl substituted with ethylenedioxy;
Y is selected from -O- and -N(R12)-;
B is selected from:
(i) heteroaryla; and
(ii) aryl;
AW- is selected from:
-(CH2)O-6-(CHR15)-(CH2)0-6-A, -(CHR12)-A, -O-(CHR12)-A, -(CH2)0-6-A, -(CH2)0-6-O-(CH2)0-6-A, -(CH2)0-6-NH-(CH2)0-6-A, -(CH2)O-6-N(R12)-(CH2)I.6-C(=0)-A, -(CH2)0-6-NH-C(=O)-(CH2)0-6-A,
-C(=0)N(R12)-(CH2)0-6-A, -(CH2)O-6-C(=0)-(CH2)0-6-A, -(CH2)0-6-(phenyl)-(CH2)0-6-A, -NH-SO2-A and -SO2-NH-A;
A is a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from N, O and S, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro; wherein when A is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system; wherein when:
(i) V is -O-, or
(ii) Z is -O-,
A is A', wherein A' is a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from N, O and S, wherein the ring system is substituted with phenyl and optionally, where possible, 1, 2, or 3 further substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl; wherein when A' is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro; wherein when A' is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system; alkoxy is OCF3, a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted, where possible, with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro; alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, -NR13R14, -C(=O)OR13, -C(=O)NR13R14, CN, CF3, halo;
alkylb is a linear saturated hydrocarbon having up to 10 carbon atoms (Ci-Cio) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkylb may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, CN, CF3, halo; small alkyl is a linear saturated hydrocarbon having up to 4 carbon atoms (C1-C4) or a branched saturated hydrocarbon of between 3 and 4 carbon atoms (C3-C4); small alkyl may optionally be substituted with 1 or 2 substituents independently selected from alkoxy, OH, NR13R14, C(=O)OR13, C(=O)NR13R14, CN, CF3, halo; aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, methylenedioxy, ethylenedioxy, OH, halo, CN, -(CH2)0-3- O-heteroaryla, arylb, -O-arylb, -(CH2)1-3-arylb, -(CH2)0-3-heteroaryla, -C(=O)OR13, -C(=O)NR13R14, -(CH2)0-3-NR13R14, OCF3 and CF3; a ry I b is phenyl, biphenyl or naphthyl; a ryl b may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, and CF3; cycloalkyl is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo; halo is F, Cl, Br, or I; heteroaryl is a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3; heteroaryla is a 5-, 6-, 9- or 10- membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O; heteroaryla may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, arylb, -(CH2)o-3-NR13R14, heteroaryl”, -C(=O)OR12, -C(=O)NR13R14 and CF3; heteroarylb is a 5-, 6-, 9- or 10- membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, N(R12), S and O; wherein
heteroarylb may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, arylb, -(CH2)1-3-arylb, and CF3; heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N, N(R12), S, and O; heterocycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo; heterocycloalkyla is a 3-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, aryl, halo, OH, CN, CF3, and heterocycloalkyl; wherein when heterocycloalkyla is a bicyclic ring system, the bicyclic ring system is spiro; heterocycloalkylb is a 3-6 membered non-aromatic carbon-containing monocyclic ring system which may be saturated or, where possible, unsaturated with 1 or 2 double bonds; heterocycloalkylb contains one or two ring members independently selected from N, N(C(=O)CH3) and O; heterocycloalkylb may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, halo, OH, CN, CF3, phenyl and oxo; wherein the point of attachment of heterocycloalkylb is not at a ring nitrogen; polycycloalkyl is a bi- or tri-cyclic saturated hydrocarbon ring system of between 5 and 10 carbon atoms (C5-C10), wherein the bi- or tri-cyclic ring system is bridged or spiro;
R8 is independently selected from H, alkyl, cycloalkyl, and heterocycloalkyl;
R12 is independently selected from H, alkyl, and cycloalkyl;
R13 and R14 are independently selected from H, alkylb, arylb and heteroarylb or R13 and R14 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkylb, alkoxy, OH, halo and CF3;
R15 is selected from alkyl, halo, CF3, CN, OH, alkoxy, NR13R14, and CONR13R14;
R16 and R17 are independently selected from H and small alkyl; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated analogues, and pharmaceutically acceptable salts and/or solvates thereof.
2. A compound of formula (I) according to numbered embodiment 1, wherein the compound is a compound of formula (la), formula (lb), or formula (Ic),
Formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
3. A compound according to numbered embodiment 1, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-.
4. A compound of formula (I) according to any of the preceding numbered embodiments, wherein the compound is a compound of formula (la) or formula (lb),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
5. A compound of formula (I) according to any of the preceding numbered embodiments, wherein the compound is a compound of formula (la),
or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
6. A compound according to numbered embodiment 3, 4 or 5, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture
thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A is a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from N, O and S, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, and CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro; wherein when A is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system.
7. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R18 or R23 are selected from C(=S)NH-aryl; C(=S)NH-R19; C(=S)N(alkyl)R19;
C(=S)NR13R14; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or
6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one substituent selected from cycloalkyl and heterocycloalkylb, and optionally one or two further substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
and
wherein R13 and R14 together with the nitrogen atom to which they are attached form a carbon- containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkylb, alkoxy, OH, halo and CF3.
8. A compound according to any of numbered embodiments 1 to 6, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R18 or R23 are selected from C(=S)NH-aryl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
9. A compound according to numbered embodiment 8, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R18 or R23 are selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2, heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one cycloalkyl substituent;
10. A compound according to numbered embodiment 9, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R18 or R23 are selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19);
C(=0)NH2; heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing one or two N ring members substituted with one cycloalkyl substituent;
11. A compound according to numbered embodiment 10, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R18 or R23 are selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- or 6- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing one or two N ring members substituted with one cycloalkyl substituent;
12. A compound according to numbered embodiment 11, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R18 or R23 are selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing one or two N ring members substituted with one cycloalkyl substituent;
13. A compound according to numbered embodiment 12, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R18 or R23 are selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a
14. A compound according numbered embodiment 13, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R18 or R23 are selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing two N ring members substituted with one
15. A compound according to any of the preceding numbered embodiments or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding numbered embodiments, or a compound of formula (lb) and R23 is C(=O)R19.
16. A compound according to numbered embodiment 15, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding numbered embodiments, or a compound of formula (lb) and R23 is C(=O)(CH2)1-3Cycloalkyl.
17. A compound according to numbered embodiment 16, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding numbered embodiments, or a compound of formula (lb) and R23 is C(=O)(CH2)1-2cycloalkyl.
18. A compound according to numbered embodiment 17, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding numbered embodiments, or a compound of formula (lb) and R23 is selected from
19. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R16 is H.
20. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R16 and R17 are both H.
21. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein:
R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22,
(C(R20)(R21))-O-phenyl, and (CH2)3-O-(CH2)-phenyl.
22. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein:
R19 is selected from (CH2)1-2-cycloalkyl, (CH2)0-1-polycycloalkyl, heterocycloalkyla, (CH2)1-2-heterocycloalkylb, (CH2)0-2-R22, (C(R2O)(R21))-(CH2)0-1-phenyl, (C(R20)(R21))-R22, and (CH2)3-O-(CH2)-phenyl.
23. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein heterocycloalkyla is a 4-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, aryl, halo, and heterocycloalkyl; wherein when heterocycloalkyla is a bicyclic ring system, the bicyclic ring system is spiro.
24. A compound according to numbered embodiment 23, or a tautomer, isomer, stereoisomer
(including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein heterocycloalkyla is selected from:
25. A compound according to numbered embodiment 24, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein heterocycloalkyla is selected from:
26. A compound according to any of numbered embodiments 1 to 22, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein heterocycloalkylb is a 4-6 membered non-aromatic carbon-containing monocyclic ring system which may be saturated or, where possible, unsaturated with 1 or 2 double bonds; heterocycloalkylb contains one or two ring members independently selected from N, N(C(=O)CH3) and O; heterocycloalkylb may optionally be substituted with 1 or 2 substituents independently selected from alkyl, phenyl and oxo; wherein the point of attachment of heterocycloalkylb is not at a ring nitrogen. 27. A compound according to numbered embodiment 26, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein heterocycloalkylb is selected from:
28. A compound according to numbered embodiment 27, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein heterocycloalkylb is selected from:
29. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein polycycloalkyl is selected from:
30. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic
mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein:
R22 is a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
31. A compound according to numbered embodiment 30, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein:
R22 is a fused 6,5- or 6,6- bicyclic ring containing a 6-membered aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkoxy, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6- bicyclic ring is not aryl substituted with ethylenedioxy.
32. A compound according to numbered embodiment 31, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R22 is selected from:
33. A compound according to numbered embodiment 31, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R22 is selected from:
34. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R20 and R21 together with the carbon atom to which they are attached form a carbon-containing 3-, 4- or 6-membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H.
35. A compound according to any of numbered embodiments 1 to 33, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R20 or R21 are independently selected from H, (C1-3)alkyl and CF3, wherein R20 and R21 are not both H.
36. A compound according to numbered embodiment 35, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R20 or R21 are independently selected from H, methyl and CF3, wherein R20 and R21 are not both H.
37. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
38. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
39. A compound according to numbered embodiment 37, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A compound according to numbered embodiment 39, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture
thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
41. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
42. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
43. A compound according to numbered embodiment 41, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R18 is selected from:
44. A compound according to numbered embodiment 43, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
45. A compound according to numbered embodiment 44, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
46. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic
mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A is a 6 to 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro.
47. A compound according to numbered embodiment 46, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A is a 6 or 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused.
48. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A is substituted, where possible, with 1, 2 or 3 substituents independently selected from alkyl and oxo.
49. A compound according to numbered embodiments 46 to 48, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A is selected from:
50. A compound according to numbered embodiment 1, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
V is -O-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -O-.
51. A compound of formula (I) according to numbered embodiment 1, 2 or 50, wherein the compound is a compound of formula (Ic),
Formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
52. A compound according to numbered embodiment 50 or 51, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R16 is H.
53. A compound according to any of numbered embodiments 50 to 52, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
R16 and R17 are both H.
54. A compound according to any of numbered embodiments 1, 2 or 50 to 53, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl and optionally, where possible, 1, 2, or 3 further substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl.
55. A compound of formula (I) according to numbered embodiment 54 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated isotope, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A' is a 5-membered monocyclic ring system containing one N ring member and optionally one further ring member selected from N and O, wherein the ring system is substituted with phenyl.
56. A compound of formula (I) according to numbered embodiment 55 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
57. A compound of formula (I) according to numbered embodiment 56 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A' is selected from:
58. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
AW- is selected from
-(CH2)0-3-(CHR15)-(CH2)0-3-A, -(CHR12)-A, -O-(CHR12)-A, -(CH2)0-3-A, -(CH2)0-3-0-(CH2)0-3-A, -(CH2)0-3-NH-(CH2)0-3-A, -(CH2)0-3-N(R12)-(CH2)I.3-C(=0)-A, -(CH2)0-3-NH-C(=0)-(CH2)0-3-A,
-C(=0)N(R12)-(CH2)0-3-A, -(CH2)0-3-C(=0)-(CH2)0-3-A, -(CH2)0-3-(phenyl)-(CH2)0-3-A, -NH-SO2-A and -SO2-NH-A.
59. A compound according to numbered embodiment 58, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
AW- is selected from -(CH2)0-3-A, and -(CH2)0-3-0-(CH2)0-3-A .
60. A compound according to numbered embodiment 59, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
AW- is selected from -(CH2)0-1-A, and -(CH2)0-1-0-A
61. A compound according to numbered embodiment 60, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A.
62. A compound according to any of numbered embodiments 1 to 49, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
AW- is -(CH2)0-1-O-A.
63. A compound according to numbered embodiment 62, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
AW- is -(CH2)-O-A.
64. A compound according to any of numbered embodiments 1, 2, or 50 to 57, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein AW- is A'W- and A'W- is selected from -(CH2)0-3-A'.
65. A compound according to numbered embodiment 64, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
A'W- is -(CH2)0-1-A'.
66. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
Y is -N(R12)-.
67. A compound according to numbered embodiment 66, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
Y is -NH- or N(CH3).
68. A compound according to any one of numbered embodiments 66 or 67, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
Y is -NH-.
69. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is aryl; or B is a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
70. A compound according to numbered embodiment 69, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is aryl; or B is a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
71. A compound according to numbered embodiment 70, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is aryl; or B is a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
72. A compound according to numbered embodiment 71, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is phenyl substituted as for aryl; or B is a 6-membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
73. A compound according to numbered embodiment 72, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is phenyl substituted as for aryl; or B is a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
74. A compound according to numbered embodiment 73, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is phenyl substituted as for aryl; or B is a 6-membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
75. A compound according to numbered embodiment 74, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B is a 6- membered monocyclic or 9- or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
76. A compound according to numbered embodiment 75, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B is a 6- membered monocyclic or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
77. A compound according to numbered embodiment 76, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl; or B is a 6- membered monocyclic or 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
78. A compound according to numbered embodiment 74 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is phenyl optionally substituted as for aryl, or B is pyridyl or isoquinolinyl, optionally substituted as for heteroaryla.
79. A compound according to numbered embodiment 78 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl, or B is pyridyl or isoquinolinyl, optionally substituted as for heteroaryla.
80. A compound according to numbered embodiment 78 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
optionally substituted as for heteroaryla, or B is phenyl optionally substituted as for aryl.
81. A compound according to numbered embodiment 80 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
optionally substituted as for heteroaryla, or B is phenyl substituted with CN and optionally 1 or 2 further substituents as for aryl.
82. A compound according to any of the preceding numbered embodiments or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is unsubstituted; or wherein B is aryl, B is substituted with CN and optionally 1 or 2 further substituents as for aryl; or wherein B is heteroaryla, B is substituted with alkyl, halo, OH, or NH2, and optionally 1 or 2 further substituents as for heteroaryla.
83. A compound according to numbered embodiment 78, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
B is selected from
optionally further substituted with 1 or 2 substituents as for heteroaryla;
or
each optionally further substituted with 1 or 2 substituents as for heteroaryla;
with no substituents ; or
with no further substituents.
84. A compound according to numbered embodiment 83, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is selected from the following groups:
optionally further substituted with 1 or 2 substituents as for
heteroaryla; or B is
with no substituents; or B is
with no further substituents.
85. A compound according to numbered embodiment 84, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is selected from
86. A compound according to any of numbered embodiments 1-68, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is heteroaryla.
87. A compound according to numbered embodiment 86 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein Y is attached to B at a carbon atom on the heteroaryla ring.
88. A compound according to numbered embodiment 86 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein Y is attached to B at a carbon atom on the heteroaryla ring, and the two ring atoms adjacent to the carbon atom on the heteroaryla ring to which Y attaches are both carbon.
89. A compound according to any of numbered embodiments 86 to 88, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is a 9 or 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
90. A compound according to numbered embodiment 89, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is a 10-membered bicyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O, optionally substituted as for heteroaryla.
91. A compound according to numbered embodiment 90, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is a 10-membered bicyclic aromatic ring, containing 1 or 2 ring members independently selected from N or N(R12), optionally substituted as for heteroaryla.
92. A compound according to numbered embodiment 91 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is isoquinolinyl, optionally substituted as for heteroaryla.
93. A compound according to numbered embodiment 92 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
optionally substituted as for heteroaryla.
94. A compound according to any of numbered embodiments 86 to 93, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof,
wherein B is substituted with NH2, and optionally substituted with 1 or 2 further substituents as for heteroaryla.
95. A compound according to numbered embodiment 94, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is isoquinolinyl, substituted with NH2 at the 1- position
optionally further substituted with 1 or 2 substituents as for heteroaryla.
96. A compound according to numbered embodiment 95, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is
optionally further substituted with 1 or 2 substituents as for heteroaryla.
97. A compound according to any of the preceding numbered embodiments, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein alkoxy is a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro.
98. A compound selected from Table 1, Table 2, Table 3, Table 4, and Table 5, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
99. A compound selected from Table 1; Table 2; compounds 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
91, and 92 of Table 3; compounds 93, 94, 95, 96, 97, 98, 99, and 101 of Table 4; and Table 5, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
100. A pharmaceutical composition comprising: a compound, or a pharmaceutically acceptable salt and/or solvate thereof, according to any of numbered embodiments 1 to 99, and at least one pharmaceutically acceptable excipient.
101. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as defined in any of numbered embodiments 1 to 99, or the pharmaceutical composition according to numbered embodiment 100, for use in medicine.
102. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as defined in any of numbered embodiments 1 to 99, or the pharmaceutical composition according to numbered embodiment 100, for use in a method of treatment of a disease or condition in which Factor XI la activity is implicated.
103. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 102, wherein the disease or condition in which Factor Xlla activity is implicated is a bradykinin-mediated angioedema, wherein the bradykinin-mediated angioedema is hereditary angioedema.
104. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 102, wherein the disease or condition in which Factor Xlla activity is implicated is a bradykinin-mediated angioedema, wherein the bradykinin-mediated angioedema is non hereditary.
105. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 102, wherein the disease or condition in which Factor Xlla activity is implicated is selected from vascular hyperpermeability, stroke including ischemic stroke and haemorrhagic accidents; retinal edema; diabetic retinopathy; impaired visual acuity; DME; retinal vein occlusion; and AMD.
106. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 102 wherein the disease or condition in which Factor Xlla activity is implicated is a thrombotic disorder.
107. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 106, wherein the thrombotic disorder is thrombosis; thromboembolism caused by increased propensity of medical devices that come into contact with blood to clot blood; prothrombotic conditions such as disseminated intravascular coagulation (DIC), Venous thromboembolism (VTE), cancer associated thrombosis, complications caused by mechanical and bioprosthetic heart valves, complications caused by catheters, complications caused by ECMO, complications caused by LVAD, complications caused by dialysis, complications caused by CPB, sickle cell disease, joint arthroplasty, thrombosis induced to tPA, Paget-Schroetter syndrome and Budd-Chari syndrome; atherosclerosis; COVID-19; acute respiratory distress syndrome (ARDS); idiopathic pulmonary fibrosis (IPF); rheumatoid arthritis (RA); and cold-induced urticarial autoinflammatory syndrome.
108. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 102 wherein the disease or condition in which Factor Xlla activity is implicated is neuroinflammation; neuroinflammatory/neurodegenerative disorders such as MS (multiple sclerosis); other neurodegenerative diseases such as Alzheimer's disease, epilepsy and migraine; sepsis; bacterial sepsis; inflammation; vascular hyperpermeability; and anaphylaxis.
109. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 102, wherein the disease or condition in which Factor Xlla activity is implicated is obesity or diabetes.
110. A compound, a pharmaceutically acceptable salt and/or solvate thereof, or a pharmaceutical composition for use as defined in numbered embodiment 102, wherein the disease or condition in which Factor Xlla activity is implicated is kidney disease, renal fibrosis, glomerulosclerosis, renal scarring, ischemia/reperfusion injury in native or transplant kidneys, and acute kidney injury.
Synthetic Methods
The compounds of the present invention can be prepared according to the procedures of the following schemes and examples, using appropriate materials, and are further exemplified by the specific examples provided herein below. Moreover, by utilising the procedures described herein, one of ordinary skill in the art can readily prepare additional compounds that fall within the scope of the present invention claimed herein. The compounds illustrated in the examples are not, however, to be construed as forming the only genus that is considered as the invention. Those skilled in the art will readily understand that known variations of the conditions, processes and order in which the synthetic steps are performed in the following preparative procedures can be used to prepare these compounds.
The compounds and intermediates of the invention may be isolated in the form of their pharmaceutically acceptable salts, such as those described previously herein above. The interconversion between free form and salt form would be readily known to those skilled in the art.
It may be necessary to protect reactive functional groups (e.g. hydroxy, amino, thio or carboxy) in intermediates used in the preparation of compounds of the invention to avoid their unwanted participation in a reaction leading to the formation of the compounds. Conventional protecting groups, for example those described by T. W. Greene and P. G. M. Wuts in "Protective groups in organic chemistry" John Wiley and Sons, 4th Edition, 2006, may be used. For example, a common amino protecting group suitable for use herein is tert-butoxy carbonyl (boc), which is readily removed by treatment with an acid such as trifluoroacetic acid or hydrogen chloride in an organic solvent such as dichloromethane. Alternatively, the amino protecting group may be a benzyloxycarbonyl (Cbz or Z) group which can be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere or 9- fluorenylmethyloxycarbonyl (Fmoc) group which can be removed by solutions of secondary organic amines such as diethylamine or piperidine in an organic solvent. Carboxyl groups are typically protected as esters such as methyl, ethyl, benzyl or tert-butyl which can all be removed by hydrolysis in the presence of bases such as lithium or sodium hydroxide. Benzyl protecting groups can also be removed by hydrogenation with a palladium catalyst under a hydrogen atmosphere whilst tert-butyl groups can also be removed by trifluoroacetic acid. Alternatively, a trichloroethyl ester protecting group is removed with zinc in acetic acid. A common hydroxy protecting group suitable for use herein is a methyl ether, deprotection conditions comprise refluxing in 48% aqueous HBr, or by stirring with borane tribromide in an organic solvent such as DCM. Alternatively, where a hydroxy group is protected as a benzyl ether, deprotection conditions comprise hydrogenation with a palladium catalyst under a hydrogen atmosphere.
Palladium catalysed cross coupling reactions to form carbon-carbon, carbon-nitrogen and carbon-oxygen bonds typically require a palladium catalyst and ligand capable of forming an in situ catalytically active LnPd(0) species. More recently, precatalysts have been identified that contain the desired ligand and a labile group capable of eliminating to rapidly generate the active LnPd(0) catalyst species in the reaction mixture (see, for example http://dx.doi.org/10.1039/c2sc20903a, http://dx.doi.org/10.1002/ange.201207750, http://dx.doi.org/10.1021/jo500355k, http://dx.doi.org/10.1021/ol401208t, http://dx.doi.org/10.1021/acs.orglett.8b00325). The choice of catalyst and ligand or precatalyst can be determined by literature or catalyst screening, by the skilled person.
The graphic representations of racemic, ambiscalemic and scalemic or enantiomerically pure compounds used herein are taken from Maehr J. Chem. Ed. 62, 114-120 (1985): solid wedges
and broken wedges ( are used to denote the absolute configuration of a chiral element; solid bold lines
and broken bold lines
are geometric descriptors indicating the relative configuration shown, but denoting racemic character;
As used herein, a depiction including wedges or broken lines (eg.
or
indicates that the structure encompasses purity of that relative or absolute configuration of at least 80% ee, preferably >90% ee.
As used herein, when a compound possesses a centre of asymmetry, its depiction with simple lines (eg.
) indicates that the structure includes any and all stereoisomers, without regard to enantiomeric purity.
The invention is illustrated by the following non-limiting examples in which the following abbreviations and definitions are used:
All reactions were carried out under an atmosphere of nitrogen unless specified otherwise.
Hydrogenations were typically carried out using an H-Cube® reactor (manufactured by Thalesnano, Inc, Hungary).
References to the use of microwave, a microwave reactor, microwave heating and microwave irradiation all refer to the use of a CEM Discover Microwave Reactor.
References to the use of a phase separator refer to columns fitted with a selectively permeable, optimized frit material that separates aqueous phase from an organic phase under gravity.
1H NMR spectra were recorded using instrumentation selected from
- Bruker (500MHz or 400MHz) spectrometer with a Bruker Avance II or Avance III console
- Oxford (400 MHz) AS400 magnet with a Inova console
- 300 MHz Varian Mercury+ NMR System and reported as chemical shift (ppm). It will be understood that, where exchangeable protons are present in any compound, the number of protons in the 1H NMR spectra may not exactly correspond to the number of protons in the structure of any compound synthesised herein.
Molecular ions were obtained using LCMS with appropriate conditions selected from
- Chromolith Speedrod RP-18e column, 50 x 4.6 mm, with a linear gradient 10% to 90% 0.1% HCO2H/MeCN into 0.1% HCO2H/H2O over 13 min, flow rate 1.5 mL/min;
- Agilent, X-Select, acidic, 5-95% MeCN/water over 4 min. Data was collected using a Thermofinnigan Surveyor MSQ mass spectrometer with electrospray ionisation in conjunction with a Thermofinnigan Surveyor LC system;
- LCMS (Waters Acquity UPLC, C18, Waters X-Bridge UPLC C18, 1.7 pm, 2.1x30mm, Basic (0.1% Ammonium Bicarbonate) 3 min method;
- LCMS (Agilent, X-Select, Waters X-Select C18, 2.5 pm, 4.6x30 mm, Acidic 4 min method, 95-5 MeCN/water);
- LCMS (Agilent, Basic, Waters X-Bridge C18, 2.5 pm, 4.6x30 mm, Basic 4 min method, 5-95 MeCN/water;
- Acquity UPLC BEH C18 1.7 pM column, 50 x 2.1 mm, with a linear gradient 10% to 90% 0.1% HCO2H/MeCN into 0.1% HCO2H/H2O over 3 min, flow rate 1 mL/min. Data was collected using a Waters Acquity UPLC mass spectrometer with quadropole dalton, photodiode array and electrospray ionisation detectors;
- Agilent 1100 LC/MSD with Kinetex® 5 pm EVO C18 100 A LC 50 x 4.6 mm and Gemini® 5 pm NX- C18 110 A LC 50 x 4.6 mm columns. Acidic mobile phases used a linear gradient of 5-95% 10 mM aq. NH4HCO2/MeCN and basic mobile phases used a linear gradient of 5-95% 10 mM aq. NI-UHCOa/MeCN. Samples were run over 3 minutes, using a flow rate of 2.2 mL/min, and a pressure range of 0-200 bar. Data was collected using a Waters 3100 Mass Detector with single high resolution quadrupole and photomultiplier detectors and High Performance ZsprayTM dual- orthoganal API sources for standard ESI, or multimode ESI/APCI/ESCi®.
- UPLC (CSH C18 Column, 130A, 1.7 pm, 2.1 mm x 30 mm, 3 min method, 0.1% Formic acid, 2-100% MeCN/water)
- LCMS (Cortecs C18+, 90A, 2.7 pm, 2.1 mm x 30 mm, 3 min method, 0.1% Formic acid, 5-100% MeCN/water)
- UPLC (BEH C18 Column, 130A, 1.7 pm, 2.1 mm x 30 mm, 3 min method, 0.1% Ammonium Hydroxide, 2-100% MeCN/water)
- LCMS (Kinetex Evo C18, 130A, 2.5 pm, 2.1 mm x 30 mm, 3 min method, 0.1% Ammonium Hydroxide, 5-100% MeCN/water)
Flash chromatography was typically carried out over 'silica' (silica gel for chromatography, 0.035 to 0.070 mm (220 to 440 mesh) (e.g. Merck silica gel 60)), and an applied pressure of nitrogen up to 10 p.s.i accelerated column elution. Alternatively, pre-prepared cartridges of silica gel were used, for example pre-packed SiliaSep™ columns from Silicycle or Sfar C18 D - Duo 100 A 30 pm columns from Biotage. Typical conditions included, for example, flow rate range of 18-200 mL/min, with an applied pressure range of 0-225 PSI. Hexanes, EtOAc, DCM, MeOH, were used as mobile phases for normal-phase chromatography purifications. MeOH, MeCN, lOmM Ammonium Formate pH 4 in H2O and lOmM Ammonium Bicarbonate pH 10 in H2O buffers were used as mobile phases for reverse-phase chromatography. It will be understood that alternative conditions (such as flow rate ranges, applied pressures, solvents and pH) may be used for flash chromatography in order to separate and purify compounds synthesised herein.
The term "prep HPLC" refers to reverse phase preparative HPLC purifications. Typical instrumentation and conditions include, for example, Waters Fraction Lynx Prep-HPLC with MWD/DAD & MSD using
- 5-95% acetonitrile/methanol with 0.1% NH4OH pH 10 in H2O as a basic mobile phase
- 5-95% acetonitrile/methanol with 0.1% HCO2H pH 3 in H2O as an acidic mobile phase
It will be understood that alternative conditions (such as choice of column, flow rate ranges, solvents, modifiers and pH) may be used for prep HPLC in order to separate and purify compounds synthesised herein.
The procedure of lyophilisation (or freeze drying) is generally well known in the art. Typically the substance is taken up in water, if necessary, with the addition of a minimum amount of MeCN to aid dissolution, and frozen, typically by rapid cooling in a cold bath at -78 °C. The resulting frozen solid mixture is evaporated to dryness in vacuo.
The term "concentrated" refers to evaporation of solvent under reduced pressure using a rotary evaporator, heating where necessary.
All solvents and commercial reagents were used as received.
IUPAC chemical names were generated using automated software such as Dotmatics Studies Notebook or ChemDraw (PerkinElmer). Compounds produced by the methods below may be isolated in salt forms. However, compound naming used herein typically refers to the compound without any salt counter ion.
The example compounds described herein can be prepared using conventional synthetic methods for example, but not limited to, the routes outlined in the General Schemes below, using, for example, the General Methods below.
General Methods
1. General Method 1: (GM1): mesylation and chlorination a. General Method la (GMla): mesylation
A solution of alcohol (1.0 eq) in DCM was cooled in an ice/water bath and MsCI (1.2 eq) was added dropwise followed by TEA (1.4 eq) maintaining cooling. The reaction was stirred at rt for 2-18 h. The reaction was diluted with DCM and washed with water. The aqueous layer was extracted with DCM (x 3) and the combined organics were washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was used without purification or purified by flash chromatography. b. General Method lb (GMlb): chlorination via a mesylate
MsCI (2.5 eq) was added to a solution of TEA (2.8 eq) and alcohol (1.0 eq) in DCM while cooling in an ice/water bath. The reaction was stirred at rt for 18 h. The reaction was diluted with DCM and washed with sat. NaHCO3 (aq). The aqueous layer was extracted with DCM (x 3) and the combined organics were
washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was purified by flash chromatography. c. General Method lc (GMlc): chlorination via NCS
A solution of indole or azaindole (1.0 eq) in DCM was protected from light and treated with NCS (3.75 eq) at rt for 12 - 48 h. The mixture was treated with IM HCI (aq) and the phases separated. The organic phase was washed with brine, dried ( Na2SO4), filtered, concentrated and purified by flash chromatography.
2. General Method 2 (GM2): SN2 alkylation (O and N) a. General Method 2a (GM2a): SN2 alkylation: NaH
To a suspension of NaH (60% wt. on mineral oil) (1.1 eq) in DMF in an ice/water bath was added a solution of alcohol, pyrrole or indole (1.0 eq) in DMF dropwise over 2 min. The mixture was allowed to warm to rt for 5 min before cooling again in an ice/water bath and treating with a solution of the alkylhalide or mesylate (1.0 eq) in DMF over 2 min. The mixture was maintained in an ice/water bath for 1 h before being allowed to warm to rt, or heated at elevated temperature and stirred for 2-18 h. Sat. NH4CI (aq) or sat. NaHCO3 (aq) was added and extracted with EtOAc (x 3). The organic phases were combined, dried (MgSO4), filtered and concentrated. The crude product was purified by flash chromatography. b. General Method 2b (GM2b): SN2 alkylation; CS2CO3 or K2CO3
A solution of alkyl halide or mesylate (1-2 eq), amine (1.0 eq), and base such as K2CO3, or CS2CO3 (2.5 eq), in a solvent such as DMF, DMSO or MeCN, was stirred at 80 °C for 2-18 h. MeOH (5 mL) was added, and the mixture was diluted with water. The product was extracted into EtOAc (x 2) and washed with brine. The organic layer was dried (Na2SO4), filtered and concentrated. The product was either used directly or purified by flash chromatography.
3. General Method 3 (GM3): Reduction a. General Method 3a (GM3a): nitrile reduction; H-Cube® with Pd/C or Raney Ni cartridge
The nitrile was dissolved in a 0.5M NH3/MeOH solution and passed through an H-Cube® reactor (Pd/C or Raney Ni cartridge) at 50 °C, 'full' hydrogen delivery mode (50 bar), flow rate: 1 mL/min. The reaction was concentrated to afford the product which was used without further purification. b. General Method 3b (GM3b): nitrile, amide and ester reduction; LiAIH4 in THF
To a solution of amide, nitrile, or ester (1.0 eq) in THF in an ice/water bath was added LiAl H4 (2M in THF) (2.0 eq) dropwise and the reaction mixture was allowed to warm to rt then stirred for 4-18 h. The reaction mixture was cooled in an ice/water bath, treated portionwise with Na2SO4.10H2O (3.5 eq) and stirred for
30 min before being dried (MgSO4), filtering and washing with THF. The filtrate was concentrated to afford the crude product which was used without purification or purified by flash chromatography. c. General Method 3c: borane-THF reduction
A solution of nitrile (1.0 eq) in THF was cooled in an ice/water bath before borane (IM in THF, 2.0 eq) was added dropwise. The reaction was allowed to warm to rt then heated to 60 °C for 16-96 h. MeOH was added and heating continued at 60 °C for 24 h before cooling to rt and concentrating. The product was isolated and purified using one of the following methods: i) The crude product was loaded onto an SCX in MeOH and washed with MeOH. The product was eluted with 7M NH3 in MeOH and the eluent concentrated. ii) The crude product was purified by flash chromatography iii) BOC2O (1.2 eq) was added to the crude reaction mixture and stirred overnight. The solvent was concentrated. The product was taken up in DCM, washed with water and brine, dried ( Na2SO4 , filtered and concentrated. The boc-protected amine was either used without further purification or purified by flash chromatography d. General Method 3d: NiCl2 reduction
A solution of nitrile (1.0 eq), NiCl.6H2O (1.0 eq) and BOC2O (3.0 eq) in MeOH was cooled in an ice/water bath and sodium borohydride (NaBH4) (5.0 eq) added portionwise. The reaction was allowed to warm to rt and stirred for 18 h. Water was added, and the reaction mixture filtered, washed with THF and concentrated. The crude product was purified by flash chromatography. e. General Method 3e: hydrogenation; Pd/C
To a solution of nitrile (1.0 eq) in MeOH or EtOH under an inert atmosphere was added 10% Pd/C (0.1-0.2 eq). Additives such as HCI, sulfuric acid, or BOC2O may optionally be added. The reaction was stirred under an atmosphere of H2 (g) for 2-72h. The catalyst was removed by filtration over Celite®, which was washed with EtOH. The product was isolated following concentration of the filtrate and used directly or purified by flash chromatography. f. General Method 3f: aromatic ring reduction
A biaryl ring (1.0 eq) was dissolved in EtOH and subjected to hydrogenation in the H-Cube® at 70 °C, 50 bar, 1 mL/min using a 10% Pd/C CatCart, recirculating when necessary. The solvent was removed in vacuo to afford the product which was used without purification.
4. General Method 4 (GM4): Buchwald coupling
A suspension of amine or alcohol (1.0 eq), aryl halide (1.1 eq) and a base such as CS2CO3, NaOtBu (2.0 eq) or LiHMDS (2.0 eq) in a degassed solvent such as THF or 1,4-dioxane was purged with N2 (g). A Buchwald palladium precatalyst, such as BrettPhos Pd G3, (0.11 eq) was added and the mixture degassed and purged with N2 (g) for 5 min. The reaction was heated in a sealed vial at rt - 60°C for 30 min - 3 days as required. The product was isolated and purified using one of the following methods: i) The reaction was quenched with AcOH (2.0 eq) and concentrated. The crude was purified by SCX, loading and washing with MeOH then eluting the product with NH3 in MeOH followed by purification by flash chromatography or prep HPLC. ii) The reaction was quenched with AcOH (2.0 eq), filtered through Celite®, washing with EtOAc and the filtrate concentrated. The crude product was purified by flash chromatography. iii) The reaction mixture was acidified with AcOH (2.0 eq) and stirred for 5 min, IM NH3 in MeOH was added and the reaction mixture was concentrated on to silica and purified by flash chromatography. iv) The reaction mixture was dry loaded on to silica and purified by flash chromatography. v) The reaction was concentrated, and the product taken forward to deprotection without purification.
5. General Method 5 (GM5): boc deprotection; HCI or TFA a. General Method 5a (GM5a): boc deprotection; HCI/dioxane
A suspension of boc protected amine (1.0 eq) in 1,4-dioxane was treated with 4M HCI in dioxane (10.0 eq) and the reaction stirred at rt for 2-24 h. The product was isolated and purified using one of the following methods: i) The reaction mixture was concentrated, optionally azeotroping with Et20 or toluene to afford the product as a hydrochloride salt. ii) The reaction mixture was concentrated, and the product converted to free base using a bicarbonate cartridge, PL-HCO3 MP SPE (Agilent), loading in MeOH. The filtrate was concentrated and triturated with Et20 to afford the product. b. General Method 5b (GM5b): boc deprotection; TFA
A mixture of boc protected amine (1.0 eq) in DCM was treated with TFA (10.0 eq) and stirred at rt for 2 h. The product was isolated and purified using one of the following methods: i) The mixture was passed directly through an SCX column and washed with MeOH. The product was eluted with a solution of 7M NH3 in MeOH and concentrated. The crude product was purified by flash chromatography or prep HPLC.
ii) The mixture was concentrated and loaded onto a PL-HCO3 MP SPE cartridge eluting with a mixture of MeCN and MeOH (1:1 v/v, 3 x 2 mL). The crude product was purified by flash chromatography or prep HPLC. iii) The mixture was diluted with aq. NaOH (2M, 10 mL) and a mixture of DCM and MeOH (9:1 v/v, 20 mL). The phases were separated and the aq. Phase was extracted with a mixture of DCM and MeOH (9:1 v/v). The combined organic phases were dried and concentrated. The residue was purified by flash chromatography or prep HPLC iv) The mixture was diluted with aq. NaOH (2M, 10 mL) and a mixture of DCM and MeOH (9:1 v/v, 20 mL). The phases were separated, and the aqueous phase was extracted with a mixture of DCM and MeOH (9:1 v/v). The combined organic layers were dried (NazSO^, filtered, and concentrated. Product was purified by PL-HCO3 MP SPE cartridge eluting with a mixture of MeCN and MeOH (1:1 v/v), followed by flash chromatography or prep HPLC.
6. General Method 6 (GM6): pyridone chlorination
Pyridone (1.0 eq) was suspended in phosphorus oxychloride (large excess) and heated at reflux for 4 h. The reaction mixture was evaporated then azeotroped with toluene (x 2). The residue was used immediately in the next step, taking care to exclude moisture.
7. General Method 7 (GM7): SNAr Alkylation (O and N) a. General Method 7a (GM7a): SNAr O-alkylation using NaH
To a suspension of NaH (60% wt. on mineral oil) (1.04 eq) in DMF in an ice/water bath was added a solution of alcohol (1.02 eq) in DMF dropwise over 2 min. The mixture was allowed to warm to rt for 5 min before cooling again in an ice/water bath and treating with pyridyl halide or aryl halide (1.0 eq). The reaction mixture was maintained in an ice/water bath for 1 h then warmed to rt for 18 h. The reaction mixture was cooled in an ice/water bath and sat. NajCOs (aq) was added followed by water. This was extracted with EtOAc (x 3) and the organic phases were combined, washed with 1:1 water/brine and brine. The organic phase was dried (MgSO4), filtered and concentrated. The crude product was purified by flash chromatography. b. General Method 7b (GM7b): SNAr O-alkylation using CS2CO3
To a solution of alcohol (1.0 eq) and pyridyl halide (1.0 eq) in MeCN was added CS2CO3 (2.0 eq) and the mixture was stirred in a sealed vial at 50 °C for 18-72 h. The product was isolated and purified using one of the following methods
i) The reaction mixture was cooled to rt and diluted with water (10 mL). The crude product was extracted into DCM, dried (MgSO4), filtered and concentrated. The residue was purified by flash chromatography ii) The reaction mixture was filtered through Celite® and the filtrate was concentrated to yield the crude product which was either used without further purification or purified by flash chromatography iii) The crude reaction mixture was passed directly through an SCX column, loading in MeOH. The SCX was washed with MeOH and the product was eluted with 7M NH3 in MeOH. The crude product was purified by flash chromatography. c. General Method 7c (GM7c): SNAr O-alkylation using NaOlBu
A solution of alcohol (1.0 eq), aryl halide (1.0 eq) and NaOlBu (3.0 eq) in NMP was stirred in the microwave at 140 °C for 4 h. The crude reaction mixture was loaded onto an SCX column in MeOH and washed with MeOH and the product was eluted with 7M NH3 in MeOH (50 mL). The product was concentrated and purified by flash chromatography or prep HPLC. d. General Method 7d (GM7d): SNAr N-alkylation
Amine (1.0 eq) and halopyridine (1.0 eq) were dissolved in MeCN. K2CO3 (3.0 eq) was added and the reaction was stirred at 60 - 120 °C for 60 - 90 min under thermal heating or microwave irradiation. The reaction was diluted with water and extracted with IPA/CHCI3 (1:10) (x 3). The combined organics were washed with brine, dried (MgSO4) and concentrated. The product was isolated and used directly or purified by flash chromatography.
8. General Method 8 (GM8): 2,4-dimethoxybenzyl deprotection
A solution of 2,4-dimethyoxybenzyl protected amine (1.0 eq) in TFA (10 eq.) was stirred at rt - 50 °C for 60 min.
The product was isolated and purified using one of the following methods: i) The reaction mixture was concentrated. The resulting residue was suspended in MeOH (2 mL) and loaded onto SCX, which was flushed with MeOH. The product was eluted with a solution of 7M NH3 in MeOH. The solvent was concentrated and the product was purified by flash chromatography or prep HPLC. ii) The mixture was concentrated and loaded onto a PL-HCO3 MP SPE cartridge eluting with a mixture of MeCN and MeOH (1:1 v/v, 3 x 2 mL). The crude product was purified by flash chromatography or prep HPLC. iii) The mixture was diluted with NaOH (aq) (2M, 10 mL) and a mixture of DCM and MeOH (9:1 v/v, 20 mL). The phases were separated, and the aqueous phase was extracted with a mixture of DCM and
MeOH (9:1 v/v). The combined organic phases were dried and concentrated. The residue was purified by flash chromatography or prep HPLC iv) The mixture was diluted with NaOH (aq) (2M, 10 mL) and a mixture of DCM and MeOH (9:1 v/v, 20 mL). The phases were separated, and the aqueous phase was extracted with a mixture of DCM and MeOH (9:1 v/v). The combined organic layers were dried (NazSO^, filtered, and concentrated. Product was purified by PL-HCO3 MP SPE cartridge eluting with a mixture of MeCN and MeOH (1:1 v/v), followed by flash chromatography or prep HPLC.
9. General Method 9 (GM9): carbamate protection
To a solution of aminopyridine (1.0 eq) and TEA (2.0 eq) in DCM in an ice/water bath was added methylchloroformate (3.0 eq) and the reaction was stirred at rt for 48 h. The reaction mixture was diluted with DCM and washed with water. The aqueous was extracted with DCM (x 3) and the combined organics dried (Na2SO4 , filtered and concentrated. The crude product was triturated with EtOAc.
10. General Method 10 (GM10): carbamate deprotection a. General Method 10a: KOH
A mixture of methyl carbamate (1 eq) and KOH (6 eq) in MeOH was stirred at 60 °C for 12 - 48 h. The product was isolated and purified using one of the following methods: i) The reaction was quenched with AcOH (6.0 eq) and the mixture was left to stir for 5 min before being concentrated. The residue was passed directly through an SCX in MeOH. The SCX was washed with MeOH and the product was eluted with 7M NH3 in MeOH and lyophilised. ii) The reaction was quenched with AcOH (6.0 eq) and the mixture was left to stir for 5 min before being concentrated. The residue was passed directly through an SCX in MeOH. The SCX was washed with MeOH and the product was eluted with 7M NH3 in MeOH. The product was purified by flash chromatography or prep HPLC iii) The reaction was quenched with AcOH (6.0 eq), concentrated, and purified by prep HPLC. b. General Method 10b: LiOH
To a solution of methyl carbamate (1 eq) in THF/water (10:1) was added lithium hydroxide monohydrate (3-5 eq) and the reaction stirred at 60 °C for 18 h - 4 days. The mixture was cooled to rt and concentrated. The crude residue was purified via flash chromatography or prep HPLC
11. General Method 11: SEM deprotection
TFA (10 eq) was added dropwise to a rapidly stirred solution of indole or azaindole (1.0 eq) in DCM. The mixture was stirred at rt for 18 h. The reaction mixture was passed directly through an SCX in MeOH. The
SCX was washed with MeOH and the product was eluted with 2.5M NH3 in MeOH and concentrated. The crude product was purified by flash chromatography or prep HPLC.
12. General Method 12: Alkylation and cyclisation
To a solution of the amino substituted heteroaryl (e.g. pyridine) (1 eq) in EtOH (3 mL) were added NaHCO3 (2 eq) and the chloromethyl aldehyde or chloromethyl ketone as applicable (2 eq). The mixture was stirred for 20 h at 75 °C. The mixture was then cooled to rt, filtered through Celite® washing with EtOAc (50 mL) and concentrated. The product was purified by flash chromatography.
13. General Method 13: Hydroxylation
A solution of the aryl bromide or heteroaryl bromide (1.0 eq), B2Pin2 (2.0 eq) and Pd(dppf)CI2 (0.1 eq) in anhydrous, degassed 1,4-dioxane was purged with N2 (g) for 5 min. KOAc (3.0 eq) was added and the reaction stirred at 90 °C for 2 - 18 h. AcOH (2.0 eq) and water (1 mL) were added and the reaction stirred at rt for 15 min - 18 h. A solution of H2O2 in water (30% w/w, 2 eq) was added and the reaction mixture stirred for 1 - 18 h. i) Typically for basic compounds: solid Na2S2O3 was added and the reaction was stirred at rt for 5 min then diluted with EtOAc, filtered through Celite ® and concentrated. The residue was purified by SCX and flash chromatography. ii) Typically for non basic compounds: sat. Na2S2O3 (aq) and sat. NaHCO3 (aq) were added and the aqueous was extracted with EtOAc. The combined organics were washed with brine, dried (MgSO4), concentrated, and purified by flash chromatography General Method 14: Esterification
To a stirred suspension of carboxylic acid (1.0 eq) in MeOH in an ice/water bath was added thionyl chloride (1.1 eq) dropwise. The reaction was warmed to rt and stirred for 20 h. The solvent was concentrated and trituration with Et20 afforded the product. General Method 15: Mitsunobu
To a mixture of alcohol (1.0 eq) and phenol (1.1 eq) in anhydrous THF at 0 °C was added PPh3 (1.5 eq) followed by DIAD (1.5 eq). The mixture was stirred at 0 °C for 10 min then warmed to rt and stirred for 24 h and then concentrated. The residue was diluted with NaOH (aq) (IM) and DCM. The phases were separated, and the aqueous phase was extracted with DCM (x 2). The combined organic phases were washed with sat. NaHCO3 (aq) and brine, dried (Na2SO4), filtered and concentrated. Purification by flash
column chromatography afforded the product. The crude product was either used without further purification or purified by flash chromatography or prep HPLC. General Method 16: Oxidation
To a solution of alcohol (1.0 eq) in DCM at 0 °C was added Dess-Martin periodinane (2.0 eq). The mixture was stirred at rt for 18 h. A further portion of Dess-Martin periodinane (0.2 eq) was added to the solution at 0 °C. The mixture was stirred at rt for 4 h and diluted with sat. NaHCO3 (aq) (50 mL) and sat. Na2S2O3 (aq) (50 mL) at rt. The mixture was stirred for 15 min at rt and the phases were separated. The aqueous phase was extracted with DCM (x 2) and the combined organic phases were washed with sat. Na2S2O3 (aq), sat. NaHCO3 (aq), brine, dried (Na2SO4), filtered and concentrated to afford the product. General Method 17 (GM17): Reductive amination
To a solution of aldehyde (1.0 eq) and amine (1.10 eq) in DCE was added AcOH (1.15 eq) and the mixture stirred for 30 min then STAB (2.0 eq) was added. The mixture was stirred for 18 - 72 h at rt before quenching with sat. NaHCO3 (aq) and extracting with DCM (x 3). The combined organic layers were dried (Na2SO4), filtered, and concentrated. Purification by flash chromatography afforded the product. General Method 18 (GM18): Amide coupling a. General Method 18a (GM18a): Amide coupling using HATU
To a solution of carboxylic acid (1.2 eq) in anhydrous DMF was added DIPEA (3 eq) and HATU (1.05 eq). The reaction was stirred at rt for 40 min then amine (1.0 eq) was added and stirring continued for 60 min. Concentration afforded the product which was either used without further purification or purified by flash chromatography or prep HPLC b. General Method 18b (GM18b): Amide coupling using PyBop
To a mixture of carboxylic acid (1.0 eq) in DCM was added amine (1.0 eq), PyBOP (1.2 eq) and DIPEA (3.0 eq). The mixture was stirred at rt for 16 h and then concentrated. The residue was partitioned between sat. NaHCO3 (aq) and EtOAc. The aqueous was washed with EtOAc (x 3). The combined organic layers were dried (Na2SO4), filtered and concentrated. Purification by flash chromatography or prep HPLC afforded the product. General Method 19 (GM19): Sulfonamide formation
To a solution of amine (1.0 eq) and TEA (2.3 eq) in anhydrous DCM (2 mL), cooled in an ice/water bath, was added sulfonyl chloride (2.0 eq). The mixture was stirred in an ice/water bath for 2 h. Concentration
afford the product. The crude product was either used without further purification or purified by flash chromatography or prep HPLC. General Method 20 (GM20): Carbamate formation a. General Method 20a (GM20a): Carbamate formation using CDI
To a solution of CDI (1.5 eq) in anhydrous MeCN at rt was added alcohol (1.0 eq). The mixture was stirred for 2h and then concentrated. The residue was partitioned between H2O and DCM and the aqueous washed with DCM (x 2). Combined organics were dried (Na2SO4), filtered and concentrated. The intermediate (2.0 eq) was dissolved in anhydrous THF and amine (1.0 eq) added followed by DBU (0.3 eq). The mixture was heated to 65 °C for 18h - 4 days then cooled and concentrated. The residue was partitioned between H2O and DCM and the aqueous washed with DCM (x 2). Combined organics were dired (Na2SO4), filtered and concentrated. Purification by flash chromatography or prep HPLC afforded the product. b. General Method 20b (GM20b): Carbamate formation using phosgene
To a stirred solution of alcohol (1.06 eq) and TEA (1.56 eq) in anhydrous DCM at rt was added phosgene (20% in toluene, 1.02 eq) and the reaction stirred for 1 h. A solution of amine (1.0 eq) and TEA (1.55 eq) in anhydrous DCM was added and stirring continued for 24 h. The mixture was quenched with 1 M NaOH and brine (1:1), and the layers were separated. The aqueous layer was extracted with DCM (x 2), and the combined organic layers were dried (Na2SO4), filtered, and concentrated. The crude product was purified by flash chromatography. General Method 21 (GM21): Urea formation a. General Method 21a (GM21a): Urea formation using CDI
To a solution of amine (1.6 eq) in DMF was added CDI (1.5 eq) and DIPEA (3.6 eq). The mixture was stirred at rt for 2 h then a solution of scaffold amine (1.0 eq) in DMF was added. The mixture was stirred at rt for 72 h and then concentrated. The crude product was either used without further purification or purified by flash chromatography or prep HPLC. b. General Method 21b (GM21b): Urea formation using triphosgene
Part 1: A mixture of amine (1.6 eq) in anhydrous THF was added to a mixture of triphosgene (0.65 eq) and pyridine (2.2 eq) in anhydrous THF at rt. The mixture was stirred for 18-72 h.
Part 2: To the reaction mixture was added a mixture of scaffold amine (1.0 eq) and TEA (3 eq) in anhydrous DMSO. The reaction was stirred for 1 - 36 h. The product was isolated and purified using one of the following methods: i) The reaction mixture was concentrated and purified by flash chromatography.
ii) The reaction was diluted with brine and extracted with a mixture of DCM and MeOH (9:1 v/v). The combined organic phases were washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was either used without further purification or purified by flash chromatography or prep HPLC c. General Method 21c (GM21c): Urea formation using isocyanates
To a solution of amine (1.0 eq) and TEA (3.0 eq) in DMSO was added isocyanate (1.1 eq), and the mixture was stirred for 16 h. The mixture was quenched with MeOH, filtered and purified by automated prep HPLC.
General Schemes
General Schemes 1-6 outline synthetic routes for certain example compounds and RgA, RgB, RgC and RgD refer to various substituents as required by the examples. For the sake of clarity General Schemes 1-6 are drawn with an oxabicyclohexyl central core group. Similar chemistry can be applied to examples with different core groups such as bicyclopentyl, azabicyclohexyl, and oxabicycloheptyl.
Alcohols such as la are typically reacted to form a suitable leaving group, such as halide or mesylate and can be generated using conditions well known in the art such as, for example; chlorination via a mesylate, bromination with PBr3, or bromination with CBr4 and PPh3, using a suitable solvent such as DCM, THF or CCL (General Method 1), to give compound 2a. Compound 2a is subsequently reacted with an alcohol or amine 3 under typical alkylation conditions (General Method 2, eg KCtBu or NaH in DMF or CS2CO3 or
K2CO3 in MeCN or DMSO, with heating as necessary). The nitrile 4 can be reduced to amine 5a under a variety of standard literature conditions well known in the art (General Method 3); for example under hydrogenation in the presence of Raney Ni, alternatively hydrogenation in the presence of Pd/C, or alternatively with NiCL and sodium borohydride (NaBH4) in the presence of BOC2O, or alternatively with borane. The amine 5a is reacted with aryl bromide or chloride 6 under Buchwald coupling conditions (General Method 4). This Buchwald coupling is carried out for example using a Buchwald pre catalyst, such as BrettPhos Pd G3, BrettPhos Pd G4 or Pd-PEPPSI-lpent, in the presence of a base such a sodium tert- butoxide, CS2CO3, or lithium hexamethyldisilazide (LiHMDS), in a solvent such as 1,4-dioxane or THF. The aryl bromide or chloride 6 can be prepared from readily available starting materials using methods known in the art, or as described herein. Depending on the identity of RgB, a deprotection step (detailed below) may be required to obtain the example compound.
Alternatively, for example as shown in General Scheme 2, where material is available as the amine, for example compound lb, a similar synthetic sequence can be applied.
The amine is protected, for example with a tert-butoxy carbamate protecting group, using standard conditions such as TEA and BOC2O in DCM or THF. Following formation of a leaving group and alkylation, the tert-butoxy carbamate protecting group is removed from compound 8a using standard conditions
such as TFA, or HCI in 1,4-dioxane (General Method 5). Finally, Buchwald coupling (General Method 4) completes the route.
An amine such as lb can undergo a Buchwald (General Method 4), followed by formation of a leaving group (General Method 1) and finally alkylation with compound 3 (General Method 2).
Furthermore, the Buchwald coupling (General Method 4), is also possible with alcohols. This requires a suitable protecting group strategy as shown in General Schemes 4 and 5.
In General Scheme 4, a protected alcohol is in the form of an ester such as Id. Following the usual sequence of steps, formation of a leaving group and alkylation, the ester 8b is reduced using standard conditions such as LiAIH4 (General Method 3) to reveal the alcohol. Finally, Buchwald coupling (General Method 4) of alcohol 5b completes the route. This typically requires an elevated temperature, for example 90 °C or above and in some cases alternative catalysts, such as RockPhos Pd G3, are more suitable.
Again, the order of steps can also be reversed, for example as shown in General Scheme 5.
The alcohol such as Id can undergo a Buchwald (General Method 4), followed by reduction of the ester, formation of a leaving group (General Method 1) and finally alkylation with compound 3 (General Method 2).
In examples, where RgA contains a bicyclic aromatic, it can be partially saturated during the synthesis, as shown in General Scheme 6.
Typically the aromatic ring such as 12 is subjected to hydrogenation at elevated temperature (General Method 3) using H2, 10% Pd/C to give compound 13. This transformation can take place on the free or protected amine.
In example compounds described herein containing a primary or secondary amine, a protecting group strategy may be required. Alternative protecting groups can be used with different deprotection conditions, that is, an orthogonal protecting group strategy can be applied. General Schemes 7-12 outline possible protecting group strategies that may be used for the synthesis of the examples.
For example, for compounds defined herein containing a 6,6 ring system, as shown in General Scheme 7, a protected amine can be installed. Initially the pyridone 14 may be chlorinated, typically using phosphorous oxychloride (General method 6). The resulting chloride 15 may be reacted with 2,4- dimethoxybenzylamine using General Method 7, for example using basic conditions such as K2CO3, CS2CO3, or pyridine in a solvent such as NMP or MeCN, either thermally and/or under microwave conditions. RgT refers to various substituents as required by the example compounds.
Typically, at the end of the synthetic sequence, the 2,4-dimethoxybenzyl protecting group is removed using TFA at 50 °C, either undiluted or diluted in DCM (General Scheme 8, General Method 8). RgT, RjA and RjB refer to various substituents as required by the examples.
Alternatively, when starting materials are available with the amine already installed, a carbamate protecting group can be used. For example, as outlined in General Scheme 9, the amine is reacted with methyl chloroformate under basic conditions with organic bases such as TEA or DIPEA in a solvent such as DCM to afford the methyl carbamate 21 (General Method 9). RjC refers to various substituents as required by the examples.
Typically, at the end of the synthetic sequence, the methyl carbamate protecting group is deprotected using basic conditions, such as KOH or LiOH in solvents such as 1,4-dioxane, MeCN, THF and optionally
10% water, at elevated temperature, typically 50 °C (General Scheme 10, General Method 10). RjC and RjD refer to various substituents as required by the examples.
Another protecting group that may be used where example compounds described herein contain a 6,6 ring system is boc.
Where, for example, example compounds described herein contain a 5,6 ring system, SEM, boc and sulfonyl protecting groups may typically be used. Protecting groups may subsequently be deprotected using standard literature procedures, for example those described by T. W. Greene and P. G. M. Wuts in "Protective groups in organic chemistry" John Wiley and Sons, 4th Edition, 2006.
An example of the installation of a SEM protecting group is shown in General Scheme 11 whereby the indole 24 is treated with a base such as NaH in a solvent such as DMF, followed by addition of SEM-CI (General Method 2).
Typically, at the end of the synthetic sequence the SEM protecting group is deprotected using acidic conditions such as TFA in DCM (General Scheme 12, General Method 11). RjD refers to various substituents as required by the examples.
In examples where RgA contains an aromatic or heteroaromatic bicycle they can be synthesised using procedures described in the literature and, for example, as depicted in General Scheme 13.
Amino pyridines such as 3a can be reacted with chloromethyl aldehydes and ketones 28 by refluxing in a solvent such as ethanol (General Method 12). Hydroxylation of the aryl bromide 3b to the corresponding aryl alcohol 3c is typically completed in a one-pot tandem process via Miyaura borylation (Palladium(O)- Catalyzed Cross-Coupling Reaction of Alkoxydiboron with Haloarenes: A Direct Procedure for Arylboronic Esters. T. Ishiyama, M. Murata, N. Miyaura, J. Org. Chem., 1995, 60, 7508-7510) and subsequent hydroxylation using hydrogen peroxide (General Method 13).
Other examples herein may be based on an azabicyclohexyl central core group, as shown in General Schemes 14 - 17. These General Schemes may also be applied to other central core groups such as bicyclopentyl, oxabicyclohexyl and oxabicycloheptyl. The starting materials may be readily available from commercial sources or may be known in the literature. Alternatively, some prior manipulation may be required, for example, as shown in General Scheme 14, a carboxylic acid such as le can be esterified using methods generally known in the art, for example via formation of the acid chloride in an appropriate alcohol solvent such as methanol (General Method 14).
When azabicyclohexyl rings are used they may be protected with a suitable nitrogen protecting group such as Boc or Cbz (General Scheme 15). Alternatively, the nitrogen can be reacted using methods generally known in the art and detailed herein below, to provide amide, urea, thiourea, alkyl, heteroaryl and sulfonamide analogues as shown in General Schemes 15 and 17.
As outlined in previous schemes and as repeated in General Scheme 16, RgA can be installed by transforming the alcohol Id to a leaving group, such as a mesylate or halide 7b and reacting with aryl alcohols (General Method 2). Alternatively, the alcohol Id can be directly reacted with phenols under Mitsunobu conditions (General Method 15) using standard conditions such as DIAD and triphenylphosphine in THF. The alcohol Id can also be coupled with aryl halides under SNAr in the presence of NaH (General Method 7a), or under Buchwald conditions (General Method 4), typically using RockPhos Pd G3 as the catalyst and elevating the temperature to 100 °C. The ester 8b is then reduced to alcohol 5c under conditions well known in the art such as lithium borohydride (LiBH4) or lithium aluminium hydride (LiAIH4) or lithium triethylborohydride (LiEt3BH) (General Method 3b) depending on other functionality contained in the compound. Oxidation to aldehyde 5d is typically achieved using a reagent such as Dess Martin periodinane (General Method 16). Finally, reductive amination (General Method 17) with amine 6a completes the route. Alternatively (not shown in the Schemes) the alcohol 5c can be transformed to an amine using methods generally known in the art, such as via conversion to a leaving group (General Method 1) then via an azide or Gabriel synthesis to provide the primary amine and finally
completing the route via a Buchwald coupling (General Method 4) as shown previously in General Scheme
When azabicyclohexyl rings are used, in which the nitrogen may be protected by a protecting group (i.e. 7b where V= NRi), a late stage functionalisation is possible, as shown in General Scheme 17. The nitrogen protecting group is removed using the appropriate conditions (for example boc deprotection via General Method 5, or Cbz deprotection via General Method 3e, 2,4-dimethoxybenzyl deprotection via General Method 8, or SEM deprotection via General Method 11). Manipulation of 7c using chemistry well known in the art can provide a variety of compound classes. For example, reductive alkylation with aldehydes (General Method 17) can give alkylated compounds such as 29a. Cross-coupling reactions with aryl halides, such as Buchwald reactions (General Method 4) or SNAr alkylation (General Method 7) can install aromatic groups to give 29f. Reaction of 7c with carboxylic acids or acid chlorides can be used to provide amides 29b (General Method 18) or reaction with sulphonyl chlorides (General Method 19) can provide sulphonamides 29c. Reaction with CDI and alcohols can provide carbamates 29d (General Method 20).
Ureas such as 29e can be formed by reaction of 7c with isocyanates, or by reacting with CDI or triphosgene and amines (General Method 21).
The routes described are also applicable to azabicyclohexyl isomers and the order of steps may vary depending on starting material availability or as chemical functionality requires.
Synthesis of Intermediates
Following General Method 9, 6-bromoisoquinolin-l-amine (1.50 g, 6.72 mmol) was protected. The crude was suspended in water (100 mL) and stirred for 30 min before being collected by filtration and dried in the vacuum oven overnight to give the product (1.12 g, 44% yield).
[M+H]+ = 281.1
1H NMR (500 MHz, DMSO-d6) 3.70 (3H, s), 7.58 - 7.72 (1H, m), 7.79 (1H, d, J = 9.0, 2.0 Hz), 8.04 (1H, d, J = 9.1 Hz), 8.25 - 8.30 (1H, m), 8.33 (1H, d, J = 5.8 Hz), 10.18 (1H, s)
Intermediate 2
Methyl N-(6-bromo-l-isoquinolyl)carbamate (100 mg, 0.36 mmol) was dissolved in chloroform (5 mL), NCS (52 mg, 0.39 mmol) was added and the reaction stirred at reflux for 18 h. To the reaction was added sat. NaHCO3 (aq.) (30 mL) and it was washed with DCM (30 mL), dried (Na2SO4) and concentrated. The crude product was purified by flash chromatography (Silica, 0-80% EtOAc in Pet. Ether) to give the product (74 mg, 59% yield).
[M+H]+ = 316.8/318.7
1H NMR (CDCI3, 400 MHz) 6 3.84 (3H, s), 7.36 (1H, s), 7.75 (1H, dd, J = 9.0, 1.9 Hz), 7.93 (1H, d, J = 9.0 Hz), 8.37 (2H, d, J = 4.9 Hz)
Intermediate 3
Methyl (5-bromoisoquinolin-l-yl)carbamate
Following General Method 9, 5-bromoisoquinolin-l-amine (1.12 g, 5.02 mmol) was protected. The product was dried under high vacuum to yield (838 mg, 56% yield).
[M+H]+ = 281.1
Intermediate 4
Following a variation of General Method 7d, to a solution of 5-bromo-l-chloroisoquinoline (0.5 g, 2.06 mmol) in pyridine (3 mL), was added 2,4-dimethoxybenzylamine (0.69 g, 4.12 mmol). The reaction was heated at 150 °C in a CEM Microwave for 60 min. The mixture was diluted with DCM (20 mL) and water (20 mL). The aqueous layer was re-extracted with DCM (3 x 10 mL) and the combined organics were washed with brine (20 mL). The organic layer was dried (Na2SO4), filtered and concentrated. Purification by flash chromatography (Silica, 20-50% EtOAc in Pet. Ether) afforded the product (276 mg, 50% yield). [M+H]+ = 373.0/375.0
1H NMR (DMSO-d6, 400 MHz) 6 3.71 (3H, d, J = 2.6 Hz), 3.82 (3H, d, J = 2.8 Hz), 4.62 (2H, d, J = 5.4 Hz), 6.41 (1H, dd, J = 8.5, 2.5 Hz), 6.56 (1H, d, J = 2.6 Hz), 6.94 - 7.14 (2H, m), 7.42 (1H, t, J = 8.0 Hz), 7.96 (3H, ddd, J = 16.4, 7.1, 3.2 Hz), 8.38 (1H, d, J = 8.2 Hz)
Intermediate 5
Nl-(2,4-Dimethoxybenzyl)isoquinoline-l,5-diamine
A mixture of 5-bromo-N-(2,4-dimethoxybenzyl)isoquinolin-l-amine (746 mg, 2.0 mmol), 2,2,2- trifluoroacetamide (339 mg, 3.0 mmol), Cul2 (38 mg, 0.2 mmol), K2CO3 (553 mg, 4.0 mmol) and N,N'- dimethylethylenediamine (35 mg, 0.4 mmol) were combined in a reaction vial. Anhydrous 1,4-dioxane (7 mL) was added, and the suspension purged with N2, before being capped and then heated to 75 °C for 24 h. The reaction was recharged with 2,2,2-trifluoroacetamide (339 mg, 3.0 mmol), Cul2 (38 mg, 0.2 mmol), K2CO3 (553 mg, 4.0 mmol) and N,N'-dimethylethylenediamine (35 mg, 0.4 mmol). The mixture was degassed with N2 and heated at 70 °C for 18 h. Water was added (3 mL) and the reaction heated at 80 °C for 6 h. The mixture was partitioned between EtOAc (30 mL) and water (10 mL). The aqueous layer was extracted with further EtOAc (2 x 30 mL) and the combined organics were washed with brine (50 mL), dried (Na2SO4 , filtered and concentrated. Purification by flash chromatography (Silica, 0-100% EtOAc/DCM) afforded the product (492 mg, 72% yield).
[M+H]+ 310.1
1H NMR (CDCI3, 400 MHz) 6 3.79 (3H, s), 3.85 (3H, s), 4.10 (2H, br s), 4.72 (2H, d, J = 5.3 Hz), 5.58 - 5.67 (1H, m), 6.44 (1H, dd, J = 8.2, 2.4 Hz), 6.49 (1H,d, J = 2.4 Hz), 6.78 - 6.86 (2H, m), 7.12 (1H, dt, J = 8.4, 1.1 Hz), 7.21 (1H, dd, J = 8.4, 7.4 Hz), 7.30 (1H, d, J = 8.2 Hz), 8.01 (1H, d, J = 6.1 Hz)
Intermediate 6
Following General Method 2a, 4-bromo-lH-pyrrolo[2,3-b]pyridine (500 mg, 2.54 mmol) was reacted with SEM-CI (494 μL, 2.79 mmol) for 2 h. The reaction mixture was quenched by the careful addition of water (10 ml) followed by repeat extraction with EtOAc (3 x 20 ml). The combined organic layers were then washed with sat. NaHCO3 (aq) (30 ml), water (30 ml) and brine (30 ml), before being dried (MgSO4), filtered and concentrated. Purification by flash chromatography (Silica, 0-100% EtOAc in iso-hexane) afforded the product (500 mg, 57% yield).
[M+H]+ - 32.7.2
1H NMR (500 MHz, DMSO-d6) 6 -0.11 (s, 9H), 0.75 - 0.86 (m, 2H), 3.43 - 3.56 (m, 2H), 5.63 (s, 2H), 6.52 (d, J
= 3.6 Hz, 1H), 7.43 (d, J = 5.1 Hz, 1H), 7.79 (d, J = 3.6 Hz, 1H), 8.16 (d, J = 5.1 Hz, 1H)
Intermediate 7
Following General Method 2a, 5-bromo-3-chloro-lH-pyrrolo[2,3-b]pyridine (480 mg, 2.07 mmol) was reacted with SEM-CI (0.4 mL, 2.28 mmol) for 2 h. The reaction was quenched with water (2 mL) and diluted with EtOAc (40 mL). The organic layer was washed with water (20 mL), IM HCI (aq) (20 mL), 1:1 water/brine (20 mL) and brine (20 mL), dried (MgSO4), filtered and concentrated. Purification by flash chromatography (Silica, 0-100% EtOAc in iso-hexane) afforded the product (485 mg, 60% yield).
[M+H]+ = 363.0
1H NMR (500 MHz, DMSO-d6) 6 -0.10 (9H, s), 0.81 (2H, t, J = 7.9 Hz), 3.51 (2H, t, J = 7.9 Hz), 5.60 (2H, s), 7.98 -8.01 (1H, m), 8.20 - 8.24 (1H, m), 8.44 - 8.47 (1H, m)
Intermediate 8
A solution of 5-bromo-2H-isoquinolin-l-one (9.0 g, 40.2 mmol) and Selectfluor® (17.1 g, 48.2 mmol) in MeCN (120 mL) and MeOH (120 mL) were heated at 50 °C for 3 h. The reaction mixture was concentrated and reacted using General Method 6, in 1,2-dichloroethane (200 mL) using benzyltriethylammonium chloride (915mg, 4.0mmol) and phosphorus oxychloride (45mL) at 90 °C for 24 h. The reaction mixture
was concentrated, and the residue partitioned between DCM (500 mL) and water (500 mL). The organic layer was washed with water (300 mL) and brine (300 mL), dried (MgSO4) and evaporated. The crude was purified by flash chromatography (Silica, 0-30% EtOAc in Pet. Ether) to give the product (5.70 g, 55% yield). [M+H]+ = 261.9
1H NMR (500 MHz, CDCI3) 6 8.39 - 8.33 (m, 1H), 8.23 (d, J= 4.0 Hz, 1H), 8.12 - 8.06 (m, 1H), 7.57 (t, J= 8.0 Hz, 1H)
Following General Method 7d, 5-bromo-l-chloro-4-fluoroisoquinoline (5.70 g, 21.9 mmol) was reacted with 2,4-dimethoxybenzylamine (4.93 mL, 32.8 mmol) in l-methyl-2-pyrrolidinone (80 mL) at 100 °C for 48 h. The crude product was purified by flash chromatography (Silica, 0-30% EtOAc in Pet. Ether) to give the product (1.05 g, 12% yield).
1H NMR (500 MHz, DMSO) 6 8.43 (dd, J= 8.1, 2.3 Hz, 1H), 8.06 (dd, J= 7.6, 0.9 Hz, 1H), 7.89 (d, J= 5.1 Hz, 1H), 7.81 (t, J= 5.6 Hz, 1H), 7.49 (t, J= 8.0 Hz, 1H), 7.05 (d, J= 8.3 Hz, 1H), 6.56 (d, J= 2.4 Hz, 1H), 6.41 (dd, J= 8.4, 2.4 Hz, 1H), 4.57 (d, J= 5.5 Hz, 2H), 3.82 (s, 3H), 3.72 (s, 3H)
19F NMR (471 MHz, DMSO) 6 -149.9(s)
[M-H] = 389.2
Intermediate 9 l-(Benzenesulfonyl)-4-bromo-2-chloropyrrolo[2,3-b]pyridine
l-(Benzenesulfonyl)-4-bromopyrrolo[2,3-b]pyridine
To a solution of 4-bromo-lH-pyrrolo[2,3-b]pyridine (5.00 g, 25.4 mmol) in DCM (130 mL) was added benzenesulfonyl chloride (4.86 mL, 38.1 mmol), 4-dimethylaminopyridine (310 mg, 2.54 mmol) and TEA (10.6 mL, 76.1 mmol). The reaction mixture was stirred at rt for 2 h. Upon completion the reaction mixture was concentrated. The product was suspended in DCM (50 mL) and concentrated onto silica. The material was purified via flash chromatography (Silica, 0-50% EtOAc in Pet. Ether) to afford the product (8.39 g, 98% yield).
[M+H]+= 338.9 l-(Benzenesulfonyl)-4-bromo-2-chloropyrrolo[2,3-b]pyridine
l-(Benzenesulfonyl)-4-bromopyrrolo[2,3-b]pyridine (1.00 g, 2.97 mmol) in anhydrous THF (16 mL) was cooled to -41 °C and lithium diisopropylamide (2M in THF) (356 mL, 7.12 mmol) was added slowly. The resulting precipitate was stirred for 30 min at -41 °C before benzenesulfonyl chloride (757 μL, 5.93 mmol) was added. The reaction mixture was stirred for 2.5 h at -41 °C. The reaction mixture was quenched with water (10 mL) and diluted with EtOAc (20 mL). The layers were separated, and the aqueous layer was back extracted with EtOAc (2 x 20 mL). The organic layers were combined, washed with brine (10 mL), dried (MgSO4), filtered and concentrated. Purification by flash chromatography (Silica, 0-60% EtOAc in Pet. Ether) afforded the product (895 mg, 49% yield).
[M+H]+= 372.9 l-(Benzenesulfonyl)-4-bromo-2-chloropyrrolo[2,3-b]pyridine
To a solution of l-(Benzenesulfonyl)-4-bromo-2-chloropyrrolo[2,3-b]pyridine (895 mg, 1.44 mmol) in 1,4- dioxane (7 mL) was added NaOtBu (324 mg, 2.89 mmol). The reaction mixture was stirred at 80 °C for 2 h, diluted with EtOAc (10 mL) and washed with brine (10 mL). Layers were separated and the organic layer was dried (MgSO4), filtered and concentrated. Purification by flash chromatography (Silica, 0-25% EtOAc in Pet. Ether) afforded the product (295 mg, 88% yield).
[M+H]+= 232.9
1H NMR (CDCl3. 400 MHz) 6 6.47 (1H, s), 7.32 (1H, d, J = 5.3 Hz), 8.11 (1H, d, J = 5.3 Hz,) NH proton not observed
Intermediate 10
According to a modification of General Method 13, 6-bromo-3-rnethylirnidazo[l,2-a]pyridine (525 mg, 2.49 mmol) was reacted with B2Pin2 (1.42 g, 5.6 mmol)at 100 °C for 5 h. The mixture was cooled to rt before AcOH (285 μL, 4.97 mmol) and water (1 mL) were added. The mixture was stirred for 15 min before a solution of H2O2 in water (30% w/w, 508 μL, 4.97 mmol) was added dropwise at 0 °C. The mixture was stirred for 90 min at rt, quenched with solid Na2S2O3 (5 mg), filtered through Celite® and concentrated. The product was passed directly through SCX and washed with MeOH. The product was eluted with a solution of IM NH3 in MeOH and concentrated to afford the product (160 mg, 33% yield). [M+H]+= 149.1
1H NMR (DMSO, 400 MHz) 6 2.36 (3H, s), 6.92 (1H, dd, J = 9.6, 2.3 Hz), 7.25 (1H, s), 7.40 (1H, d, J = 9.5 Hz), 7.59 (1H, d, J = 1.9 Hz), 9.45 (1H, s)
Intermediate 11
Ethyl 7-hydroxy-5-oxo-2,3-dihydro-lH-indolizine-8-carboxylate (125 mg, 0.56 mmol) was dissolved in 12M HCI (aq) (1.87 mL, 22.4 mmol) and stirred at reflux for 18 h. The solution was cooled to rt, then azeotroped with Et2O ( 3 x 5 mL) and concentrated to provide the product (123 mg, 87% yield) which was used for the next step without further purification.
[M+H]+ = 152.1
Intermediate 12
The product was prepared from 4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-l-carboxylic acid (CAS 1522098-73-2, Tetrahedron Letters 55 (2014) 466-468) following the procedure described in ChemistrySelect 2019, 4, 4933 - 493.
Intermediate 13
Following General Method 14, 5-(hydroxymethyl)-2-oxabicyclo[3.1.1]heptane-l-carboxylic acid sodium salt (600 mg, 2.8 mmol) was reacted for 22 h. The reaction mixture was diluted with DCM (40 mL) and washed with water (20 mL). The aq layer was extracted with DCM (30 mL). The combined organic fractions were dried (Na2SO4) and concentrated to afford the product (409 mg, 71% yield).
[M+H]+ = 187.1
1H NMR (CDCI3, 400 MHz) 6 1.94 - 2.05 (4H, m), 2.33 (2H, ddt, J = 7.2, 2.3, 1.0 Hz), 3.54 (2H, s), 3.77 (3H, s), 4.19 - 4.27 (2H, m)
Methyl 5-(methylsulfonyloxymethyl)-2-oxabicyclo[3.1.1]heptane-l-carboxylate
According to General Method la, methyl 5-(hydroxymethyl)-2-oxabicyclo[3.1.1]heptane-l-carboxylate (404 mg, 1.95 mmol) was reacted with MsCI (227 μL, 2.93 mmol for 22 h. Aqueous work up afforded the product (372 mg, 58% yield).
1H NMR (CDCI3, 400 MHz) 6 2.05 - 2.13 (4H, m), 2.35 - 2.44 (2H, m), 3.05 (3H, s), 3.78 (3H, s), 4.12 (2H, s), 4.19 - 4.26 (2H, m)
A suspension of methyl 5-(methylsulfonyloxymethyl)-2-oxabicyclo[3.1.1]heptane-l-carboxylate (100 mg, 0.303 mmol) and potassium phthalimide (62.0 mg, 0.333 mmol) in DMF (4 mL) was stirred at 100 °C for 3 h. The mixture was cooled to rt, taken up in water (20 mL) and washed with EtOAc (2x30 mL). The combined organic layers were washed with brine (10 mL), dried (Na2SO4) and concentrated to afford the product (98 mg, 82% yield).
[M+H]+ = 316.0
1H NMR (CDCI3, 400 MHz) 6 2.01 - 2.14 (4H, m), 2.30 - 2.39 (2H, m), 3.73 (5H, s), 4.15 - 4.21 (2H, m), 7.71
- 7.79 (2H, m), 7.83 - 7.90 (2H, m)
To a stirred solution of methyl 5-[(1,3-dioxoisoindol-2-yl)methyl]-2-oxabicyclo[3.1.1]heptane-l- carboxylate (98 mg, 0.25 mmol) in IPA (4 mL) and water (1 mL), was added NaBF (56 mg, 1.49 mmol).
After stirring for 24 h, AcOH (256 μL, 4.48 mmol) was added slowly and when the foaming subsided, the reaction was heated to 80 °C for 22 h. The reaction mixture was concentrated, the residue taken up in MeOH (1 mL) and the mixture was passed directly through an SCX column and washed with MeOH. The product was eluted with a solution of IM NH3 in MeOH and concentrated to afford the product (39 mg, 100% yield).
[M+H]+ = 158.1
1H NMR (CDCI3, 400 MHz) 6 1.60 - 1.67 (2H, m), 1.82 (2H, dd, J = 7.2, 2.7 Hz), 1.92 - 1.98 (2H, m), 2.64 (2H, s), 3.51 (2H, s), 4.07 - 4.16 (2H, m)
To a solution of [l-(aminomethyl)-2-oxabicyclo[3.1.1]heptan-5-yl]methanol hydrochloride (500 mg, 2.58 mmol) and TEA (1260 μL, 9.04 mmol) in THF (10 mL) at 0 °C was added BOC2O (676 mg, 3.1 mmol) and the mixture was stirred for 10 min at 0 °C. After that time the reaction was stirred for 18 h at rt. The reaction was quenched with water (30 mL), washed with EtOAc (2 x 50 mL), dried (MgSO4) and concentrated to afford the product (760 mg, 92% yield).
[M+Na]+ = 280.2
1H NMR (CDCI3) 6 1.43 (9H, s), 1.74 - 1.79 (4H, m), 1.94 (2H, t, J = 6.9 Hz), 2.53 (1H, d, J = 4.4 Hz), 3.17 (2H, d, J = 5.8 Hz), 3.46 (2H, d, J = 5.5 Hz), 4.07 (2H, t, J = 6.9 Hz), 4.94 (1H, s)
Intermediate 15
[l-[[(2-Methylpropan-2-yl)oxycarbonylamino]methyl]-2-oxabicyclo[3.1.1]heptan-5-yl]methyl methanesulfonate
According to a modification of General Method la, tert-butyl N-[[5-(hydroxymethyl)-2- oxabicyclo[3.1.1]heptan-l-yl]methyl]carbamate (760 mg, 2.36 mmol) was reacted with MsCI (219 μL, 2.84
mmol) at 0 °C for 90 min. Aqueous work up afforded the product (950 mg, 96% yield) which was used without further purification.
[M+Na]+ = 358.3
1H NMR (CDCI3) 6 1.44 (9H, s), 1.81 - 1.89 (4H, m), 2.00 (2H, t, J = 6.8 Hz), 3.02 (3H, s), 3.18 (2H, d, J = 6.0
Hz), 4.06 - 4.10 (4H, m), 4.90 (1H, s)
Intermediate 16
To a solution of methyl 4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-l-carboxylate;hydrochloride (40.5 g, 176 mmol) and TEA (75 mL, 538 mmol) in anhydrous DCM (200 mL) and anhydrous MeOH (200 mL) at rt was added BOC2O (42.1 g, 193 mmol). After stirring for 16 h. The reaction was quenched with brine (200 mL). The layers were separated, and the aqueous layer was extracted with DCM (2 x 100 mL). The combined organic phases were dried (Na2SO4), filtered, and concentrated. Purification by flash chromatography (Silica, 0-20% MeOH in DCM) provided the product (37.1 g, 74% yield).
[M+H]+ = 272.1
1H NMR (CDCI3, 400 MHz) 6 1.41 (9H, s), 1.75 (2H, dd, J = 4.7, 1.9 Hz), 1.95 - 2.06 (2H, m), 2.17 (1H, s),
3.37 (2H, s), 3.76 (3H, s), 3.79 (2H, s)
Intermediate 17
Methyl 4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-l-carboxylate hydrochloride (600 mg, 2.89 mmol) was dissolved in DCM (15 mL) and cooled to 0 °C. TEA (805 μL, 5.78 mmol) was added followed by benzyl chloroformate (407 μL, 2.89 mmol). The reaction was stirred at rt overnight before retreating with benzyl chloroformate (200 μL, 1.42 mmol) at 0 °C and stirring at rt for an additional 1 h. DCM (30 mL) and water (10 mL) were added. The organic layer was dried (MgSO4), filtered and concentrated. The crude product was purified by flash chromatography (Silica, 20-100% EtOAc in Pet. Ether) to afford the product (465 mg, 53% yield).
[M+H]+ = 306.2
1H NMR (DMSO-d6, 400 MHz) 6 1.56 - 1.66 (2H, m), 1.89 - 1.97 (2H, m), 3.32 (2H, s), 3.50 - 3.65 (5H, m), 4.74 - 4.78 (1H, m), 5.04 (2H, s), 7.30 - 7.42 (5H, m)
Following General Method la, 2-O-benzyl 1-O-methyl 4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-l,2- dicarboxylate (1206 mg, 3.95 mmol) was reacted with MsCI (367 μL, 4.74 mmol) for 90 min, after which time aqueous work up afforded the product (1480 mg, 98% yield).
[M+H]+ = 384.1.
1H NMR (CDCI3, 400 MHz) 6 1.91 (2H, dd, J = 4.8, 1.9 Hz), 2.12 (2H, dd, J = 5.0, 1.9 Hz), 3.04 (3H, s), 3.51 (2H, s), 3.67 (3H, s), 4.40 (2H, s), 5.11 (2H, s), 7.27 - 7.44 (5H, m).
Intermediate 18
2-(tert-Butyl) 1-methyl 4-(((tert-butyldiphenylsilyl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-l,2- dicarboxylate
To a solution of 2-(tert-butyl) 1-methyl 4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-l,2-dicarboxylate (30 g, 111 mmol) and imidazole (8.28 g, 122 mmol) in anhydrous DCM (150 mL) at 0 °C was added TBDPS- Cl (31.6 mL, 122 mmol) and the reaction stirred for 1 h at 0 °C, then at rt and for 16 h. After quenching with brine (200 mL) and EtOAc (100 mL), the layers were separated, and the aqueous layer was extracted with EtOAc (2 x 100 mL). The combined organic layers were washed with IM HCI (aq) (200 mL), brine (200 mL), IM NaOH (aq) (200 mL), dried (Na2SO4, filtered, and concentrated to afford the product (59.5 g, 95% yield).
1H NMR (CDCI3, 300 MHz) 6 1.06 (9H, s), 1.44 (9H, s), 1.75 (2H, d, J = 4.6 Hz), 2.01 (2H, d, J = 4.7 Hz), 3.37 (2H, s), 3.78 - 3.79(3H, m), 3.80 (2H, s), 7.35 - 7.46 (6H, m), 7.58 - 7.67 (4H, m)
Intermediate 19 tert-Butyl 4-(((1,6-dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-l-(hydroxymethyl)-2- azabicyclo[2.1.1]hexane-2-carboxylate
2-(tert-Butyl) 1-methyl 4-(((1,6-dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-2- azabicyclo[2.1.1]hexane-l,2-dicarboxylate
According to General Method 15, 2-(tert-butyl) 1-methyl 4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane- 1,2-dicarboxylate (10.0 g, 36.8 mmol) was reacted with 4-hydroxy-l,6-dimethyl-pyridin-2-one (6.00 g, 41.0 mmol). The reaction mixture was filtered over Celite®. The solid was washed with EtOAc (200 mL) and the filtrate was concentrated. Purification by flash chromatography (silica, 0-7% MeOH in EtOAc) afforded the product (6.20 g, 30% yield, 70% pure).
[M+H]+ = 393.2
1H NMR (DMSO-d6, 400 MHz) 6 1.36 (9H, s), 1.67 (2H, dd, J = 4.5, 1.9 Hz), 2.01 - 2.09 (2H, m), 3.32 (3H, s), 3.35 (2H, s), 3.66 (3H, s), 3.69 (3H, s), 4.16 (2H, s), 5.69 (1H, d, J = 2.8 Hz), 5.89 (1H, dd, J = 2.8, 0.9 Hz) tert-Butyl 4-(((1,6-dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-l-(hydroxymethyl)-2- azabicyclo[2.1.1]hexane-2-carboxylate
According to a variation of General Method 3b, 2-(tert-butyl) 1-methyl 4-(((1,6-dimethyl-2-oxo-l,2- dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-l,2-dicarboxylate (6.20 g, 11.1 mmol) was reduced in the presence of LiBH4 (2M in THF, 11 mL, 22.0 mmol) for 72 h. The mixture was quenched with H2O (30 mL) and concentrated. The aqueous phase was extracted with DCM (3 x 60 mL). The combined organic layers were dried (Na2SO4), filtered, and concentrated. Purification by flash chromatography (Silica, 0-12% MeOH in EtOAc) afforded the product (2.70 g, 67% yield). [M+H]+ = 366.1
1H NMR (CDCI3, 400 MHz) 6 1.48 (9H, s), 1.66 (1H, s), 1.70 - 1.79 (4H, m), 2.30 (3H, d, J = 0.7 Hz), 3.37 (2H, s), 3.45 (3H, s), 3.94 (2H, d, J = 6.4 Hz), 4.04 (2H, s), 5.79 (2H, d, J = 0.8 Hz)
Intermediate 20
(4-(((1-((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-oxabicyclo[2.1.1]hexan-l- yl)methanol
According General Method 4, a suspension of [4-(aminomethyl)-2-oxabicyclo[2.1.1]hexan-l-yl]methanol (500 mg, 3.49 mmol), 5-bromo-N-(2,4-dimethoxybenzyl)isoquinolin-l-amine (1434 mg, 3.84 mmol) and NaOlBu (503 mg, 5.24 mmol) in 1,4-dioxane (5 mL) was reacted in the presence of Brettphos Pd G4 (241 mg, 0.26 mmol) in a sealed vial at 40 °C for 18 h and then at 60 °C for 2 h. Flash chromatography (Silica, 20-100% EtOAc in Pet. Ether) afforded the product (861 mg, 57% yield).
[M+H]+ = 436.2 Intermediate 21 (4-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-oxabicyclo[2.1.1]hexan-l- yl)methyl methanesulfonate
According to General Method la, a solution of (4-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5- yl)amino)methyl)-2-oxabicyclo[2.1.1]hexan-l-yl)methanol (800 mg, 1.84 mmol) was reacted with methane sulfonyl chloride (252 mg, 2.2 mmol) to afford the product (914 mg, 97% yield) which was used without purification. [M+H]+ = 514.2
Intermediate 22 (1-(((1-((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-oxabicyclo[2.1.1]hexan-4- yl)methanol
According to General Method 4, a suspension of [l-(aminomethyl)-2-oxabicyclo[2.1.1]hexan-4- yl]methanol hydrochloride (250 mg, 1.39 mmol), 5-bromo-N-(2,4-dimethoxybenzyl)isoquinolin-l-amine (571 mg, 1.53 mmol) and NaCtBu (334 mg, 3.48 mmol) in 1,4-dioxane (5 mL) was reacted in the presence of Brettphos Pd G4 (96 mg, 0.1 mmol) in a sealed vial at 40 °C for 18 h. Flash chromatography (Silica, 20- 100% EtOAc in Pet. Ether) afforded the product (429 mg, 71% yield).
[M+H]+ = 436.2
Intermediate 23
(1-(((1-((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-oxabicyclo[2.1.1]hexan-4- yl)methyl methanesulfonate
According to General Method la, a solution of (1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5- yl)amino)methyl)-2-oxabicyclo[2.1.1]hexan-4-yl)methanol (429 mg, 0.99 mmol) was reacted with methane sulfonyl chloride (135 mg, 1.18 mmol) to afford the product (440 mg, 87% yield) which was used without purification by chromatography.
[M+H]+= 514.2
Intermediate 24 (1-(((1-((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-oxabicyclo[3.1.1]heptan-5- yl)methanol
According to General Method 4, a suspension of [l-(aminomethyl)-2-oxabicyclo[3.1.1]heptan-5- yl]methanol hydrochloride (300 mg, 1.55 mmol), 5-bromo-N-(2,4-dimethoxybenzyl)isoquinolin-l-amine (578 mg, 1.55 mmol) and NaCfBu (372 mg, 3.87 mmol) in 1,4-dioxane (6 mL) was reacted in the presence of Brettphos Pd G4 (107 mg, 0.12 mmol) in a sealed vial at 40 °C for 3 days and at 60 °C for 18 h. Flash
chromatography (Silica, 0-100% EtOAc in Pet. Ether followed by 0-12% MeOH in EtOAc) afforded the product (190 mg, 27% yield).
[M+H]+= 450.3
Intermediate 25 (1-(((1-((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-oxabicyclo[3.1.1]heptan-5- yl)methyl methanesulfonate
According to General Method la, a solution of (1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5- yl)amino)methyl)-2-oxabicyclo[3.1.1]heptan-5-yl)methanol (160 mg, 0.36 mmol) was reacted with MsCI (36 μL, 0.46 mmol) to afford the product (190 mg, 91% yield) which was used without purification.
[M+H]+= 528.2
1H NMR (CDCI3) 6 1.45 (9H, s), 1.92 (4H, s), 2.07 (2H, t, J = 6.9 Hz), 3.23 (2H, d, J = 5.9 Hz), 3.74 (2H, s), 4.09 - 4.14 (2H, m), 5.03 (1H, t, J = 5.9 Hz), 6.96 (1H, dd, J = 9.7, 2.3 Hz), 7.48 - 7.51 (2H, m), 7.56 (1H, d, J = 0.8 Hz), 7.66 (1H, d, J = 1.8 Hz)
Intermediate 26
4-((4-(((1*((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-l- yl)methoxy)-l-methylpyridin-2(1H)-one
To 2-O-benzyl 1-O-methyl 4-(methylsulfonyloxymethyl)-2-azabicyclo[2.1.1]hexane-l,2-dicarboxylate (458 mg, 1.19 mmol) in DMF (5 mL) was added NaN3 (155 mg, 2.39 mmol) at rt. The mixture was stirred at rt for 4 days. The mixture was diluted with EtOAc (50 mL) and washed with water (4 x 10 mL) and brine (10 mL), dried (MgSO4) and concentrated to afford the product (330 mg, 75% yield). [M+H]+ = 331.1
1H NMR (CD3CN) 6 1.73 (2H, dd, J = 4.7, 1.9 Hz), 2.01 (2H, dd, J = 4.6, 1.4 Hz), 3.38 (2H, s), 3.56 (5H, s), 5.04 (2H, s), 7.28 - 7.37 (5H, m)
2-O-Benzyl 1-O-methyl 4-(azidomethyl)-2-azabicyclo[2.1.1]hexane-l,2-dicarboxylate (330 mg, 0.9 mmol) was dissolved in THF (6 mL). Triphenylphosphine, polymer bound (3mmol/ lg of resin) (453 mg, 1.35 mmol) was added and the reaction stirred at rt for 2 h. Water (162 μL, 8.99 mmol) was added and the
reaction heated at reflux for 3 h. The mixture was cooled to rt and filtered, washing the resin with 10% MeOH in DCM (25 mL). The filtrate was concentrated to afford the product (240 mg, 79% yield).
[M+H]+ = 305.1
1H NMR (CDCk) 6 1.29 (2H, br s), 1.70 (2H, dd, J = 4.6, 1.7 Hz), 1.90 (2H, d, J = 4.6 Hz), 2.85 (2H, s), 3.34
(2H, s), 3.53 (3H, br s), 5.02 (2H, s), 7.19 - 7.28 (5H, m)
2-Benzyl 1-methyl 4-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2- azabicyclo[2.1.1]hexane-l,2-dicarboxylate
According to a variation of General Method 4, 5-bromo-N-(2,4-dimethoxybenzyl)isoquinolin-l-amine (2239 mg, 6.00 mmol) was reacted with 2-O-benzyl 1-O-methyl 4-(aminomethyl)-2- azabicyclo[2.1.1]hexane-l,2-dicarboxylate (1927 mg, 5.70 mmol), CS2CO3 (5610 mg, 17.0 mmol) and Brettphos Pd G4 (801 mg, 0.852 mmol) in 1,4-dioxane (25 mL) at 65 °C for 6 h. The reaction mixture was cooled, filtered (Celite®) washing with EtOAc (200 mL), and the filtrate was concentrated. Purification by flash chromatography (Silica, 0-70% EtOAc in hexanes) afforded the product (2580 mg, 76%).
[M+H]+ = 597.3
1H NMR (CDCI3, 500 MHz) 6 1.91 (2H, dd, J = 4.7, 1.9 Hz), 2.11 (2H, d, J = 4.8 Hz), 3.51 - 3.70 (7H, m), 3.80
(3H, s), 3.86 (3H, s), 4.26 (1H, s), 4.72 (2H, d, J = 5.3 Hz), 5.12 (2H, s), 5.63 (1H, t, J = 5.3 Hz), 6.45 (1H, dd, J = 8.3, 2.4 Hz), 6.50 (1H, d, J = 2.4 Hz), 6.66 (1H, d, J = 7.7 Hz), 6.75 (1H, d, J = 6.1 Hz), 7.08 (1H, d, J = 8.3 Hz), 7.28 - 7.39 (7H, m), 8.02 (1H, d, J = 6.1 Hz)
Benzyl 4-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-l-(hydroxymethyl)-2- azabicyclo[2.1.1]hexane-2-carboxylate
Following a variation of General Method 3b, 2-benzyl 1-methyl 4-(((1-((2,4- dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexane-l,2-dicarboxylate (1713 mg, 2.87 mmol) was reduced in the presence of lithium triethylborohydride (IM in THF, 7.2 mL, 7.20 mmol) at 0 °C for 2.5 h. The reaction mixture was diluted with water (10 mL), brine (20 mL) and EtOAc (90 mL). The phases were separated, and the aqueous phase was extracted with EtOAc (2 x 50 mL). The combined organic phases were dried (MgSO4) and concentrated. Purification by flash chromatography (Silica, 20-68% EtOAc in hexanes) afforded the product (1096 mg, 67% yield).
[M+H]+ = 569.8
1H NMR (CDCI3, 400 MHz) 6 1.78 (4H, s), 3.51 (2H, s), 3.54 (2H, s), 3.80 (3H, s), 3.86 (3H, s), 3.98 (2H, d, J = 7.4 Hz), 4.24 (1H, s), 4.54 (1H, s), 4.72 (2H, d, J = 5.3 Hz), 5.14 (2H, s), 5.63 (1H, t, J = 5.4 Hz), 6.45 (1H, dd, J = 8.2, 2.4 Hz), 6.50 (1H, d, J = 2.4 Hz), 6.67 (1H, dd, J = 7.8, 0.8 Hz), 6.76 (1H, dd, J = 6.1, 0.9 Hz), 7.05 - 7.11 (1H, m), 7.37 (7H, d, J = 4.6 Hz), 8.02 (1H, d, J = 6.1 Hz)
Benzyl 4-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-l-(((1-methyl-2-oxo-l,2- dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate
According to General Method 15, benzyl 4-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5- yl)amino)methyl)-l-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (1046 mg, 1.84 mmol), was reacted with 4-hydroxy-l-methyl-pyridin-2-one (254 mg, 1.93 mmol). After aqueous work up, purification by flash column chromatography (Silica, 0-20% MeOH in EtOAc) afforded the product (319 mg, 26% yield). [M+H]+ = 676.4
1H NMR (CDCI3, 400 MHz) 6 1.73 (2H, dd, J = 4.5, 1.9 Hz), 2.01 - 2.04 (2H, m), 3.46 (3H, s), 3.55 (2H, s), 3.57 (3H, s), 3.80 (3H, s), 3.86 (3H, s), 4.26 (1H, s), 4.47 - 4.56 (2H, m), 4.73 (2H, d, J = 5.3 Hz), 5.10 (2H, s), 5.62 (1H, d, J = 5.5 Hz), 5.82 - 5.94 (2H, m), 6.45 (1H, dd, J = 8.2, 2.4 Hz), 6.50 (1H, d, J = 2.4 Hz), 6.68 (1H, d, J = 7.7 Hz), 6.77 (1H, dd, J = 6.2, 0.9 Hz), 7.08 (2H, dd, J = 8.0, 4.4 Hz), 7.28 - 7.39 (6H, m), 8.03 (1H, d, J = 6.1 Hz)
4-((4-(((1*((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-l- yl)methoxy)-l-methylpyridin-2(1H)-one
According to a variation of General Method 3e, a solution of benzyl 4-(((1-((2,4- dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-l-(((1-methyl-2-oxo-l,2-dihydropyridin-4- yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (319 mg, 0.472 mmol) in MeOH (3 mL) was added to a mixture of Pd(OH)2/C (20 wt%, 82.0 mg, 0.0117 mmol) in MeOH (1.8 mL). The mixture was subjected to hydrogenation at 1 atmosphere at rt for 4 h. The mixture was filtered over Celite® washing with MeOH (2 x 25 mL), and the filtrate was concentrated to afford the product (234 mg, 91% yield).
[M+H]+ = 542.4
1H NMR (DMSO-d6, 500 MHz) 6 1.34 (2H, dd, J = 4.0, 1.7 Hz), 1.62 (2H, dd, J = 4.2, 1.6 Hz), 2.83 (2H, s), 3.17 (1H, d, J = 2.6 Hz), 3.31 (3H+H2O, s), 3.49 (2H, d, J = 5.8 Hz), 3.71 (3H, s), 3.82 (3H, s), 4.03 (2H, s), 4.58 (2H, d, J = 5.6 Hz), 5.76 (1H, d, J = 2.8 Hz), 5.89 (1H, dd, J = 7.5, 2.8 Hz), 5.95 (1H, t, J = 6.0 Hz), 6.39 (1H, dd, J = 8.4, 2.4 Hz), 6.55 (1H, d, J = 2.4 Hz), 6.66 (1H, d, J = 7.7 Hz), 7.02 (1H, d, J = 8.4 Hz), 7.12 (1H, d, J = 6.2 Hz), 7.23 (1H, t, J = 8.0 Hz), 7.36 (1H, t, J = 5.8 Hz), 7.42 (1H, d, J = 8.4 Hz), 7.52 (1H, d, J = 7.6 Hz), 7.72 (1H, d, J = 6.0 Hz)
Intermediate 27
4-((1-(((1-((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l-methylpyridin-2(1H)-one
2-O-Benzyl 1-O-methyl 4-[(1-methyl-2-oxopyridin-4-yl)oxymethyl]-2-azabicyclo[2.1.1]hexane-l,2- dicarboxylate
According to General Method 2b, 2-O-benzyl 1-0-methyl 4-(methylsulfonyloxymethyl)-2- azabicyclo[2.1.1]hexane-l,2-dicarboxylate (703 mg, 1.56 mmol) was reacted with 4-hydroxy-l-methyl-2- pyridone (195 mg, 1.56 mmol) and K2CO3 (646 mg, 4.68 mmol) in DMF (10 mL) at 90 °C for 17 h. After aqueous work up the residue was purified by flash chromatography (Silica, 0-9% MeOH in DCM) to afford the product (620 mg, 96% yield).
[M+H]+ = 413.4
1H NMR (DMSO-d6, 400 MHz) 6 1.74 (2H, dd, J = 4.6, 1.9 Hz), 2.10 (2H, dd, J = 4.7, 1.8 Hz), 3.32 (3H, s),
3.45 (2H, s), 3.57 (3H, s), 4.19 (2H, s), 5.06 (2H, s), 5.79 (1H, d, J = 2.8 Hz), 5.93 (1H, dd, J = 7.6, 2.8 Hz),
7.36 (5H, m), 7.56 (1H, d, J = 7.5 Hz)
Benzyl l-(hydroxymethyl)-4-[(1-methyl-2-oxopyridin-4-yl)oxymethyl]-2-azabicyclo[2.1.1]hexane-2- carboxylate
According to a modification of General Method 3b, 2-O-Benzyl 1-O-methyl 4-[(1-methyl-2-oxopyridin-4- yl)oxymethyl]-2-azabicyclo[2.1.1]hexane-l,2-dicarboxylate (582 mg, 1.41 mmol) was reduced in the presence of lithium borohydride (IJBH4) (2M solution in THF) (776 μL, 1.55 mmol) over 72 h. Water (10 mL) and DCM (30 mL) were added. The organic layer was isolated and the aqueous layer re-extracted with DCM (3 x 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to afford the product (464 mg, 86% yield).
[M+H]+= 385.3
1H NMR (DMSO-d6, 400 MHz) 6 1.46 (2H, dd, J = 4.4, 1.8 Hz), 1.83 - 1.95 (2H, m), 3.33 (3H, s), 3.41 (2H, s), 3.90 (2H, d, J = 6.1 Hz), 4.17 (2H, s), 4.70 (1H, t, J = 6.2 Hz), 5.06 (2H, s), 5.80 (1H, d, J = 2.8 Hz), 5.93 (1H, dd, J = 7.5, 2.8 Hz), 7.27 - 7.36 (1H, m), 7.37 (4H, d, J = 3.7 Hz), 7.56 (1H, d, J = 7.6 Hz)
According to General Method 16 benzyl l-(hydroxymethyl)-4-[(1-methyl-2-oxo-4-pyridyl)oxymethyl]-2- azabicyclo[2.1.1]hexane-2-carboxylate (1.20 g, 3.12 mmol) was oxidised. Aqueous work up afforded the product (2.00 g, 99% yield).
[M+H]+ = 384.4
1H NMR (DMSO-d6, 400 MHz) 6 1.73 (2H, dd, J = 4.4, 1.8 Hz), 2.05 (2H, d, J = 5.7 Hz), 3.32 (3H, s), 3.50 (2H, s), 4.20 (2H, s), 5.12 (2H, s), 5.80 (1H, d, J = 2.7 Hz), 5.94 (1H, dd, J = 7.5, 2.8 Hz), 7.27 - 7.44 (5H, m), 7.56 (1H, d, J = 7.6 Hz), 9.77 (1H, s)
Benzyl l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1-methyl-2-oxo-l,2- dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate
Following General Method 17, benzyl l-formyl-4-[(1-methyl-2-oxo-4-pyridyl)oxymethyl]-2- azabicyclo[2.1.1]hexane-2-carboxylate (2.00 g, 60% purity, 3.14 mmol) was reacted with Nl-(2,4- dimethoxybenzyl)isoquinoline-l,5-diamine (0.97 g, 3.14 mmol) for 24h. After aqueous work up, the crude
product was purified by flash chromatography (Silica, 0-30% MeOH in EtOAc) to afford the product (1.60 g, 67% yield).
[M+H]+ = 676.8
1H NMR (DMSO-d6, 400 MHz) 6 1.55 (2H, d, J = 3.1 Hz), 1.91 (2H, s), 3.31 (3H, s), 3.42 (2H, d, J = 6.9 Hz), 3.71 (3H, s), 3.83 (3H, s), 3.95 (2H, d, J = 6.1 Hz), 4.13 (2H, s), 4.59 (2H, d, J = 5.6 Hz), 5.12 (2H, s), 5.76 (1H, d, J = 2.7 Hz), 5.88 (1H, dd, J = 7.5, 2.8 Hz), 6.01 (1H, s), 6.39 (1H, dd, J = 8.4, 2.4 Hz), 6.55 (1H, d, J = 2.4 Hz), 6.73 (1H, d, J = 7.7 Hz), 6.88 (1H, d, J = 6.1 Hz), 7.02 (1H, d, J = 8.4 Hz), 7.24 (1H, t, J = 8.0 Hz), 7.29 - 7.42 (6H, m), 7.46 (1H, d, J = 8.4 Hz), 7.51 (1H, d, J = 7.6 Hz), 7.71 (1H, d, J = 6.1 Hz)
4-((1_(((1_((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l-methylpyridin-2(1H)-one
Following a variation of General Method 3e, a solution of benzyl l-(((1-((2,4- dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1-methyl-2-oxo-l,2-dihydropyridin-4- yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (1350 mg, 2.00 mmol) in MeOH (10 mL) was added to a mixture of Pd(OH)2/C (20 wt%) (338 mg, 0.481 mmol) in MeOH (10 mL). The mixture was subjected to hydrogenation at 1 atmosphere at rt for 66 h. The mixture was filtered over Celite® washing with MeOH (3 x 20 mL) and the filtrate was concentrated to afford the product (1100 mg, 95% yield). [M+H]+ = 542.4
1H NMR (DMSO-d6, 400 MHz) 6 1.41 (2H, s), 1.65 (2H, s), 2.87 (2H, s), 3.35 (3H, s), 3.44 (2H, d, J = 5.1 Hz), 3.71 (3H, s), 3.82 (3H, s), 4.14 (2H, s), 4.59 (2H, d, J = 5.4 Hz), 5.77 (1H, d, J = 2.7 Hz), 5.83 - 5.94 (2H, m), 6.39 (1H, dd, J = 8.4, 2.3 Hz), 6.55 (1H, d, J = 2.3 Hz), 6.68 (1H, d, J = 7.9 Hz), 7.02 (1H, d, J = 8.3 Hz), 7.08 (1H, d, J = 6.1 Hz), 7.25 (1H, s), 7.38 (1H, s), 7.45 (1H, d, J = 8.4 Hz), 7.52 (1H, d, J = 7.6 Hz), 7.73 (1H, d, J = 6.1 Hz)
Intermediate 28
4-((1-(((1*Aminoisoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l- methylpyridin-2(1H)-one
According to General Method 8, 4-((1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)- 2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one (553 mg, 0.935 mmol) was deprotected in DCM (7.0 mL) at rt for 18h. The reaction mixture was diluted with Et2O (25 mL), stirred for 15 min and the resulting precipitate filtered-off and triturated with Et2O (3 x 25 mL). The solid was diluted with MeOH (30 mL) and Amberlite IRN78 (10 mL) was added. The mixture was stirred for 2 h and filtered. The resin was washed with MeOH (100 mL). The filtrate was concentrated to afford the product (281 mg, 77% yield).
[M+H]+ = 392.3
1H NMR (DMSO-d6, 400 MHz) 6 1.33 - 1.43 (2H, m), 1.57 - 1.67 (2H, m), 2.54 (1H, s), 2.83 (2H, s), 3.31 (3H, s), 3.40 (2H, d, J =5.4 Hz), 4.14 (2H, s), 5.74 - 5.81 (2H, m), 5.89 (1H, dd, J = 7.5, 2.8 Hz), 6.48 (2H, s), 6.64 (1H, dd, J = 7.7, 0.9 Hz), 7.10 (1H, dd, J= 6.3, 0.9 Hz), 7.20 (1H, t, J = 8.0 Hz), 7.32 (1H, d, J = 8.3 Hz), 7.52 (1H, d, J = 7.6 Hz), 7.72 (1H, d, J = 6.1 Hz)
Intermediate 29
4-((1-(((1-((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l,6-dimethylpyridin-2(1H)-one
tert-Butyl 4-(((1,6-dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-l-formyl-2- azabicyclo[2.1.1]hexane-2-carboxylate
Following General Method 16, tert-butyl 4-[(1,2-dimethyl-6-oxo-4-pyridyl)oxymethyl]-l- (hydroxymethyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (6500 mg, 17.8 mmol) was oxidised. Aqueous work up afforded the product (6.28 g, 78% yield, 80% pure).
1H NMR (CDCI3, 400 MHz) 6 1.46 (9H, s), 1.78 (2H, dd, J = 4.6, 1.9 Hz), 2.11 (2H, dd, J = 4.6, 1.8 Hz), 2.30 (3H, s), 3.45 (3H, s), 3.47 (2H, s), 4.06 (2H, s), 5.76 (1H, dt, J = 2.8, 0.9 Hz), 5.83 (1H, d, J = 2.8 Hz), 9.83 (1H, s) tert-Butyl l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1,6-dimethyl-2- oxo-1, 2-dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxyl ate
According to General Method 17, tert-butyl 4-[(1,2-dimethyl-6-oxo-4-pyridyl)oxymethyl]-l-formyl-2- azabicyclo[2.1.1]hexane-2-carboxylate (6.28 g, 13.9 mmol) was reacted with Nl-[(2,4- dimethoxyphenyl)methyl]isoquinoline-l,5-diamine (4.99 g, 15.3 mmol) for 72 h. The reaction was quenched with a mixture of sat. NaHCO3 (aq) and brine (1:1 v/v, 40 mL). The mixture was stirred for 30 min at rt and the phases were separated. The aqueous phase was extracted with DCM (3 x 40 mL), and
the combined organic layers were dried (Na2SO4), filtered, and concentrated. Purification by flash chromatography (Silica, 0-9% MeOH in EtOAc) afforded the product (2.90 g, 63% yield).
[M+H]+ = 655.8
1H NMR (DMSO-d6, 400 MHz) 6 1.44 (3H, s), 1.48 (10H, s), 1.53 (2H, d, J = 4.9 Hz), 1.91 (3H, s), 2.03 (1H, s), 2.29 (3H, s), 2.33 (6H, t, J = 0.7 Hz), 3.34 (3H, s), 3.36 (8H, d, J = 2.7 Hz), 3.73 (4H, s), 3.75 (3H, s), 3.87 (3H, s), 3.95 (2H, d, J = 5.9 Hz), 4.13 (2H, s), 4.63 (2H, d, J = 5.4 Hz), 5.67 - 5.78 (3H, m), 5.84 - 5.96 (3H, m), 6.07 (1H, s), 6.43 (1H, dd, J = 8.4, 2.4 Hz), 6.59 (1H, d, J = 2.4 Hz), 6.77 (1H, d, J = 7.9 Hz), 6.99 (1H, d, J = 6.2 Hz), 7.07 (1H, d, J = 8.3 Hz), 7.30 (1H, t, J = 8.0 Hz), 7.45 (1H, d, J = 5.9 Hz), 7.51 (1H, d, J = 8.4 Hz), 7.77 (1H, d, J = 6.1 Hz)
4-((1_(((1_((2,4-Dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l,6-dimethylpyridin-2(1H)-one
According to a variation of General Method 5a, HCI (4M in 1,4-dioxane, 26.7 mL, 107 mmol) was added to a mixture of tert-butyl l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1,6- dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (7.00 g, 10.7 mmol) in anhydrous THF (55 mL) at 0 °C. The mixture was warmed to rt, stirred for 18 h and filtered washing with Et2O (5 x 25 mL) to afford the product as an HCI salt. The resulting solid was taken up in a mixture of DCM and MeOH (9:1 v/v, 200 mL) and sat. NaHCO3 (aq) (125 mL, pH 9). The phases were separated, and the aqueous phase was extracted with a mixture of DCM and MeOH (9:1, 2 x 150 mL). The combined organic phases were dried (Na2SO4 , filtered, and concentrated. Purification by flash chromatography (Silica, 0-20% (5% Et3N in MeOH)) in DCM) afforded the product (3.30 g, 53% yield). [M+H]+ = 556.8
1H NMR (DMSO-d6, 400 MHz) 6 1.41 (2H, s), 1.66 (2H, d, J = 3.8 Hz), 2.30 (3H, s), 2.87 (2H, s), 3.20 (1H, d, J = 5.0 Hz), 3.34 (3H, s), 3.38 (2H, s), 3.45 (2H, d, J = 5.3 Hz), 3.75 (3H, s), 3.86 (3H, s), 4.15 (2H, s), 4.62 (2H, d, J = 5.4 Hz), 5.72 (1H, d, J = 2.8 Hz), 5.89 (1H, dd, J = 2.8, 0.9 Hz), 5.93 (1H, t, J = 5.6 Hz), 6.42 (1H, dd, J = 8.4, 2.4 Hz), 6.59 (1H, d, J = 2.4 Hz), 6.70 (1H, d, J = 7.8 Hz), 7.05 (1H, d, J = 8.3 Hz), 7.12 (1H, d, J = 6.1 Hz), 7.28 (1H, t, J = 8.0 Hz), 7.45 (1H, d, J = 5.9 Hz), 7.49 (1H, d, J = 8.5 Hz), 7.76 (1H, d, J = 6.1 Hz)
Intermediate 30
4-((1-(((1*Aminoisoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6- dimethylpyridin-2(1H)-one
4-((1-(((1*Aminoisoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6- dimethylpyridin-2(1H)-one
According to General Method 8, 4-((1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)- 2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one (1.51 g, 12.58 mmol) was deprotected in DCM (25 mL) at rt for 18 h. The mixture was diluted with Et2O (75 mL), stirred for 15 min and the precipitate was isolated by filtration and triturated with Et2O (3 x 25 mL). The solid was taken up in MeOH (25 mL) and Amberlite IRN78 (20 mL) was added. The mixture was stirred for 2 h and filtered.
The resin was washed with MeOH (100 mL) and the filtrate concentrated to afford the product (889 mg, 85% yield).
[M+H]+ = 406.2
1H NMR (DMSO-d6, 400 MHz) 6 1.32 - 1.43 (2H, m), 1.58 - 1.64 (2H, m), 2.26 (3H, s), 2.55 (1H, t, J = 6.2 Hz), 2.82 (2H, d, J = 5.3 Hz), 3.30 (3H, s), 3.40 (2H, d, J = 5.5 Hz), 4.11 (2H, s), 5.68 (1H, d, J = 2.8 Hz), 5.80 (1H, t, J = 5.6 Hz), 5.85 (1H, dd, J = 2.8, 0.9 Hz), 6.50 (2H, s), 6.64 (1H, d, J = 7.7 Hz), 7.11 (1H, d, J = 6.1 Hz), 7.20 (1H, t, J = 8.0 Hz), 7.33 (1H, d, J = 8.3 Hz), 7.73 (1H, d, J = 6.1 Hz)
Intermediate 31
N5-((4-(((tert-Butyldiphenylsilyl)oxy)methyl)-2-azabicyclo[2.1.1]hexan-l-yl)methyl)-Nl-(2,4- dimethoxybenzyl)isoquinoline-l,5-diamine
tert-Butyl 4-(((tert-butyldiphenylsilyl)oxy)methyl)-l-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-2- carboxylate
According to a variation of General Method 3b, 2-(tert-butyl) 1-methyl 4-(((tert- butyldiphenylsilyl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-l,2-dicarboxylate (90%, 59.5 g, 105 mmol) was reduced using LiBH4 (8.00 g, 330 mmol). The mixture was cooled to 0 °C and quenched with sat. NH4CI (aq) (350 mL), H2O (500 mL), and EtOAc (500 mL). The layers were separated, and the aqueous layer was extracted with EtOAc (2 x 500 mL). The combined organic layers were dried (Na2SO4 , filtered, and concentrated to afford the product (51.1 g, 91% yield).
[M-tBu+H]+ = 426.4
1H NMR (CDCI3, 300 MHz) 6 1.06 (9H, s), 1.47 (9H, s), 3.25 (2H, s), 3.80 (2H, s), 3.91 (2H, s), 7.32 - 7.47 (6H, m), 7.57 - 7.68(4H, m)
tert-Butyl 4-(((tert-butyldiphenylsilyl)oxy)methyl)-l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5- yl)amino)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate
Following General Method 16, tert-butyl 4-(((tert-butyldiphenylsilyl)oxy)methyl)-l-(hydroxymethyl)-2- azabicyclo[2.1.1]hexane-2-carboxylate (7.00 g, 13.1 mmol, 90% purity) was oxidised for 16 h. Aqueous work up afforded the intermediate tert-butyl 4-(((tert-butyldiphenylsilyl)oxy)methyl)-l-formyl-2- azabicyclo[2.1.1]hexane-2-carboxylate which was reacted directly with Nl-(2,4- dimethoxybenzyl)isoquinoline-l,5-diamine (4.50 mg, 14.5 mmol) following General Method 17 for 16 h. Aqueous work up and purification by flash chromatography (Silica, 0-52% EtOAc in hexanes) afforded the product (4.05 g, 40% yield).
[M+H]+ = 774.8
1H NMR (DMSO-d6, 300 MHz) 6 0.93 (9H, s), 1.41 (11H, s), 1.78 (2H, s), 3.22 (2H, s), 3.70 (3H, s), 3.78 (2H, s), 3.82 (3H, s), 3.88 (2H, d, J = 5.5 Hz), 4.59 (2H, d, J = 5.6 Hz), 5.96 (1H, s), 6.36 (1H, d, J = 8.4 Hz), 6.55 (1H, d, J = 2.3 Hz), 6.71 (1H, d, J = 7.8 Hz), 6.95 (1H, d, J = 6.4 Hz), 7.02 (1H, d, J = 8.4 Hz), 7.26 (1H, t, J = 8.0 Hz), 7.34 - 7.49 (8H, m), 7.53 (4H, d, J = 7.6 Hz), 7.72 (1H, d, J = 6.1 Hz)
N5-((4-(((tert-Butyldiphenylsilyl)oxy)methyl)-2-azabicyclo[2.1.1]hexan-l-yl)methyl)-Nl-(2,4- dimethoxybenzyl)isoquinoline-l,5-diamine
Following General Method 5a, tert-butyl 4-(((tert-butyldiphenylsilyl)oxy)methyl)-l-(((1-((2,4- dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (4.05 g, 4.72 mmol) was deprotected in THF (30 mL) at rt for 72 h. After concentration and trituration with Et2O, the residue was diluted with NaOH (aq) (IN, 100 mL) and 1:8 MeOH:DCM (100 mL). The layers were separated and extracted with 1:8 MeOH/DCM (3 x 75 mL). The combined organic layers were washed with brine (200 mL), dried (Na2SO4), filtered, and concentrated. Purification by flash chromatography (Silica, 0- 10% (10% NH4OH in MeOH) in DCM) afforded the product (1.3 g, 41% yield).
[M+H]+ = 673.5
1H NMR (DMSO-d6, 300 MHz) 6 0.97 (9H, s), 1.29 - 1.37 (2H, m), 1.49 - 1.57 (2H, m), 2.77 (2H, s), 3.39 (2H, d,J = 5.3 Hz), 3.71 (3H, s), 3.83 (5H, s), 4.59 (2H, d, J = 5.4 Hz), 5.72 - 5.77 (1H, m), 6.34 - 6.42 (1H, m), 6.55(1H, d, J = 2.0 Hz), 6.67 (1H, d, J = 7.8 Hz), 7.03 (1H, d, J = 8.3 Hz), 7.07 (1H, d, J = 6.0 Hz), 7.25 (1H, t, J =8.1 Hz), 7.35 - 7.49 (8H, m), 7.54 - 7.61 (4H, m), 7.73 (1H, d, J = 6.0 Hz)
Intermediate 32
4-(((1,6-Dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-2-(5-methoxybenzo[d]oxazol-2-yl)-2- azabicyclo[2.1.1]hexane-l-carbaldehyde
4-((1-(Hydroxymethyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one
Following general Method 5a, tert-butyl 4-[(1,2-dimethyl-6-oxopyridin-4-yl)oxymethyl]-l- (hydroxymethyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (2.10 g, 5.76 mmol) was deprotected at rt for 18 h. Concentration afforded the product (1.70 g, 98% yield).
[M+H]+ = 265.1
4-((1-(Hydroxymethyl)-2-(5-methoxybenzo[d]oxazol-2-yl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6- dimethylpyridin-2(1H)-one
According to General Method 2b, 4-[[l-(hydroxymethyl)-2-azabicyclo[2.1.1]hexan-4-yl]methoxy]-l,6- dimethylpyridin-2-one hydrochloride (1.50 mg, 4.99 mmol) was reacted with 2-chloro-5- methoxybenzo[d]oxazole (1.10 mg, 5.98 mmol) in DMSO (3 mL) using K2CO3 (2.76 mg, 19.95 mmol), at rt for 3 days. The solvent was removed (Biotage V10) and the residue was partitioned between DCM (50 mL) and water (50 mL). The organic phase was dried (MgSO4) and concentrated to afford the product (2.00 g, 97% yield).
[M+H]+ = 412.2
4-(((1,6-Dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-2-(5-methoxybenzo[d]oxazol-2-yl)-2- azabicyclo[2.1.1]hexane-l-carbaldehyde
Following General Method 16, 4-[[l-(hydroxymethyl)-2-(5-methoxy-l,3-benzoxazol-2-yl)-2- azabicyclo[2.1.1]hexan-4-yl]methoxy]-l,6-dimethylpyridin-2-one (200 mg, 0.49 mmol) was oxidised. After quenching with 1:1 sat. Na2S2O3 (aq) (10 mL) and sat. NaHCO3 (aq) (10 mL), aqueous work up afforded the product (195 mg, 98% yield).
[M+H]+ = 410.1
Intermediate 33
Copper(ll) acetate (304 mg, 1.59 mmol) was added to a solution of Nl-[(2,4- dimethoxyphenyl)methyl]isoquinoline-l,5-diamine (249 mg, 0.645 mmol) and pyridine (180 μL, 2.21 mmol) in 1,4-dioxane (8 mL) at rt. The mixture was stirred for 10 min at rt and methylboronic acid (98.8 mg, 1.62 mmol) was added. The mixture was heated at reflux for 18 h, cooled to rt, filtered over Celite® and washed with EtOAc (3 x 20 mL). The filtrate was concentrated, and the residue was purified by flash chromatography (silica, 0-88% EtOAc in hexanes) to afford the product (127 mg, 61%).
[M+H]+ = 324.2
1H NMR (DMSO-d6, 400 MHz) 6 2.81 (3H, d, J = 4.8 Hz), 3.71 (3H, s), 3.82 (3H, s), 4.59 (2H, d, J = 5.6 Hz), 6.12 (1H, q, J = 4.9 Hz), 6.39 (1H, dd, J = 8.3, 2.4 Hz), 6.52 - 6.58 (2H, m), 7.02 (1H, d, J = 2.7 Hz), 7.04 (1H, d, J = 0.8 Hz), 7.28 (1H, t, J = 8.0 Hz), 7.36 (1H, t, J = 5.9 Hz), 7.44 (1H, d, J = 8.4 Hz), 7.72 (1H, d, J = 6.0 Hz)
Specific Examples of the Present Invention
Example number 1
N5-((4-(5-Phenyloxazol-2-yl)-2-oxabicyclo[2.1.1]hexan-l-yl)methyl)isoquinoline-l,5-diamine
tert-Butyl ((4-(hydroxymethyl)-2-oxabicyclo[2.1.1]hexan-l-yl)methyl)carbamate
To a solution of [l-(aminomethyl)-2-oxabicyclo[2.1.1]hexan-4-yl]methanol hydrochloride (1.26 g, 7.01 mmol) and TEA (2.50 mL, 17.94 mmol) in THF (35 mL) at 0 °C was added BOC2O (2.00 g, 9.16 mmol) and the mixture was stirred for 10 min at 0 °C. The reaction was then stirred for 18 h at rt. The reaction was quenched with water (30 mL) and washed with EtOAc (2 x 50 mL), dried (MgSO4) and concentrated. Purification by flash chromatography (Silica, 0-20% MeOH in DCM) afforded the product (1.29g 75% yield).
[M+Na]+ = 266.2
1H NMR (DMSO-d6, 400 MHz) 6 1.26 - 1.34 (2H, m), 1.37 (9H, s), 1.52 - 1.66 (2H, m), 3.18 (2H, d, J = 6.1 Hz), 3.51 (2H, s), 3.61 (2H, d, J = 5.4 Hz), 4.62 (1H, t, J = 5.5 Hz), 6.84 (1H, t, J = 6.1 Hz) l-(((tert-Butoxycarbonyl)amino)methyl)-2-oxabicyclo[2.1.1]hexane-4-carboxylic acid
To a mixture of tert-butyl N-[[4-(hydroxymethyl)-2-oxabicyclo[2.1.1]hexan-l-yl]methyl]carbamate (500 mg, 2.06 mmol) and NaICU (1758 mg, 8.22 mmol) in CCI4 (4mL), MeCN (4 mL) and H2O (6 mL) was added RUCI3.H2O (15 mg, 0.07 mmol). The mixture was stirred at rt for 2 h and diluted with EtOAc (25 mL) and sat. NH4CI (aq) (25 mL). The aqueous phase was extracted with EtOAc (3 x 20 mL) and the combined organic phases were washed brine (50 mL), dried (Na2SO4), filtered and concentrated. The residue was diluted in EtOAc (10 mL) and filtered on a Florisil pad. The filtrate was concentrated to afford the product (390 mg, 74% yield).
1H NMR (DMSO-d6, 300 MHz) 6 1.38 (9H, s), 1.61 (2H, d, J = 4.2 Hz), 1.92 (2H, d, J = 4.0 Hz), 3.20 (2H, d, J = 6.0 Hz), 3.74(2H, s), 6.92 (1H, t, J = 5.9 Hz), 12.66 (1H, s)
Tert-butyl ((4-((2-oxo-2-phenylethyl)carbamoyl)-2-oxabicyclo[2.1.1]hexan-l-yl)methyl)carbamate
According to General Method 18b, l-[(tert-butoxycarbonylamino)methyl]-2-oxabicyclo[2.1.1]hexane-4- carboxylic acid (130 mg, 0.51 mmol) was coupled to 2-amino-l-phenyl-ethanone hydrochloride (87 mg, 0.51 mmol). After aqueous work up, purification by flash chromatography (Silica, 0-90% EtOAc in hexanes) afforded the product (137 mg, 72% yield).
[M-H]’ 373.4
1H NMR (CDCI3, 300 MHz) 6 1.45 (9H, s), 1.95 (2H, d, J = 4.4 Hz), 2.05 (2H, d, J = 4.5 Hz), 3.44 - 3.54 (2H, m), 3.97 (2H, s),4.72 - 4.86 (3H, m), 6.70 (1H, s), 7.52 (2H, t, J = 7.6 Hz), 7.65 (1H, t, J = 7.3 Hz), 7.99 (2H, d, J = 7.6 Hz)
A mixture of tert-butyl N-[[4-(phenacylcarbamoyl)-2-oxabicyclo[2.1.1]hexan-l-yl]methyl]carbarriate (120 mg, 0.32 mmol) in IM H2SO4 (aq) (1 mL) was stirred at rt for 1 h. The mixture was basified with a solution of IM NH4OH (aq) and extracted with EtOAc (3 x 10 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated to afford the product (52mg, 38% yield).
[M+H]+ 257.3
Following a variation on General Method 4, [4-(5-phenyloxazol-2-yl)-2-oxabicyclo[2.1.1]hexan-l- yl]methanamine (50 mg, 0.12 mmol, 60% pure) was coupled to 5-bromo-N-(2,4- dimethoxybenzyl)isoquinolin-l-amine (53mg, 0.14 mmol) in the presence of NaOlBu (30 mg, 0.31 mmol)
and Pd-175 (15 mg, 0.02 mmol) in 1,4-dioxane at 100 °C for 16 h. After cooling to rt, the reaction mixture was filtered over Celite® washing with EtOAc (3 x 25 mL) and the filtrate was concentrated to afford the intermediate Nl-[(2,4-dimethoxyphenyl)methyl]-N5-[[4-(5-phenyloxazol-2-yl)-2- oxabicyclo[2.1.1]hexan-l-yl]methyl]isoquinoline-l,5-diamine.
[M+H]+ = 549.3
Deprotection was performed according to a variation of General Method 8, in DCM (2 mL) at rt for 3 h. After concentration and aqueous work up, purification by flash chromatography (C18, 10-60% MeCN in 10 mM NH4HCO3 (aq)), followed by automated prep HPLC (mass directed, 42-52% MeCN in 10 mM NH4HCO3 (aq) over 9 min) afforded the product (11 mg, 24% yield).
[M+H]+ = 399.3
1H NMR (DMSO-d6, 300 MHz) 6 1.94 (2H, d, J = 4.2 Hz), 2.32 (2H, d, J = 4.4 Hz), 3.63 (2H, d, J = 5.4 Hz), 4.06 (2H, s), 6.00(1H, t, J = 5.8 Hz), 6.51 (2H, s), 6.74 (1H, d, J = 7.7 Hz), 7.14 (1H, d, J = 6.1 Hz), 7.23 (1H, t, J = 7.9 Hz), 7.32 - 7.40 (2H, m), 7.41 -7.50 (2H, m), 7.63 (1H, s), 7.66 - 7.77 (3H, m)
Example number 15
4-((1-(((1-Aminoisoquinolin-5-yl)amino)methyl)-2-(2-(chroman-6-yl)acetyl)-2-azabicyclo[2.1.1]hexan-
According to General Method 18a, 2-chroman-6-ylacetic acid (28 mg, 0.14 mmol) was coupled to 4-((1- (((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l-methylpyridin-2(1H)-one (61 mg, 0.11 mmol). Concentratration afforded 4-((2-(2- (chroman-6-yl)acetyl)-l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one which was deprotected according to
General Method 8 in DCM (1 mL) at rt for 18 h. Purification by flash chromatography (C18, 20-47% MeCN in 10 mM (NH4)HCO3 (aq)) provided the product (41 mg, 65% yield).
[M+H]+ = 566.6
1H NMR (DMSO-d6, 500 MHz) 6 1.47 - 1.53 (2H, m), 1.87 - 1.94 (4H, m), 2.69 (2H, t, J = 6.4 Hz), 3.31 (3H, s), 3.52 (2H, s), 3.56 (2H, s), 3.98 (2H, d, J = 6.6 Hz), 4.07 - 4.13 (2H, m), 4.14 (2H, s), 5.78 (1H, d, J = 2.7 Hz), 5.88 (1H, dd, J = 7.5, 2.8 Hz), 6.16 (1H, t, J = 6.6 Hz), 6.51 (2H, d, J = 5.3 Hz), 6.66 (1H, d, J = 8.1 Hz), 6.79 (2H, t, J = 7.5 Hz), 6.97 (2H, d, J = 8.9 Hz), 7.21 (1H, t, J = 8.0 Hz), 7.33 (1H, d, J = 8.3 Hz), 7.54 (1H, d, J = 7.5 Hz), 7.70 (1H, d, J = 6.1 Hz)
Example numbers 24 and 25
4-((1-(((1-Aminoisoquinolin-5-yl)amino)methyl)-2-(2-trans-(-4-methoxycyclohexyl)acetyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one
And
4-((1-(((1-aminoisoquinolin-5-yl)amino)methyl)-2-(2-cis-(4-methoxycyclohexyl)acetyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one
According to General Method 18a, 2-(4-methoxycyclohexyl)acetic acid (55 mg, 0.30 mmol) was coupled with 4-((1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l-methylpyridin-2(1H)-one (154 mg, 0.26 mmol). Concentration afforded 4-((1-(((1-((2,4- dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-(2-(4-methoxycyclohexyl)acetyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one which was deprotected according to
General Method 8 in DCM (4 mL) at rt for 18 h. Purification by flash chromatography (C18, 20-42% MeCN in 10 mM (NH4)HCO3 (aq)) followed by automated prep. HPLC (mass directed, 30-40% MeCN in 10 mM (NH4)HCO3 (aq) over 9 min) provided the product 4-((1-(((1-aminoisoquinolin-5-yl)amino)methyl)-2- (2-trans-(-4-methoxycyclohexyl)acetyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin- 2(1H)-one (46 mg, 31% yield) as the first eluting isomer.
[M+H]+ = 560.6
1H NMR (DMSO-d6, 400 MHz) 6 0.93 - 1.17 (4H, m), 1.45 - 1.50 (2H, m), 1.71 - 1.81 (3H, m), 1.84 - 1.90 (2H, m), 1.93 - 2.01 (2H, m), 2.15 (2H, d, J = 6.5 Hz), 2.26 (3H, s, 2.99 - 3.08 (1H, m), 3.22 (3H, s), 3.31 (3H, s), 3.46 (2H, s), 3.97 (2H, d, J = 6.5 Hz), 4.10 (2H, s), 5.68 (1H, d, J = 2.8 Hz), 5.84 (1H, dd, J = 2.8, 0.9 Hz), 6.20 (1H, t, J = 6.8 Hz), 6.52 (2H, s), 6.76 - 6.84 (2H, m), 7.20 (1H, t, J = 8.0 Hz), 7.32 (1H, d, J = 8.3 Hz), 7.70 (1H, d, J = 6.1 Hz) and 4-((1-(((1-aminoisoquinolin-5-yl)amino)methyl)-2-(2-cis-(4-methoxycyclohexyl)acetyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one (18 mg, 12% yield) as the second eluting iomer.
[M+H]+ = 560.7
1H NMR (DMSO-d6, 500 MHz) 6 1.22 - 1.32 (2H, m), 1.37 - 1.51 (6H, m), 1.73 - 1.82 (2H, m), 1.83 - 1.92 (3H, m), 2.15 (2H, d, J = 7.0 Hz), 2.26 (3H, s), 3.19 (3H, s), 3.31 (3H, s), 3.34 - 3.38 (1H, m), 3.48 (2H, s), 3.98 (2H, d, J = 6.6 Hz), 4.10 (2H, s), 5.68 (1H, d, J = 2.8 Hz), 5.84 (1H, dd, J = 2.8, 0.9 Hz), 6.23 (1H, t, J = 6.7 Hz), 6.60 (2H, s), 6.78 - 6.86 (2H, m), 7.22 (1H, t, J = 8.0 Hz), 7.33 (1H, d, J = 8.3 Hz), 7.70 (1H, d, J = 6.0 Hz)
Example number 29
N-(1-(1-(((1-Aminoisoquinolin-5-yl)amino)methyl)-4-(((1,6-dimethyl-2-oxo-l,2-dihydropyridin-4- yl)oxy)methyl)-2-azabicyclo[2.1.1]hexan-2-yl)-l-oxopropan-2-yl)acetamide
According to General Method 4, 4-((1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)- 2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one (60 mg, 0.11 mmol) was coupled to 5-bromo-2,4-dimethyl-oxazole (24 mg, 0.13 mmol) using NaOtBu (27 mg, 0.27 mmol) and Pd-PEPPSI- IPent (9 mg, 0.01 mmol) in 1,4-dioxane (1 mL) at reflux for 24 h. 5-Bromo-2,4-dimethyl-oxazole (23.5 mg, 0.130 mmol) and Pd-PEPPSI-IPent (9 mg, 0.0108 mmol) were added and the mixture was refluxed for 48 h, cooled to rt, diluted with MeOH (500 μL), filtered washing with MeOH (5 mL) and concentrated to afford N-(1-(1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1,6-dimethyl-2- oxo-1, 2-dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexan-2-yl)-l-oxopropan-2-yl)acetamide which was deprotected according to General Method 8 in DCM (2 mL) at rt for 18 h. Flash chromatography (C18, 20-60% MeCN in 10 mM (NH4)HCO3 (aq)) followed by an automated prep HPLC (UV directed 30-40% MeCN in 10 mM (NH4)HCO3 (aq) over 8 min) provided the product (24 mg, 45% yield).
[M+H]+ = 518.8
1H NMR (DMSO-d6, 400 MHz) 6 1.27 (3H, d, J = 6.9 Hz), 1.53 (1H, d, J = 3.4 Hz), 1.89 (3H, s), 1.92 (2H, t, J = 5.9 Hz), 2.30 (3H, s), 3.34 (4H, s), 3.57 (1H, d, J = 7.4 Hz), 3.72 (1H, d, J = 7.5 Hz), 3.94 - 4.11 (2H, m), 4.17 (2H, s), 4.47 (1H, t, J = 7.1 Hz), 5.73 (1H, d, J = 2.8 Hz), 5.89 (1H, dd, J = 2.9, 0.9 Hz), 6.16 (1H, t, J = 6.5 Hz), 6.56 (2H, s), 6.82 (1H, d, J = 7.7 Hz), 6.87 (1H, d, J = 6.2 Hz), 7.25 (1H, t, J = 8.0 Hz), 7.37 (1H, d, J = 8.0 Hz), 7.74 (1H, d, J = 8.0 Hz) 8.24 (1H, d, J = 8.0 Hz)
Example number 30 l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-4-(((1-methyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-
N-(1-phenylcyclopropyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
According to General Method 21a, 1-phenylcyclopropanamine (20 μL, 0.16 mmol) was reacted with CDI (25.8 mg, 0.151 mmol) and 4-((1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one (60 mg, 0.10 mmol). The mixture was concentrated to afford l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1- methyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-N-(1-phenylcyclopropyl)-2-azabicyclo[2.1.1]hexane-2- carboxamide which was deprotected according to General Method 8 in DCM (1 mL) at rt for 18 h. Flash chromatography (C18, 10-40% MeCN in 10 mM (NH4)HCO3 (aq)) afforded the product (33 mg, 61% yield).
[M+H]+ = 552.4
1H NMR (DMSO-d6, 500 MHz) 6 1.13 - 1.22 (4H, m), 1.45 - 1.50 (2H, m), 1.78 - 1.83 (2H, m), 3.31 (3H, s), 3.36 (2H, s), 3.90 (2H, d, J = 6.4 Hz), 4.15 (2H, s), 5.78 (1H, d, J = 2.8 Hz), 5.89 (1H, dd, J = 7.5, 2.7 Hz), 6.19 (1H, t, J = 6.5 Hz), 6.55 (2H, s), 6.75 (1H, d, J = 7.7 Hz), 6.79 (1H, d, J = 6.2 Hz), 7.13 - 7.32 (8H, m), 7.53 (1H, d, J = 7.6 Hz), 7.64 (1H, d, J = 6.1 Hz)
Example number 59 l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-4-(((5-oxo-l,2,3,5-tetrahydroindolizin-7-yl)oxy)methyl)-N- (1-phenylcyclopropyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
2-(tert-Butyl) 1-methyl 4-(((5-oxo-l,2,3,5-tetrahydroindolizin-7-yl)oxy)methyl)-2- azabicyclo[2.1.1]hexane-l,2-dicarboxylate
According to General Method 2b, 2-O-tert-butyl 1-O-methyl 4-(methylsulfonyloxymethyl)-2- azabicyclo[2.1.1]hexane-l,2-dicarboxylate (300 mg, 0.86 mmol) was reacted with 7-hydroxy-2,3-
dihydro-lH-indolizin-5-one (143 mg, 0.94 mmol) in DMF (3 mL) using K2CO3 (356 mg, 2.58 mmol) at 60 °C for 20 h. Aqueous work up afforded the product (356 mg, 95% yield).
[M+H]+ = 405.3 tert-Butyl l-(hydroxymethyl)-4-(((5-oxo-l,2,3,5-tetrahydroindolizin-7-yl)oxy)methyl)-2- azabicyclo[2.1.1]hexane-2-carboxylate
2-(tert-Butyl) 1-methyl 4-(((5-oxo-l,2,3,5-tetrahydroindolizin-7-yl)oxy)methyl)-2- azabicyclo[2.1.1]hexane-l,2-dicarboxylate (356 mg, 0.82 mmol) was reduced using LiBI- (2M in THF, 700 μL, 1.4 mmol) in anhydrous THF (5 mL) at rt for 4 days. Water (10 mL) and DCM (20 mL) were added. The organic layer was separated and the aqueous layer washed with DCM (2 x 10 mL). The combined organic layers were dried (MgSO4), filtered and concentrated to afford the product (320 mg, 88% yield). [M+H]+ = 377.2 tert-Butyl l-formyl-4-(((5-oxo-l,2,3,5-tetrahydroindolizin-7-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-
According to General Method 16, tert-butyl l-(hydroxymethyl)-4-[(5-oxo-2,3-dihydro-lH-indolizin-7- yl)oxymethyl]-2-azabicyclo[2.1.1]hexane-2-carboxylate (376 mg, 0.85 mmol) was oxidised over 48 h. Aqueous work up afforded the product (271 mg, 85% yield).
[M+H]+ = 375.2 tert-Butyl l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((5-oxo-l,2,3,5- tetrahydroindolizin-7-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate
According to General Method 17, tert-butyl l-formyl-4-[(5-oxo-2,3-dihydro-lH-indolizin-7- yl)oxymethyl]-2-azabicyclo[2.1.1]hexane-2-carboxylate (271 mg, 0.72 mmol) was reacted with l-N-[(2,4- dimethoxyphenyl)methyl]isoquinoline-l,5-diamine (335 mg, 1.08 mmol) for 20 h. Aqueous work up and purification by flash chromatography (Silica, 0-100% EtOAc in Pet. Ether, followed by 0-20% MeOH in EtOAc) afforded the product (403 mg, 84% yield).
[M+H]+ = 668.4 7-((1-(((1-Aminoisoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-2,3- dihydroindolizin-5(1H)-one
tert-Butyl l-(((1-((2, 4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((5-oxo-l, 2,3,5- tetrahydroindolizin-7-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (100 mg, 0.15 mmol) was deprotected according to General Method 8 at rt for 60 min to afford the product (55 mg, 70% yield). [M+H]+ = 418.2
To a solution of 1-phenylcyclopropan-l-amine (500 mg, 3.75 mmol) and DBU (95 μL, 0.64 mmol) in dry DCM (10 mL) was added CDI (621 mg, 3.83 mmol) and stirred at rt for 1 h. The mixture was quenched with water (50 mL), extracted with DCM (2 x 50 mL), washed with brine (50 mL), dried (MgSO4) and concentrated to afford the product (570 mg, 53% yield).
[M+H]+ = 228.1 l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-4-(((5-oxo-l,2,3,5-tetrahydroindolizin-7-yl)oxy)methyl)-N- (1-phenylcyclopropyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
To a solution of N-(1-phenylcyclopropyl)imidazole-l-carboxamide (45 mg, 0.2 mmol) and 7-[[l-[[(1- aminoisoquinolin-5-yl)amino]methyl]-2-azabicyclo[2.1.1]hexan-4-yl]methoxy]-2,3-dihydro-lH-indolizin- 5-one (70 mg, 0.13 mmol) in dry DMF (1.5 mL) was added DBU (30 μL, 0.2 mmol) after 10 min. The reaction was stirred at rt for 18 h, quenched with water (10 mL) and concentrated. The residue was partitioned between EtOAc (10 mL) and water (10 mL). The aqueous layer was re-extracted with EtOAc (3 x 20 mL) and the combined organics were dried (MgSO4) and concentrated. Purification by automated HPLC (mass directed 2-60% MeCN in [2.5% NH3 in water]) afforded the product (24 mg, 32% yield). [M+H]+ = 577.3
1H NMR (DMSO-d6, 400 MHz) 6 1.12 - 1.24 (4H, m), 1.41 - 1.53 (2H, m), 1.76 - 1.84 (2H, m), 1.97 - 2.10 (2H, m), 2.95 (2H, t, J = 7.7 Hz), 3.36 (2H, s), 3.79 - 3.86 (2H, m), 3.90 (2H, d, J = 6.4 Hz), 4.13 (2H, s), 5.61 (1H, d, J = 2.5 Hz), 5.80 - 5.89 (1H, m), 6.18 (1H, t, J = 6.5 Hz), 6.51 (2H, s), 6.73 (1H, d, J = 7.7 Hz), 6.78 (1H, d, J = 6.0 Hz), 7.13 - 7.22 (4H, m), 7.23 - 7.32 (4H, m), 7.64 (1H, d, J = 6.1 Hz)
Example number 65 l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-N-(2,3-dihydro-lH-inden-5-yl)-4-(((1,6-dimethyl-2-oxo- l,2-dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
According to General Method 21c, 5-indanyl isocyanate (30 mg, 0.18 mmol) was reacted with 4-((1-(((1- ((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)- l,6-dimethylpyridin-2(1H)-one (77 mg, 0.13 mmol) for 2 h. Concentration afforded the intermediate N- (2,3-dihydro-lH-inden-5-yl)-l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1,6- dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide which was deprotected according to General Method 8, using TFA (250 μL, 3.33 mmol) in DCM (2 mL) at rt for 18 h. Following work up (iv), purification by flash chromatography (C18, 20-52% MeCN in 10 mM (NH4)HCO3 (aq)) afforded the product (23 mg, 32%).
[M+H]+ = 565.7
1H NMR (DMSO-d6, 400 MHz) 6 1.52 - 1.58 (2H, m), 1.84 (2H, d, J = 4.6 Hz), 1.99 (2H, p, J = 7.4 Hz), 2.26 (3H, s), 2.80 (4H, dt,J = 11.3, 7.4 Hz), 3.30 (3H, s), 3.50 (2H, s), 3.99 (2H, d, J = 6.2 Hz), 4.14 (2H, s), 5.69 (1H, d, J = 2.8 Hz), 5.84 (1H, dd, J = 2.8, 0.9Hz), 6.20 (1H, t, J = 6.4 Hz), 6.50 (2H, s), 6.74 (1H, d, J = 7.7 Hz), 6.98 (1H, d, J = 6.2 Hz), 7.07 (1H, d, J = 8.1 Hz), 7.17 - 7.26(2H, m), 7.33 (1H, d, J = 8.3 Hz), 7.41 (1H, s), 7.71 (1H, d, J = 6.0 Hz), 8.40 (1H, s)
Example number 66
l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-4-(((1-methyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-
According to General Method 21b, 2-phenylpropan-2-amine (24 mg, 0.25 mmol) was reacted for 18h and a further 3h following the addition of 4-((1-(((1-aminoisoquinolin-5-yl)amino)methyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one (53 mg, 0.13 mmol). Concentration and purification by flash chromatography (C18, 20-47% MeCN in 10 mM (NH4)HCO3 (aq)) followed by automated prep HPLC (UV directed 31-41% MeCN in 10 mM (NH4)HCO3 (aq)) over 8 min) afforded the product (70 mg, 94% yield).
[M+H]+ = 553.7
1H NMR (DMSO-d6, 500 MHz) 6 1.44 - 1.53 (2H, m), 1.56 (6H, s), 1.76 - 1.81 (2H, m), 3.31 (3H, s), 3.46 (2H, s), 3.81 (2H, d, J =6.3 Hz), 4.16 (2H, s), 5.79 (1H, d, J = 2.8 Hz), 5.91 (1H, dd, J = 7.5, 2.7 Hz), 6.04 (1H, t, J = 6.4 Hz), 6.42 (1H, s), 6.47 (2H, s), 6.63- 6.72 (2H, m), 7.13 - 7.22 (2H, m), 7.25 - 7.32 (3H, m), 7.35 - 7.41 (2H, m), 7.54 (1H, d, J = 7.6 Hz), 7.64 (1H, d, J = 6.1 Hz)
Example number 71
4-(((1,6-Dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-l-(((2-hydroxypyridin-3- yl)amino)methyl)-N-(1-phenylcyclopropyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
tert-Butyl 4-(((1,6-dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-l-(((2-methoxypyridin-3- yl)amino)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate
According to General Method 17, tert-butyl 4-[(1,2-dimethyl-6-oxopyridin-4-yl)oxymethyl]-l-formyl-2- azabicyclo[2.1.1]hexane-2-carboxylate (100 mg, 0.28 mmol) was reacted with 3-amino-2- methoxypyridine (38 mg, 0.3 mmol) at rt for 18 h. Aqueous work up and purification by HPLC (mass directed 2-60% MeCN in [2.5% NH4OH in water]) afforded the product (53 mg, 41% yield).
[M+H]+ = 471.3
4-[[l-[[(2-Hydroxypyridin-3-yl)amino]methyl]-2-azabicyclo[2.1.1]hexan-4-yl]methoxy]-l,6- dimethylpyridin-2-one hydrochloride
According to General Method 5a, tert-butyl 4-(((1,6-dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)- l-(((2-methoxypyridin-3-yl)amino)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (54 mg, 0.11 mmol) was deprotected at rt for 3 days. The solution was concentrated to afford the product (44 mg, 98% yield).
[M+H]+ = 357.2
4-(((1,6-Dimethyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-l-(((2-hydroxypyridin-3- yl)amino)methyl)-N-(1-phenylcyclopropyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
To a solution of 4-[[l-[[(2-hydroxypyridin-3-yl)amino]methyl]-2-azabicyclo[2.1.1]hexan-4-yl]methoxy]- l,6-dimethylpyridin-2-one hydrochloride (43 mg, 0.11 mmol) in MeCN (2 mL) and DMF (1 mL) was added DBU (33 μL, 0.22 mmol). After 10 min N-(1-phenylcyclopropyl)imidazole-l-carboxamide (64 mg, 0.22 mmol) was added and the reaction stirred at rt for 36 h. The reaction mixture was quenched with water (10 mL) and extracted with EtOAc (3 x 20 mL) before being washed with brine (2 x 10 mL), dried (MgSO4) and concentrated. Purification by HPLC (mass directed 2-60% MeCN in [2.5% NH4OH in water]) afforded the product (21 mg, 37% yield). [M+H]+ = 516.3
1H NMR (DMSO-d6, 400 MHz) 6 1.05 - 1.23 (4H, m), 1.39 - 1.53 (2H, m), 1.75 (2H, d, J = 4.3 Hz), 2.28 (3H, s), 3.32 (3H, s), 3.35 (2H, s), 3.73 (2H, d, J = 6.5 Hz), 4.15 (2H, s), 5.50 (1H, t, J = 6.7 Hz), 5.72 (1H, d, J = 2.8 Hz), 5.89 (1H, d, J = 2.5 Hz), 6.02 (1H, t, J = 6.8 Hz), 6.24 (1H, dd, J = 7.2, 1.6 Hz), 6.49 - 6.60 (1H, m), 7.06 - 7.18 (3H, m), 7.19 - 7.30 (3H, m), 11.32 (1H, s)
Example number 90 l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-N-(2,3-dihydrobenzofuran-3-yl)-4-(((1,6-dimethyl-2-oxo- l,2-dihydropyridin-4-yl)oxy)methyl)-N-methyl-2-azabicyclo[2.1.1]hexane-2-carboxamide
BOC2O (766 μL, 3.33 mmol) was added to a mixture of 2,3-dihydrobenzofuran-3-amine hydrochloride
(500 mg, 2.91 mmol) and TEA (1.3 mL, 9.33 mmol) in DCM (10 mL) at rt and stirred for 18 h. The mixture was quenched with brine (20 mL) and DCM (20 mL). The layers were separated, and the organic layer was washed with brine (20 mL), dried (Na2SO4), filtered, and concentrated to afford the product (648 mg, 85% yield).
1H NMR (CDCI3, 400 MHz) 6 1.46 (9H, s), 4.33 (1H, dd, J = 10.0, 4.1 Hz), 4.65 (1H, dd, J = 10.0, 7.8 Hz),
4.88 (1H, s), 5.35 (1H, s), 6.81 - 6.85 (1H, m), 6.91 (1H, td, J = 7.5, 1.0 Hz), 7.22 (1H, dddd, J = 8.0, 7.4, 1.4,
According to General Method 2a, tert-butyl N-(2,3-dihydrobenzofuran-3-yl)carbamate (648 mg, 2.48 mmol) was reacted with Mel (231 μL, 3.72 mmol) at rt for 18 h. The mixture was quenched with brine
(20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (20 mL), dried (Na2SO4), filtered, and concentrated to afford the product.
According to a variation on General Method 5a, tert-butyl (2,3-dihydrobenzofuran-3- yl)(methyl)carbamate was deprotected in MeOH (5mL) for 96 h at rt. The mixture was concentrated. THF (3 mL) was added, and the mixture was sonicated for 1 min, filtered, and washed with THF (2 x 5 mL), hexanes (2 x 5 mL), and Et2O (2 x 5 mL) to afford the product (501 mg, 44% yield).
1H NMR (D2O, 400 MHz) 6 2.72 (3H, s), 4.72 (1H, dd, J = 12.0, 7.3 Hz), 4.84 (1H, d, J = 12.0 Hz), 5.09 (1H, d, J = 7.2 Hz), 7.06 (1H, d, J = 8.1 Hz), 7.14 (1H, t, J = 7.6 Hz), 7.49 (1H, t, J = 7.9 Hz), 7.61 (1H, d, J = 7.6 Hz)
According to a modification of General Method 21b Part 1, N-methyl-2,3-dihydrobenzofuran-3-amine HCI (100 mg, 0.27 mmol, 40% pure) was reacted in anhydrous DCM (ImL) at 0 °C for 30 min then at rt for 18 h. After quenching with IM HCI (aq) (15 mL), the aqueous phase was extracted with DCM (3 x 25 mL). The combined organic layers were washed with IM HCI (aq) (25 mL), sat. NaHCO3 (aq) (25 mL), dried (Na2SO4), filtered, and concentrated. The product was used directly in the next step.
1H NMR (CDCI3, 500 MHz) 6 0.32 (4H, s), 1.25 (1H, d, J = 6.5 Hz), 1.36 - 1.39 (3H, m), 3.25 - 3.28 (4H, m) l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-N-(2,3-dihydrobenzofuran-3-yl)-4-(((1,6-dimethyl-2-oxo- l,2-dihydropyridin-4-yl)oxy)methyl)-N-methyl-2-azabicyclo[2.1.1]hexane-2-carboxamide
According to a modification of General Method 21b, part 2, 4-[[l-[[(1-amino-5- isoquinolyl)amino]methyl]-2-azabicyclo[2.1.1]hexan-4-yl]methoxy]-l,6-dimethylpyridin-2-one (50 mg, 0.12 mmol, 95% purity) was reacted with N-(2,3-dihydrobenzofuran-3-yl)-N-methyl-carbamoyl chloride
(61 mg, 0.14 mmol) in THF (2.00 mL) at rt for 72 h. The mixture was concentrated. Purification by flash chromatography (C18, 25-56% MeCN in 10 mM (NH4)HCO3 (aq)) followed by automated prep HPLC (UV directed 38-48% MeCN in 10 mM (NH4)HCO3 (aq) over 8 min) afforded the product (19 mg, 28% yield). [M+H]+ = 581.4
1H NMR (DMSO-d6, 400 MHz) 6 1.59 (2H, t, J = 4.2 Hz), 1.77 (2H, t, J = 6.2 Hz), 2.25 (3H, s), 2.52 - 2.55 (3H, m), 3.28 - 3.30 (4H, m), 3.38 (1H, d, J = 7.3 Hz), 3.83 (1H, dd, J = 14.5, 6.2 Hz), 3.92 (1H, dd, J = 14.5, 6.0 Hz), 4.10 (2H, s), 4.45 (1H, dd, J = 10.3, 4.2 Hz), 4.65 (1H, dd, J = 10.2, 9.2 Hz), 5.66 (1H, d, J = 2.8 Hz), 5.83 (1H, d, J = 2.6 Hz), 5.97 (1H, dd, J = 9.1, 4.2 Hz), 6.17 (1H, t, J = 6.2 Hz), 6.48 (2H, s), 6.75 (1H, d, J = 7.8 Hz), 6.87 (1H, d, J = 8.0 Hz), 6.92 (1H, ddd, J = 8.3, 7.0, 0.9 Hz), 7.10 (1H, d, J = 6.2 Hz), 7.20 (1H, t, J = 8.0 Hz), 7.22 - 7.29 (2H, m), 7.30 (1H, d, J = 8.6 Hz), 7.71 (1H, d, J = 6.1 Hz)
Example number 63
1-(((1-Aminoisoquinolin-5-yl)amino)methyl)-4-(((1-methyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-
2-azabicyclo[2.1.1]hexane-2-carboxamide
According to General Method 21b, cumylamine (30 mg, 0.22 mmol) was reacted in DCM (1.5 mL) at rt for 90 min and then with 4-((1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one ( 81 mg, 0.142mmol) for 36 h.
Aqueous work up afforded l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-4-(((1- methyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-N-(2-phenylpropan-2-yl)-2-azabicyclo[2.1.1]hexane-2- carboxamide which was deprotected according to General Method 8 in DCM (2 mL) and TFA (250 μL, 3.33 mmol) at rt for 18 h. Purification by flash chromatography (C18, 20-32% MeCN in 10 mM (NH4)HCO3 (aq)) followed by automated prep HPLC (UV directed 14-24% MeCN in 10 mM (NH4)HCO3 (aq) over 8 min) afforded the product (12.8 mg, 13% yield).
[M+H]+ = 435.6
1H NMR (DMSO-d6, 400 MHz) 6 1.45 - 1.52 (2H, m), 1.77 - 1.85 (2H, m), 3.30 (2H, s), 3.30 (3H, s), 3.89 (2H, d, J = 6.2 Hz), 4.13 (2H, s), 5.77 (1H, d, J = 2.7 Hz), 5.89 (1H, dd, J = 7.5, 2.7 Hz), 5.92 (2H, s), 6.50 - 6.59 (3H, m), 6.77 (1H, d, J = 7.7 Hz), 6.88 (1H, d, J = 6.2 Hz), 7.20 (1H, t, J = 8.0 Hz), 7.31 (1H, d, J = 8.3
Hz), 7.53 (1H, d, J = 7.5 Hz), 7.70 (1H, d, J = 6.1 Hz)
Example number 91
l-(((1-Aminoisoquinolin-5-yl)amino)methyl)-4-(((1-methyl-2-oxo-l,2-dihydropyridin-4-yl)oxy)methyl)-
A solution of 4-[[l-[[(1-amino-5-isoquinolyl)amino]methyl]-2-azabicyclo[2.1.1]hexan-4-yl]methoxy]-l- methylpyridin-2-one (18 mg, 0.05 mmol) and TEA (20 μL, 0.14 mmol) in DMSO (750 μL) was added to isothiocyanatobenzene (8 mg, 0.06 mmol), and the mixture was stirred for 16 h. The mixture was quenched with MeOH (250 μL), filtered and purified by HPLC (mass directed, MeCN in 10 mM (NH4)HCO3 (aq)) to provide the product (16 mg, 64% yield).
[M+H]+ = 527.1
1H NMR (DMSO-d6, 300 MHz) 6 1.90 (2H, s), 2.04 (2H, s), 3.32 (3H, s), 3.74 (2H, s), 4.07 (2H, s), 4.23 (2H, s), 5.83 (1H, d, J = 2.6 Hz), 5.93 (1H, dd, J = 7.5, 2.7 Hz), 6.20 (1H, br s), 6.59 (2H, s), 6.83 - 6.97 (2H, m), 7.05 - 7.20 (5H, m), 7.24 (1H, t, J = 8.0 Hz), 7.49 (1H, d, J = 8.6 Hz), 7.56 (1H, d, J = 7.6 Hz), 7.79 (1H, d, J = 6.0 Hz), 9.93 (1H, s)
Example number 95
4-((1-(((1_Aminoisoquinolin-5-yl)amino)methyl)-2-(6-cyclopropylpyridazin-3-yl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one
According to General Method 4, 4-((1-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)- 2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one (60 mg, 0.11 mmol) was reacted with 3-chloro-6-cyclopropyl-pyridazine (20 mg, 0.129 mmol), using NaC Bu (16 mg, 0.16 mmol), RuPhosPd-G3 (13mg, 0.0148 mmol) and RuPhos (7 mg, 0.0147 mmol) in THF (1 mL) at reflux for 16 h. The mixture was cooled to rt, diluted with MeOH (500 μL), filtered, washing with MeOH (5 mL) and the filtrate was concentrated to afford the intermediate 4-((2-(6-cyclopropylpyridazin-3-yl)-l-(((1-((2,4- dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6- dimethylpyridin-2(1H)-one which was deprotected according to General Method 8, in DCM (2 mL) at rt for 4 h. Aqueous work up and purification by flash chromatography (C18, 20-50% MeCN in 10 mM (NH4)HCO3 (aq)) afforded the product (32 mg, 57% yield).
[M+H]+ = 524.4
1H NMR (DMSO-d6, 300 MHz) 6 0.88 - 1.02 (4H, m), 1.66 (2H, d, J = 3.3 Hz), 1.91 (2H, d, J = 4.2 Hz), 2.05 - 2.16 (1H, m), 2.25(3H, s), 3.30 (3H, s), 3.42 (2H, s), 4.14 (2H, s), 4.18 (2H, d, J = 6.1 Hz), 5.68 (1H, d, J = 2.6 Hz), 5.83 (1H, d, J = 2.6 Hz), 6.43 -6.55 (3H, m), 6.76 (1H, d, J = 7.6 Hz), 6.96 (1H, d, J = 9.2 Hz), 7.01 (1H, d, J = 6.1 Hz), 7.17 - 7.29 (2H, m), 7.32 (1H, d, J = 8.4Hz), 7.69 (1H, d, J = 6.1 Hz)
Example number 97
4-((1-(((1-Aminoisoquinolin-5-yl)amino)methyl)-2-(4,5-dihydrooxazol-2-yl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l,6-dimethylpyridin-2(1H)-one
According to General Method 21c, 4-((1-(((1-aminoisoquinolin-5-yl)amino)methyl)-2- azabicyclo[2.1.1]hexan-4-yl)methoxy)-l,6-dimethylpyridin-2(1H)-one (100 mg, 0.25 mmol) was reacted
with l-chloro-2-isocyanato-ethane (31 μL, 0.35 mmol) in anhydrous THF (5 mL) at 80 °C for 42 h. Concentration and purification by flash chromatography (C18, 20-51% MeCN in 10 mM NH4HCO3 (aq)) followed by automated prep HPLC (UV directed 30-40% MeCN in (10 mM NH4HCO3 (aq)) over 8 min) afforded the product (4 mg, 4% yield).
[M+H]+ = 475.4
1H NMR (DMSO-d6, 400 MHz) 6 1.55 (2H, s), 1.86 (2H, d, J = 4.7 Hz), 2.29 (3H, s), 3.32 (3H, s), 3.37 (2H, s), 3.79 (2H, t, J =8.7 Hz), 3.95 (2H, d, J = 5.8 Hz), 4.14 (2H, s), 4.27 (2H, t, J = 8.7 Hz), 5.70 (1H, d, J = 2.8 Hz), 5.87 (1H, d, J = 2.8 Hz), 6.52 (2H,d, J = 4.2 Hz), 6.69 - 6.79 (2H, m), 7.00 (1H, d, J = 6.2 Hz), 7.23 (1H, t, J = 8.0 Hz), 7.34 (1H, d, J = 8.3 Hz), 7.75 (1H, d, J = 6.1Hz)
Example number 102
4-((4-(((1-Aminoisoquinolin-5-yl)amino)methyl)-2-(3-cyclohexylpropanoyl)-2-azabicyclo[2.1.1]hexan-l- yl)methoxy)-l-methylpyridin-2(1H)-one
According to General Method 18a, 3-cyclohexylpropanoic acid (25 mg, 0.16 mmol) was coupled to 4-((1- (((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5-yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4- yl)methoxy)-l-methylpyridin-2(1H)-one (80 mg, 0.15 mmol) over 18 h. The mixture was concentrated to afford 4-((2-(3-cyclohexylpropanoyl)-l-(((1-((2,4-dimethoxybenzyl)amino)isoquinolin-5- yl)amino)methyl)-2-azabicyclo[2.1.1]hexan-4-yl)methoxy)-l-methylpyridin-2(1H)-one which was deprotected according to General Method 8 in DCM (1 mL) and TFA (1379 μL, 13.5 mmol) at rt for 24 h. Purification by flash chromatography (C18, 5-60% MeCN in 10 mM (NH4)HCO3 (aq)) provided the product (38 mg, 48% yield).
[M+H]+ = 530.3
1H NMR (400 MHz, DMSO-d6) 6 0.86 (2H t, J = 11.7 Hz), 1.06 - 1.26 (5H, m), 1.37 (2H, q, J = 7.3 Hz), 1.57 (3H, s ), 1.65 (6H, s), 1.86 - 1.95 (2H, m), 2.12 - 2.23 (2H, m), 3.51 -3.53 (4H, m), 4.59 (2H, s), 5.65 (1H, s), 5.84 - 5.90 (1H, m,), 5.96 (1H, s), 6.48 (2H, d, J = 4.4 Hz), 6.68 (1H, d, J = 7.7 Hz), 7.15 - 7.18 (1H, d, J = 6.0 Hz), 7.20 (1H, t, J = 8.0 Hz), 7.33 (1H, d, J = 8.3 Hz), 7.52 (1H, d, J = 7.5 Hz), 7.72 (1H, d, J = 6.0 Hz)
Example Number 104 l-(((1-aminoisoquinolin-5-yl)(methyl)amino)methyl)-N-(chroman-6-yl)-4-(((1,6-dimethyl-2-oxo-l,2- dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
tert-Butyl 4-[[tert-butyl(diphenyl)silyl]oxymethyl]-l-[[[l-[(2,4-dimethoxyphenyl)methylamino]-5- isoquinolyl]-methyl-amino]methyl]-2-azabicyclo[2.1.1]hexane-2-carboxylate
Dess-Martin periodinane (524 mg, 1.17 mmol) was added to a solution of tert-butyl 4-[[tert- butyl(diphenyl)silyl]oxymethyl]-l-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (400 mg, 0.748 mmol) in DCM (7 mL) at 0 °C and stirred for 15 min. The mixture was warmed to rt and stirred for 3 h. Sat. NaHCO3 (aq) (5mL) and sat. Na2S2O3 (aq) (5 mL) were added. The layers were separated, and the aqueous layer was extracted with DCM (3x15 mL). The combined organic layers were washed with sat.
Na2S2O3 (aq)(15 mL), sat. NaHCO3 (aq)(15 mL), and brine (15 mL), dried (Na2SO4) and concentrated to afford the aldehyde intermediate which was used without further purification in the next step.
[M+H]+ = 478.9
AcOH (60 μL, 1.0 mmol) was added to a mixture of the aldehyde intermediate and Nl-[(2,4- dimethoxyphenyl)methyl]-N5-methyl-isoquinoline-l,5-diamine (274 mg, 1.17 mmol) in DCE (7 mL) at rt and stirred for 5 min. NaBH(OAc)3 (435 mg, 1.64 mmol) was added and the mixture stirred at rt for 16 h. The mixture was cooled in an ice/water bath and sat. NaHCO3 (aq) (5 mL) and brine (5 mL) were added. The layers were separated and the aqueous layer extracted with DCM (3 x 15 mL). The combined organic layers were dried (Na2SO4), filtered and concentrated, and the residue purified by flash chromatography (Silica, 0-48% EtOAc in hexanes) to afford the product (184 mg, 30% yield over two steps).
[M+H]+ = 787.5
1H NMR (DMSO-d6, 500 MHz) 6 0.92 (9H, s), 1.25 (2H, dd, J = 4.4, 1.8 Hz), 1.38 (9H, s), 1.73 - 1.80 (2H, m), 2.78 (3H, s), 3.13 (2H, s), 3.70 (3H, s), 3.73 (2H, s), 3.82 (3H, d, J = 1.3 Hz), 3.84 (2H, s), 4.60 (2H, d, J = 5.6 Hz), 6.36 (1H, dd, J = 8.4, 2.4 Hz), 6.55 (1H, d, J = 2.3 Hz), 7.06 (1H, d, J = 8.3 Hz), 7.10 (1H, dd, J = 6.0, 0.8 Hz), 7.34 - 7.41 (6H, m), 7.41 - 7.47 (2H, m), 7.49 - 7.54 (4H, m), 7.58 (1H, t, J = 5.9 Hz), 7.76 (1H, d, J = 6.0 Hz), 7.99 (1H, d, J = 8.1 Hz) tert-Butyl l-[[[l-[(2,4-dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl-amino]methyl]-4-
TBAF (IM in THF, 500 μL, 0.500 mmol) was added to a mixture of tert-butyl 4-[[tert- butyl(diphenyl)silyl]oxymethyl]-l-[[[l-[(2,4-dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl- amino]methyl]-2-azabicyclo[2.1.1]hexane-2-carboxylate (184 mg, 0.222 mmol) in THF (1.5 mL). The mixture was stirred at rt for 2 h then concentrated. The residue was diluted with DCM (20 mL) and washed with a mixture of sat. NaHCO3 (aq) and brine (1:1 v/v, 10 mL). The layers were separated, and the aqueous layer was extracted with DCM (2x 20 mL). The combined organic layers were dried (Na2SO4), filtered, and
concentrated. The residue was purified by flash chromatography (Silica, 100% EtOAc) to afford the product (91 mg, 74%).
[M+H]+ = 549.8 tert-Butyl l-[[[l-[(2,4-dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl-amino]methyl]-4-[(1,2- dimethyl-6-oxo-4-pyridyl)oxymethyl]-2-azabicyclo[2.1.1]hexane-2-carboxylate
DIAD (50 μL, 0.25 mmol) was added to a mixture of tert-butyl l-[[[l-[(2,4-dimethoxyphenyl)methylamino]- 5-isoquinolyl]-methyl-amino]methyl]-4-(hydroxymethyl)-2-azabicyclo[2.1.1]hexane-2-carboxylate (91 mg, 0.17 mmol), triphenylphospine (68 mg, 0.26 mmol) and 4-hydroxy-l,6-dimethyl-pyridin-2-one (28 mg, 0.19 mmol) in THF (2 mL) at rt. The mixture was stirred at rt for 18 h and filtered (Celite®). The solid was washed with EtOAc and the filtrate was concentrated. The residue was purified by flash chromatography (silica, 0-100% hexanes in EtOAc followed by 0-18% MeOH in EtOAc) to afford the product (75 mg, 68% yield).
[M+H]+ = 670.8
4-[[4-[[[l-[(2,4-Dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl-amino]methyl]-2- azabicyclo[2.1.1]hexan-l-yl]methoxy]-l,6-dimethyl-pyridin-2-one
HCI (IM in EtOAc, 2 mL, 2 mmol) was added to a mixture of tert-butyl 4-[[[l-[(2,4- dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl-amino]methyl]-l-[(1,2-dimethyl-6-oxo-4-
pyridyl)oxymethyl]-2-azabicyclo[2.1.1]hexane-2-carboxylate (75 mg, 0.11 mmol) at rt The mixture was heated to 30 °C and stirred for 18 h and concentrated. The solid was diluted with a mixture of DCM and MeOH (9:1 v/v, 20 mL) and with NaOH (aq) (2M, 5 mL). The phases were separated, and the aqueous phase was extracted with a mixture of DCM and MeOH (9:1, 2 x 20 mL). The combined organic layers were dried (Na2SO4 , filtered, and concentrated to afford the product (63 mg, 99% yield).
[M+H]+ = 570.3 l-(((1-aminoisoquinolin-5-yl)(methyl)amino)methyl)-N-(chroman-6-yl)-4-(((1,6-dimethyl-2-oxo-l,2- dihydropyridin-4-yl)oxy)methyl)-2-azabicyclo[2.1.1]hexane-2-carboxamide
Chroman-6-amine (24 mg, 0.15 mmol) in a mixture of THF (500 μL) and DCM (500 μL) was added to a mixture of triphosgene (16.4 mg, 0.0542 mmol) and pyridine (20 μL, 0.245 mmol) in THF (500 μL) at rt. The mixture was stirred at rt for 4 h and added to a mixture of 4-[[l-[[[l-[(2,4- dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl-amino]methyl]-2-azabicyclo[2.1.1]hexan-4- yl]methoxy]-l,6-dimethyl-pyridin-2-one (63 mg, 0.11 mmol) and TEA (30 μL, 0.22 mmol) in DCM (1 mL) at rt. The mixture was stirred for 1 h and concentrated to afford the intermediate N-chroman-6-yl-l-[[[l- [(2,4-dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl-amino]methyl]-4-[(1,2-dimethyl-6-oxo-4- pyridyl)oxymethyl]-2-azabicyclo[2.1.1]hexane-2-carboxamide.
[M+H]+ = 745.7
TFA (250 μL, 3.33 mmol) was added to a mixture of intermediate N-chroman-6-yl-l-[[[l-[(2,4- dimethoxyphenyl)methylamino]-5-isoquinolyl]-methyl-amino]methyl]-4-[(1,2-dimethyl-6-oxo-4- pyridyl)oxymethyl]-2-azabicyclo[2.1.1]hexane-2-carboxamide in DCM (2 mL) at rt. The mixture was stirred at rt for 18 h and diluted with NaOH (aq) (2M, 10 mL) and a mixture of DCM and MeOH (9:1 v/v, 20 mL). The phases were separated, and the aqueous phase was extracted with a mixture of DCM and MeOH (9:1 v/v, 2 x 20 mL). The combined organic phases were concentrated, and the residue was purified by automated prep HPLC (UV directed 34-44% MeCN in 10 mM NH4HCO3 (aq) over 9 min) and lyophilized to afford the product (26 mg, 40% yield over two steps).
[M+H]+ = 595.5
1H NMR (DMSO-d6, 500 MHz) 6 1.43 (2H, dd, J = 4.6, 1.7 Hz), 1.75 - 1.81 (2H, m), 1.83 - 1.89 (2H, m), 2.27 (3H, s), 2.61 (2H, t, J = 6.5 Hz), 2.81 (3H, s), 3.37 (2H, s), 3.91 (2H, s), 4.02 - 4.06 (2H, m), 4.10 (2H, s), 5.67 (1H, d, J = 2.8 Hz), 5.82 (1H, dd, J = 2.8, 0.9 Hz), 6.52 - 6.58 (1H, m), 6.68 (2H, s), 7.01 - 7.08 (2H, m), 7.11 - 7.16 (1H, m), 7.37 (1H, t, J = 7.9 Hz), 7.42 (1H, dd, J = 7.6, 1.1Hz), 7.78 (1H, d, J = 6.0 Hz), 7.87 (1H, d, J =
8.2 Hz), 8.56 (1H, s); 3H under the water peak.
EXAMPLES
Biological Methods Determination of FXIIa inhibition
In vitro inhibition of Factor XI la was determined using an IC5o assay based on standard literature methods (see e.g Baeriswyl et al., ACS Chem. Biol., 2015, 10 (8) 1861; Bouckaert et al., European Journal of
Medicinal Chemistry 110 (2016) 181). Human Factor Xlla (Enzyme Research Laboratories) was incubated at 25 °C with the fluorogenic substrate H-DPro-Phe-Arg-AFC (Peptide Protein Science) and various concentrations of the test compound. Protease activity was measured by monitoring the accumulation of liberated fluorescence from the substrate over 5 min at 25 °C. The linear rate of fluorescence increase per minute was expressed as percentage (%) activity. The Km for the cleavage of the substrate by FXIIa was determined by standard transformation of the Michaelis-Menten equation. The compound inhibitor assays were performed at substrate Km concentration. IC5o values were calculated as the concentration of inhibitor giving 50% inhibition ( IC5o) of the uninhibited enzyme activity (100%). Data acquired from this assay are shown in Table 16 below using the following scale:
Determination of related protease inhibition
In vitro inhibition of related proteases was determined using an IC5o assay based on standard literature methods (see e.g. Shori et al., Biochem. Pharmacol., 1992,43, 1209; Bouckaert et al., European Journal of Medicinal Chemistry 110 (2016) 181). Human serine protease enzyme Plasma Kallikrein, KLK1, FXa, Plasmin, Thrombin and Trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate at Km concentration, FXIa at fixed substrate concentration of lOOpM and various concentrations of the test compound. Protease activity was measured by monitoring the accumulation of liberated fluorescence from the substrate over 5 min at 25 °C. The linear rate of fluorescence increase per minute was expressed as percentage (%) activity. IC5o values were calculated as the concentration of inhibitor giving 50% inhibition of the uninhibited enzyme activity (100%).
Data acquired from this assay are shown in Table 17 using the scale shown in Table 18. Table 9: Enzyme selectivity data
Claims
Formula (I), wherein:
V is selected from -O- and -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is selected from -O- and -N(R18)-; wherein R18 or R23 are selected from C(=S)NH-aryl; C(=S)NH-R19; C(=S)N(alkyl)R19; C(=S)NR13R14; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; heterocycloalkylb; a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members independently selected from N and, where possible, O, wherein the carbon-containing aromatic ring is substituted with one substituent selected from cycloalkyl and heterocycloalkylb, and optionally one or two further substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3;
R19 is selected from (CH2)1-3-cycloalkyl, (CH2)0-3-polycycloalkyl, heterocycloalkyla, (CH2)1-3-heterocycloalkylb, (CH2)0-3-R22, (C(R2O)(R21))-(CH2)0-3-phenyl, (C(R20)(R21))-R22, (C(R20)(R21))-O-phenyl, and (CH2)1-3-O-(CH2)-phenyl;
R20 and R21 are independently selected from H, alkyl and CF3, or R20 and R21 together with the carbon atom to which they are attached form a carbon-containing 3-, 4-, 5- or 6- membered saturated ring, optionally containing an O ring member, wherein R20 and R21 are not both H;
R22 is a fused 6,5- or 6,6- bicyclic ring containing an aromatic ring fused to a non-aromatic ring, wherein the bicyclic ring optionally contains one or two ring members selected from N and O, wherein the fused 6,5- or 6,6- bicyclic ring may be optionally substituted with one or two substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo, and oxo, wherein the 6,5- bicyclic ring may be attached via the 6- or 5- membered ring, wherein the 6,5-bicyclic ring is not aryl substituted with methylenedioxy, and wherein the 6,6bicyclic ring is not aryl substituted with ethylenedioxy;
Y is selected from -O- and -N(R12)-;
B is selected from:
(i) heteroaryla; and
(ii) aryl;
AW- is selected from:
-(CH2)O-6-(CHR15)-(CH2)0-6-A, -(CHR12)-A, -O-(CHR12)-A, -(CH2)O.6-A, -(CH2)0-6-O-(CH2)0-6-A, -(CH2)0-6-NH-(CH2)0-6-A, -(CH2)O-6-N(R12)-(CH2)I.6-C(=0)-A, -(CH2)0-6-NH-C(=O)-(CH2)0-6-A,
-C(=0)N(R12)-(CH2)0-6-A, -(CH2)O-6-C(=0)-(CH2)0-6-A, -(CH2)0-6-(phenyl)-(CH2)0-6-A, -NH-SO2-A and -SO2-NH-A;
A is a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from N, O and S, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro; wherein when A is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system; wherein when:
(i) V is -O-, or
(ii) Z is -O-,
A is A', wherein A' is a 4- to 15- membered mono-, bi-, or tri- cyclic ring system, containing one N ring member and optionally one, two or three further ring members independently selected from
N, O and S, wherein the ring system is substituted with phenyl and optionally, where possible, 1, 2, or 3 further substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN, and phenyl; wherein when A' is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro; wherein when A' is a tricyclic ring system, each of the three rings in the tricyclic ring system is either fused, bridged or spiro to at least one of the other rings in the tricyclic ring system; alkoxy is OCF3, a linear O-linked hydrocarbon of between 1 and 6 carbon atoms (C1-C6), or a branched O-linked hydrocarbon of between 3 and 6 carbon atoms (C3-C6); alkoxy may optionally be substituted, where possible, with 1 or 2 substituents independently selected from OH, CN, CF3, and fluoro; alkyl is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkyl may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, -NR13R14, -C(=O)OR13, -C(=O)NR13R14, CN, CF3, halo; alkylb is a linear saturated hydrocarbon having up to 10 carbon atoms (C1-C10) or a branched saturated hydrocarbon of between 3 and 10 carbon atoms (C3-C10); alkylb may optionally be substituted with 1, 2 or 3 substituents independently selected from alkoxy, OH, CN, CF3, halo; small alkyl is a linear saturated hydrocarbon having up to 4 carbon atoms (C1-C4) or a branched saturated hydrocarbon of between 3 and 4 carbon atoms (C3-C4); small alkyl may optionally be substituted with 1 or 2 substituents independently selected from alkoxy, OH, NR13R14, C(=O)OR13, C(=O)NR13R14, CN, CF3, halo; aryl is phenyl, biphenyl or naphthyl; aryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, methylenedioxy, ethylenedioxy, OH, halo, CN, -(CH2)0-3- O-heteroaryla, arylb, -O-arylb, -(CH2)1-3-arylb, -(CH2)0-3-heteroaryla, -C(=O)OR13, -C(=O)NR13R14, -(CH2)0-3-NR13R14, OCF3 and CF3; a ry I b is phenyl, biphenyl or naphthyl; a ryl b may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, and CF3;
cycloalkyl is a monocyclic saturated hydrocarbon ring of between 3 and 6 carbon atoms (C3-C6); cycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo; halo is F, Cl, Br, or I; heteroaryl is a 5- or 6- membered carbon-containing aromatic ring containing one, two or three ring members that are selected from N, NR8, S, and O; heteroaryl may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, and CF3; heteroaryla is a 5-, 6-, 9- or 10- membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2, 3 or 4 ring members independently selected from N, N(R12), S and O; heteroaryla may be optionally substituted with 1, 2 or 3 substituents independently selected from alkyl, alkoxy, OH, OCF3, halo, CN, arylb, -(CH2)o-3-NR13R14, heteroarylb, -C(=O)OR12, -C(=O)NR13R14 and CF3; heteroarylb is a 5-, 6-, 9- or 10- membered mono- or bi-cyclic aromatic ring, containing, where possible, 1, 2 or 3 ring members independently selected from N, N(R12), S and O; wherein heteroarylb may be optionally substituted with 1, 2 or 3 substituents independently selected from alkylb, alkoxy, OH, halo, CN, arylb, -(CH2)i-3-arylb, and CF3; heterocycloalkyl is a non-aromatic carbon-containing monocyclic ring containing 3, 4, 5, or 6, ring members, wherein at least one ring member is independently selected from N, N(R12), S, and O; heterocycloalkyl may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, OH, CN, CF3, halo; heterocycloalkyla is a 3-10 membered non-aromatic carbon-containing mono- or bi- cyclic ring system containing one or two ring members independently selected from N and O; heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, aryl, halo, OH, CN, CF3, and heterocycloalkyl; wherein when heterocycloalkyla is a bicyclic ring system, the bicyclic ring system is spiro; heterocycloalkylb is a 3-6 membered non-aromatic carbon-containing monocyclic ring system which may be saturated or, where possible, unsaturated with 1 or 2 double bonds; heterocycloalkylb contains one or two ring members independently selected from N, N(C(=O)CH3)
and O; heterocycloalkyla may optionally be substituted with 1 or 2 substituents independently selected from alkyl, alkoxy, halo, OH, CN, CF3, phenyl and oxo; wherein the point of attachment of heterocycloalkylb is not at a ring nitrogen; polycycloalkyl is a bi- or tri-cyclic saturated hydrocarbon ring system of between 5 and 10 carbon atoms (C5-C10), wherein the bi- or tri-cyclic ring system is bridged or spiro;
R8 is independently selected from H, alkyl, cycloalkyl, and heterocycloalkyl;
R12 is independently selected from H, alkyl, and cycloalkyl;
R13 and R14 are independently selected from H, alkylb, arylb and heteroarylb or R13 and R14 together with the nitrogen atom to which they are attached form a carbon-containing 4-, 5-, 6- or 7-membered heterocyclic ring, optionally containing an additional heteroatom selected from N, N(R12), S, SO, SO2, and O, which may be saturated or unsaturated with 1 or 2 double bonds and which may be optionally mono- or di-substituted with substituents selected from oxo, alkylb, alkoxy, OH, halo and CF3;
R15 is selected from alkyl, halo, CF3, CN, OH, alkoxy, NR13R14, and CONR13R14;
R16 and R17 are independently selected from H and small alkyl; and tautomers, isomers, stereoisomers (including enantiomers, diastereoisomers and racemic and scalemic mixtures thereof), deuterated analogues, and pharmaceutically acceptable salts and/or solvates thereof.
2. A compound of formula (I) according to claim 1, wherein the compound is a compound of formula (la), formula (lb), or formula (Ic),
Formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
3. A compound according to claim 1, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein V is -N(R23)-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -N(R18)-.
4. A compound of formula (I) according to any of the preceding claims, wherein the compound is a compound of formula (la),
Formula (la), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
5. A compound according to any of the preceding claims, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
6. A compound according to claim 5, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein R18 or R23 are selected from C(=S)NH-phenyl; C(=O)R19; C(=O)NHR19; C(=O)N(alkyl)(R19); C(=O)NH2; 5- membered heterocycloalkylb ring, optionally substituted as for heterocycloalkylb; a 6- membered carbon-containing aromatic ring containing two N ring members substituted with one
7. A compound according to any of the preceding claims or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof,
wherein the compound is a compound of formula (la), wherein R18 is as described in any of the preceding claims, or a compound of formula (lb) and R23 is C(=O)R19.
8. A compound according to any of claims 3 to 7, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein A is a 6 to 9 membered mono or bi- cyclic ring system containing one N ring member, optionally wherein the ring system is substituted, where possible, with 1, 2, 3 or 4 substituents independently selected from halo, alkyl, OH, oxo, cycloalkyl, alkoxy, -(CH2)0-2-heteroaryl, heterocycloalkyl, C(=O)R12, C(=O)OR13, C(=O)NR13R14, NR13R14, CF3, CN; wherein when A is a bicyclic ring system, the bicyclic ring system is fused, bridged or spiro.
9. A compound according to claim 8, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
10. A compound according to claim 1 or 2, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
V is -O-, and Z is selected from -C(R16)(R17)-CH2- and -C(R16)(R17)-; or,
V is selected from -CH2-C(R16)(R17)- and -C(R16)(R17)-, and Z is -O-.
Formula (Ic), or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof.
12. A compound according any of the preceding claims, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein AW- is selected from -(CH2)0-1-A, and -(CH2)-O-A.
13. A compound according to any of the preceding claims, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
Y is -N(R12)-.
14. A compound according to claim 13, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein
Y is -NH-.
15. A compound according to any of the preceding claims, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is heteroaryla.
16. A compound according to claim 15, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is isoquinolinyl, optionally substituted as for heteroaryla.
17. A compound according to claim 16 or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is
optionally substituted as for heteroaryla.
18. A compound according to claim 16 or 17, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is isoquinolinyl, substituted with NH2 at the 1- position
optionally further substituted with 1 or 2 substituents as for heteroaryla.
19. A compound according to claim 18, or a tautomer, isomer, stereoisomer (including an enantiomer, a diastereoisomer and a racemic and scalemic mixture thereof), a deuterated analogue, and a pharmaceutically acceptable salt and/or solvate thereof, wherein B is
optionally further substituted with 1 or 2 substituents as for heteroaryla.
20. A compound selected from Table 1, Table 2, Table 3, Table 4, and Table 5, or a pharmaceutically acceptable salt, solvate, or solvate of a salt thereof.
21. A pharmaceutical composition comprising: a compound, or a pharmaceutically acceptable salt and/or solvate thereof, according to any of claims 1 to 20, and at least one pharmaceutically acceptable excipient.
22. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as defined in any of claims 1 to 20, or the pharmaceutical composition according to claim 21, for use in medicine.
23. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as defined in any of claims 1 to 20, or the pharmaceutical composition according to claim 21, for use in a method of treatment of a disease or condition in which Factor XI la activity is implicated; wherein the disease or condition in which Factor Xlla activity is implicated is a bradykinin-mediated angioedema, wherein the bradykinin-mediated angioedema is hereditary angioedema.
24. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as defined in any of claims 1 to 20, or the pharmaceutical composition according to claim 21 for use in a method of treatment of a disease or condition in which Factor Xlla activity is implicated; wherein the disease or condition in which Factor Xlla activity is implicated is a bradykinin-mediated angioedema, wherein the bradykinin-mediated angioedema is non hereditary.
25. A compound, or a pharmaceutically acceptable salt and/or solvate thereof, as defined in any of claims 1 to 20, or the pharmaceutical composition according to claim 21, for use in a method of treatment of a disease or condition in which Factor Xlla activity is implicated; wherein the disease or condition in which Factor Xlla activity is implicated is a thrombotic disorder.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263399075P | 2022-08-18 | 2022-08-18 | |
GB2212081.0 | 2022-08-18 | ||
GBGB2212081.0A GB202212081D0 (en) | 2022-08-18 | 2022-08-18 | Enzyme inhibitors |
US63/399,075 | 2022-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024038282A1 true WO2024038282A1 (en) | 2024-02-22 |
Family
ID=87800892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2023/052166 WO2024038282A1 (en) | 2022-08-18 | 2023-08-18 | 2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024038282A1 (en) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
WO2012120128A1 (en) | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
WO2017123518A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
WO2017205296A1 (en) | 2016-05-23 | 2017-11-30 | The Rockefeller University | Aminoacylindazole immunomodulators for treatment of autoimmune diseases |
WO2018093695A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
WO2018093716A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
WO2019108565A1 (en) | 2017-11-29 | 2019-06-06 | The Rockefeller University | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases |
WO2019113642A1 (en) | 2017-12-15 | 2019-06-20 | Csl Limited | Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
WO2019186164A1 (en) | 2018-03-29 | 2019-10-03 | University Of Leeds | Factor xiia inhibitors |
WO2019211585A1 (en) | 2018-04-30 | 2019-11-07 | University Of Leeds | FACTOR XIIa INHIBITORS |
WO2022118016A2 (en) * | 2020-12-01 | 2022-06-09 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
WO2022175675A1 (en) * | 2021-02-19 | 2022-08-25 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
-
2023
- 2023-08-18 WO PCT/GB2023/052166 patent/WO2024038282A1/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2281885A1 (en) | 2003-08-27 | 2011-02-09 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
WO2012120128A1 (en) | 2011-03-09 | 2012-09-13 | Csl Behring Gmbh | Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces |
WO2017123518A1 (en) | 2016-01-11 | 2017-07-20 | The Rockefeller University | Aminotriazole immunomodulators for treating autoimmune diseases |
WO2017205296A1 (en) | 2016-05-23 | 2017-11-30 | The Rockefeller University | Aminoacylindazole immunomodulators for treatment of autoimmune diseases |
WO2018093695A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
WO2018093716A1 (en) | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
WO2019108565A1 (en) | 2017-11-29 | 2019-06-06 | The Rockefeller University | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases |
WO2019113642A1 (en) | 2017-12-15 | 2019-06-20 | Csl Limited | Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
WO2019186164A1 (en) | 2018-03-29 | 2019-10-03 | University Of Leeds | Factor xiia inhibitors |
WO2019211585A1 (en) | 2018-04-30 | 2019-11-07 | University Of Leeds | FACTOR XIIa INHIBITORS |
WO2022118016A2 (en) * | 2020-12-01 | 2022-06-09 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
WO2022175675A1 (en) * | 2021-02-19 | 2022-08-25 | Kalvista Pharmaceuticals Limited | Factor xiia inhibitors |
Non-Patent Citations (88)
Title |
---|
"The Practice of Medicinal Chemistry", 2003, pages: 561 - 585 |
A DEMENTIEV ET AL.: "Structures of human plasma β factor Xlla cocrystallized with potent inhibitors", BLOOD ADVANCES, vol. 2, no. 5, 2018, pages 549 - 558, XP055901041, DOI: 10.1182/bloodadvances.2018016337 |
ABDALLAH ET AL., J BIOL CHEM., vol. 285, no. 45, 5 November 2010 (2010-11-05), pages 35206 - 15 |
ABID ET AL., J BIOL CHEM., vol. 284, no. 37, 11 September 2009 (2009-09-11), pages 24715 - 24 |
ARYLBORONIC ESTERST. ISHIYAMAM. MURATAN. MIYAURA, J. ORG. CHEM., vol. 60, 1995, pages 7508 - 7510 |
B. K. HAMAD: "Journal< of Thrombois and Haemostasis", OF THROMBOSIS AND HAEMOSTASIS, vol. 15, pages 1818 - 1828 |
BARBIERI ET AL., J PHARMACOL EXP THER, vol. 360, no. 3, March 2017 (2017-03-01), pages 466 - 475 |
BAS ET AL., N ENGL J MED, 2015 |
BENDER ET AL., FRONT IMMUNOL, vol. 8, 15 September 2017 (2017-09-15), pages 1115 |
BJBRKQVIST ET AL., J CLIN INVEST, vol. 125, no. 8, 3 August 2015 (2015-08-03), pages 3132 - 46 |
BRESLOW ET AL., AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES |
CAS , no. 1522098-73-2 |
CHEMISTRYSELECT, vol. 4, 2019, pages 4933 - 493 |
CLERMONT ET AL., ARVO TALK, 2019 |
CLERMONT ET AL., INVEST OPHTHALMOL VIS SCI, vol. 57, no. 6, 1 May 2016 (2016-05-01), pages 2390 - 9 |
CRAIG ET AL., THE LANCET, vol. 401, no. 10382, 2023, pages 1079 - 1090 |
DATABASE Registry [online] 22 April 2021 (2021-04-22), ENAMINE LLC: "1H-Pyrrole-2-carboxamide, N-[1-[[(6-methoxy-4-pyrimidinyl)amino]methyl]-3-methyl-2-oxabicyclo[2.1.1]hex-4-yl]-1-methyl-", XP093084075, Database accession no. 2636674-43-4 * |
DAVIE ET AL., SCIENCE, vol. 145, no. 3638, 18 September 1964 (1964-09-18), pages 1310 - 2 |
DE MAAT ET AL., J ALLERGY CLIN IMMUNOL, vol. 138, no. 5, November 2016 (2016-11-01), pages 1414 - 1423 |
DIDIASOVA ET AL., CELL SIGNAL., vol. 51, November 2018 (2018-11-01), pages 257 - 265 |
DIESTRO ET AL., J STROKE CEREBROVASC DIS, vol. 28, no. 5, May 2019 (2019-05-01), pages e44 - e45 |
ELMAN MAIELLO LBECK R ET AL.: "Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema", OPHTHALMOLOGY, 27 April 2010 (2010-04-27) |
F. J. LEINWEBER: "Drug Metab. Res", vol. 18, 1987, pages: 379 |
FROHLICH ET AL., STROKE, 11 June 2019 (2019-06-11), pages STROKEAHA119025260 |
GAO ET AL., NAT MED., vol. 13, no. 2, 28 January 2007 (2007-01-28), pages 181 - 8 |
GAO ET AL., PROTEOME RES, vol. 7, no. 6, June 2008 (2008-06-01), pages 2516 - 25 |
GHEBREHIWET ET AL., IMMUNOL REV, vol. 274, no. 1, November 2016 (2016-11-01), pages 281 - 289 |
GHEBREHIWET ET AL., J EXP MED., vol. 153, no. 3, 1 March 1981 (1981-03-01), pages 665 - 76 |
GIARD ET AL., DERMATOLOGY, vol. 225, no. 1, 2012, pages 62 - 9 |
GOBEL ET AL., NAT COMMUN., vol. 7, 18 May 2016 (2016-05-18), pages 11626 |
GOBEL ET AL., PROC NATL ACAD SCI USA., vol. 116, no. 1, 2 January 2019 (2019-01-02), pages 271 - 276 |
GOBEL ET AL.: "The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review", FRONT. IMMUNOL, 26 July 2018 (2018-07-26) |
H. LIEBERMANL. LACHMAN: "Pharmaceutical Dosage Forms", vol. 1, 1980, MARCEL DEKKER |
HAN ET AL., JCI, 2002 |
HERMANRUD ET AL., BMJ CASE REP, vol. 2017, 10 January 2017 (2017-01-10), pages bcr2016217802 |
HILL ET AL., NEUROLOGY, vol. 60, no. 9, 13 May 2003 (2003-05-13), pages 1525 - 7 |
HOPP ET AL., J NEUROINFLAMMATION, vol. 14, no. 1, 20 February 2017 (2017-02-20), pages 39 |
INVANOV, BLOOD, vol. 129, no. 11, 16 March 2017 (2017-03-16), pages 1527 - 1537 |
IRMSCHER ET AL., J INNATE IMMUN, vol. 10, no. 2, 2018, pages 94 - 105 |
KAPLAN ET AL., ADV IMMUNOL, vol. 121, 2014, pages 41 - 89 |
KEDARISETTY ET AL., OTOLARYNGOL HEAD NECK SURG, 30 April 2019 (2019-04-30), pages 194599819846446 |
KIM ET AL., BASIC CLIN PHARMACOL TOXICOL, vol. 124, no. 1, January 2019 (2019-01-01), pages 115 - 122 |
KITA ET AL., DIABETES, vol. 64, no. 10, October 2015 (2015-10-01), pages 3588 - 99 |
KONINGS ET AL., THROMB RES, vol. 136, no. 2, August 2015 (2015-08-01), pages 474 - 80 |
KRUPKA ET AL., PLOS ONE, vol. 11, no. 1, 27 January 2016 (2016-01-27), pages e0146783 |
LEIBFRIEDKOVARY, J PHARM PRACT, 2017 |
LEKOUBOU ET AL., NEUROL RES, vol. 36, no. 7, July 2014 (2014-07-01), pages 687 - 94 |
LEUNG ET AL., TRANSL STROKE RES, vol. 3, no. 3, September 2012 (2012-09-01), pages 381 - 9 |
LIANGCHEN, EXPERT OPINION IN THERAPEUTIC PATENTS, vol. 11, no. 6, 2001, pages 981 - 986 |
LIU ET AL., BIOL CHEM, vol. 394, no. 3, March 2013 (2013-03-01), pages 319 - 28 |
LIU ET AL., NAT MED., vol. 17, no. 2, February 2011 (2011-02-01), pages 206 - 10 |
LONG ET AL., NANOTOXICOLOGY, vol. 10, no. 4, 2016, pages 501 - 11 |
M. PATHAK ET AL.: "Crystal structures of the recombinant β-factor XIIa protease with bound Thr-Arg and Pro-Arg substrate mimetics", ACTA. CRYST, vol. D75, 2019, pages 1 - 14 |
MAAT ET AL., J THROMB HAEMOST, vol. 17, no. 1, January 2019 (2019-01-01), pages 183 - 194 |
MAEHR, J. CHEM. ED, vol. 62, 1985, pages 114 - 120 |
MANSI ET AL., 2014 THE ASSOCIATION FOR THE PUBLICATION OF THE JOURNAL OF INTERNAL MEDICINE JOURNAL OF INTERNAL MEDICINE, vol. 277, 2015, pages 585 - 593 |
MORRISON ET AL., J EXP MED., vol. 140, no. 3, 1 September 1974 (1974-09-01), pages 797 - 811 |
MURUGESAN ET AL., EXP EYE RES, vol. 186, 24 July 2019 (2019-07-24), pages 107744 |
NOLTE ET AL., FACTOR XII INHIBITORS FOR THE ADMINISTRATION WITH MEDICAL PROCEDURES COMPRISING CONTACT WITH ARTIFICIAL SURFACES |
PEYROU ET AL.: "The kallikrein-kinin pathway as a mechanism for auto-control of brown adipose tissue activity", NATURE COMMUNICATIONS, vol. 11, 2020, pages 2132, Retrieved from the Internet <URL:https://doi.org/10.1038/s41467-020-16009-x> |
PHILIPPOU ET AL., FACTOR XLLA INHIBITORS |
PONDA, AMINACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES |
PUY ET AL., J THROMB HAEMOST, vol. 11, no. 7, July 2013 (2013-07-01), pages 1341 - 52 |
RADCLIFFE ET AL., BLOOD, vol. 50, no. 4, October 1977 (1977-10-01), pages 611 - 7 |
RATHBUN, OXF MED CASE REPORTS, vol. 2019, no. 1, 24 January 2019 (2019-01-24), pages omy112 |
RECKE ET AL., CLIN TRANSL ALLERGY, vol. 9, 14 February 2019 (2019-02-14), pages 9 |
REICHMAN ET AL., PHARMACOEPIDEMIOL DRUG SAF, vol. 26, no. 10, October 2017 (2017-10-01), pages 1190 - 1196 |
RENNE ET AL., J EXP MED., vol. 202, no. 2, 18 July 2005 (2005-07-18), pages 271 - 81 |
S. PATEL, RETINA, vol. 29, June 2009 (2009-06-01), pages S45 - 8 |
SALA-CUNILL ET AL., J ALLERGY CLIN IMMUNOL, vol. 135, no. 4, April 2015 (2015-04-01), pages 1031 - 43 |
SCHEFFEL ET AL.: "Cold-induced urticarial autoinflammatory syndrome related to factor XII activation", NATURE COMMUNICATIONS, vol. 11, 2020 |
SCOTT ET AL., CURR DIABETES REV, vol. 14, no. 4, 2018, pages 327 - 333 |
SHATZEL ET AL., RES PRACT THROMB HAEMOST, vol. 4, no. 4, 15 May 2020 (2020-05-15), pages 500 - 505 |
SIMAO ET AL., BLOOD, vol. 129, no. 16, 20 April 2017 (2017-04-20), pages 2280 - 2290 |
SIMAO ET AL., FRONT MED (LAUSANNE)., vol. 4, 31 July 2017 (2017-07-31), pages 121 |
SIMOES ET AL., J NEUROCHEM, vol. 150, no. 3, August 2019 (2019-08-01), pages 296 - 311 |
STAHLWERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection and Use", 2002, WILEY-VCH |
STONE ET AL., IMMUNOL ALLERGY CLIN NORTH AM, vol. 37, no. 3, August 2017 (2017-08-01), pages 483 - 495 |
T. W. GREENEP. G. M. WUTS: "Protective groups in organic chemistry", 2006, JOHN WILEY AND SONS |
TETRAHEDRON LETTERS, vol. 55, 2014, pages 466 - 468 |
VAN DEN ELZEN ET AL., CLINIC REV ALLERG IMMUNOL, 2018 |
VERONEZ ET AL., FRONT MED (LAUSANNE, vol. 6, 21 February 2019 (2019-02-21), pages 28 |
WILBS ET AL., NAT COMMUN, vol. 11, 2020, pages 3890 |
WONG ET AL.: "CSL312, a Novel Anti-FXII Antibody, Blocks FXII-Induced IL-6 Production from Primary Non-Diseased and Idiopathic Pulmonary Fibrosis Fibroblasts", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE, vol. 201, 2020, pages A6363 |
WORM ET AL., ANN TRANSL MED, vol. 3, no. 17, October 2015 (2015-10-01), pages 247 |
WYGRECKA ET AL., USE OF A FXLLA-LNHIBITOR IN THE TREATMENT OF RENAL FIBROSIS AND/OR KIDNEY DISEASE |
WYGRECKA ET AL.: "Coagulation factor XII regulates inflammatory responses in human lungs", EUROPEAN RESPIRATORY JOURNAL, vol. 50, 2017, pages PA339 |
ZAMOLODCHIKOV ET AL., PROC NATL ACAD SCI USA., vol. 112, no. 13, 31 March 2015 (2015-03-31), pages 4068 - 73 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110678176B (en) | Sulfonamide substituted cyanopyrrolidines with DUB inhibitor activity | |
JP2019517460A (en) | N-[(6-Cyano-2-fluoro-3-methoxyphenyl) methyl] -3- (methoxymethyl) -1-({4-[(2-oxopyridin-1-yl) methyl] as a kallikrein inhibitor Polymorphs of (phenyl) methyl) pyrazole-4-carboxamide | |
CA3147566A1 (en) | Enzyme inhibitors | |
WO2021032933A1 (en) | Enzyme inhibitors | |
AU2020331720A1 (en) | Enzyme inhibitors | |
AU2020333222A1 (en) | Enzyme inhibitors | |
TW201808908A (en) | Factor XIa inhibitors | |
AU2022222458A1 (en) | Factor xiia inhibitors | |
AU2021393080A1 (en) | Enzyme inhibitors | |
WO2024038282A1 (en) | 2-aza- and 2-oxabicyclo[2.1.1]hexane derivatives as factor xiia enzyme inhibitors | |
TW202412765A (en) | Enzyme inhibitors | |
CN116829547A (en) | Factor XIIa inhibitors | |
CN116745278A (en) | Enzyme inhibitors | |
WO2024084217A1 (en) | 3a,4,5,6-tetrahydro-1 h-pyrazolo[3,4-c]pyridin-7(7ah)-one derivatives as factor xiia inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23761217 Country of ref document: EP Kind code of ref document: A1 |